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Background. The implication of platelets in inflammatory disorders, such as asthma, has 
become increasingly more apparent. Following an inflammatory insult, platelets modulate 
inflammation by a number of distinct mechanisms, including pulmonary-leukocyte 
recruitment and release of platelet specific mediators. However, little is known regarding the 
role of platelets in the regulation of pulmonary infection. Pulmonary colonisation of bacteria, 
including Pseudomonas aeruginosa (P.aeruginosa) and Staphylococcus aureus (S.aureus) 
presents a therapeutic challenge due to antimicrobial resistance (AMR). 
 
Objectives. In this study, the effect of experimentally induced platelet depletion was 
investigated on infection and inflammatory parameters in a murine model of pulmonary 
infection. A new approach in targeting AMR was also tested, using a novel antibiotic enhancer 
compound, HT61.  
 
Methods. C57/B16 mice were experimentally depleted of platelets, 24 hours prior to 
infection with either sham, P.aeruginosa or S.aureus embedded agar beads. Bronchoalveolar 
lavage (BAL) fluid and lungs, kidney and spleen were analysed for inflammatory cells and 
bacterial load respectively. The role of platelet purinergic receptors was also assessed. In vitro 
assays were performed to investigate the effect of bacteria on platelet function, through 
measurements of platelet-leukocyte complexes and mediator release. Additional in vivo 
experiments were performed to test enhancer compound, HT61. 
 
Results. Infection induced pulmonary platelet recruitment (p<0.01) in addition to a mild state 
of thrombocytopenia (p<0.05). Evidence of platelet activation was detected in infected mice 
through increased levels of platelet-derived mediators Platelet Factor-4 (PF-4) and Regulated 
upon activation, normal T-cell expressed and secreted (RANTES) in BAL fluid and platelet-
neutrophil complexes (p<0.01) in blood. In mice depleted of circulating platelets, there was 
evidence of systemic bacterial dissemination and weight loss was increased compared to mice 
with normal platelet levels. Furthermore, pulmonary neutrophil recruitment was significantly 
reduced 24 hours post infection in mice depleted of circulating platelets. These results were 
reproduced following inhibition of the P2Y14 receptor and use of the ATP/ADP hydrolysing 
agent, Apyrase. 
HT61 as a singular treatment showed no inhibition of P.aeruginosa or S.aureus bacterial load, 
however, in combination with Tobramycin an enhanced reduction in bacterial load was 
observed for two strains of P.aeruginosa (p<0.05) when compared to treatment with either 
drug alone. 
 
Conclusions. Here it is demonstrated that infection induces platelet activation and 
accumulation in the lungs. Mice depleted of circulating platelets or treated with Apyrase or a 
P2Y14 receptor antagonist demonstrated increased weight loss and increased systemic 
infection, this therefore suggests that in addition to the role played by neutrophils, platelets 
also have a distinct role in the host defence against bacterial infection.  
 
Furthermore, I demonstrated an enhancement of Tobramycin’s efficacy when administered 
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1.1 Pulmonary infection with Pseudomonas aeruginosa and Staphylococcus aureus 
1.1.1 Pseudomonas aeruginosa 
 
 P.aeruginosa is a highly motile, gram-negative bacterium, preliminarily identified by its 
distinctive grape-like odour and white, pearlescent appearance of colonies. P.aeruginosa is a 
versatile bacterium able to grow in soil and aqueous environments, in addition to on plant 
and animal tissue (Stover et al., 2000) (Gellatly and Hancock, 2013). P.aeruginosa is a major 
opportunistic pathogen, accounting for between 17-26% of all nosocomial infections 
(Nanvazadeh et al., 2013) and it typically establishes itself in the respiratory, urinary and 
gastrointestinal tracts of immunodeficient individuals, with infection prevalent in patients 
with severe burns, acute leukaemia, urinary-tract infections in catheterised patients and in 
patients who have received organ transplants (Di Lorenzo et al., 2015) (Stover et al., 2000) 
(Nanvazadeh et al., 2013) (Gellatly and Hancock, 2013). P.aeruginosa is now recognised as a 
major colonising pathogen in the pathophysiology of cystic fibrosis (CF) (Di Lorenzo et al., 
2015) (Van Heeckeren et al., 1997), with P.aeruginosa infection established in 70-80% of CF 
patients (Lyczak et al., 2002). P.aeruginosa is also the predominant cause of morbidity and 
mortality in CF patients (Stover et al., 2000).  
P.aeruginosa can exist in non-mucoid and mucoid forms; non-mucoid strains initially colonise 
the lung, causing transient pulmonary infections in early life (Di Lorenzo et al., 2015) (Friedl 
et al., 1992), followed by the predominance of the mucoid form in the subsequent course of 
disease. Mucoid strains are frequently isolated from the respiratory tracts of patients with CF 
and chronic obstructive pulmonary disease (COPD) (Friedl et al., 1992), and these strains 
produce large quantities of viscous polysaccharide. Mucoid strains of P.aeruginosa persist in 
the lung forming biofilms (Patrauchan et al., 2007). This establishes a chronic, persistent 
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infection (Di Lorenzo et al., 2015) (Costerton et al., 1999), associated with incessant cycles of 
airway obstruction and chronic inflammation, leading to the progressive loss of respiratory 
function (Gibson et al. , 2003) (Dhooghe et al., 2014).  
 
1.1.2 Biofilm Formation 
 
Several species of bacteria possess the ability to become associated with one another and 
irreversibly adhere to wet, solid surfaces to form a coat, called a biofilm (Klausen et al., 2003). 
A biofilm may be defined as a highly organised, structured community of bacterial cells 
embedded in a self-producing matrix of extracellular polymeric substance (EPS) (Bjarnsholt, 
2013).  Biofilms preferentially develop on both living surfaces, in the case of endocarditis, and 
inert, non-living surfaces, such as on medical devices and sequestra of dead bone (Costerton 
et al., 1999). Furthermore, biofilms can be present in natural, industrial or hospital 
environments. 
P.aeruginosa is a bacterium that can form a structured consortium of bacteria on moist 
surfaces, acting as a protective mechanism of growth in a hostile environment. Biofilm 
formation is a major survival mechanism of P.aeruginosa and aides evasion of the host 
defences (Bjarnsholt, 2013). It has been suggested that mucoid forms of P.aeruginosa can 
form a bioﬁlm on host tissues and epithelial surfaces during chronic infections, particularly in 
the CF lung (Gellatly and Hancock, 2013) (Friedl et al., 1992) (Dötsch et al., 2012). Biofilms are 
a hallmark of P.aeruginosa chronic infection, and the incessant cycles of infection and 
inflammation experienced by patients with long term pulmonary colonisation by 
P.aeruginosa exemplifies most biofilm infections (Costerton et al., 1999).   
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Nasal carriage of the gram-positive S.aureus allows bacteria to disseminate to other parts of 
the body, where it is either removed by the immune system of the host, or attaches to 
extracellular matrix proteins of the host to form a multi-layered, heterogeneous biofilm 
(Archer et al., 2011). S.aureus infections possess the ability to rapidly develop multiple-
antibiotic resistance, and transform acute, transient infections into ones of a recurrent, 
chronic nature (Archer et al., 2011). 
Biofilm formation is a sequential process, involving several different phases (Figure 1.1). 
Initially, bacteria migrate towards a nutrient rich surface (Klausen et al., 2003). This is followed 
by the attachment phase; whereby motile and non-motile subpopulations of bacteria attach 
to the solid surface. This reversible interaction is mediated by van der Waals and electrostatic 
forces, and reinforced by host and tissue-specific adhesins, such as flagella and pili (Kaplan, 
2010). Maturation and clonal growth follows the attachment phase, where microcolonies 
differentiate into ‘true’ biofilms of EPS encased communities (Costerton et al., 1999). During 
this phase, the motile bacterial subpopulation spread out along the substratum and non-
motile bacteria form a microcolony (Bjarnsholt, 2013). Immobilised aggregates of bacteria 
begin to spontaneously secrete EPS, composed of nucleic acids, polysaccharide and 
macromolar components. This forms a matrix, which attracts motile bacteria and forms 
mushroom-like shaped structures (Bjarnsholt, 2013) (Klausen et al., 2003). The final stage of 
biofilm development is the detachment of sessile bacteria from the biofilm, and dispersal into 
the environment to colonise new areas (Kaplan, 2010) (Costerton et al., 1999). 








Figure 1. 1 The Process of Biofilm Formation 
 
Sessile bacteria present in biofilms are significantly less susceptible to antimicrobial agents 
than their planktonic (non-attached, free swimming) counterparts (Gellatly and Hancock, 
2013) (Archer et al., 2011), due to the heterogeneous subpopulations of bacteria contained 
within them (Stewart, 2002). Antibiotic therapy often alleviates the symptoms of pulmonary 
infection, yet fails to eradicate the infection within a biofilm community (Costerton et al., 
1999). One potential mechanism of biofilm resistance to antimicrobial agents is the inability 
of antimicrobials to penetrate the entire depth of the biofilm, with components of the matrix 
slowing down the diffusion rate of antibiotics and host defence molecules (Gellatly and 
Hancock, 2013) (Stewart, 2002) (Costerton et al., 1999). Furthermore, mature biofilms are 
highly heterogeneous; microenvironments established within the biofilm are exposed to 
different physiochemical characteristics, such as varying gradients in pH, O2, nutrients and 
waste material (Batoni et al., 2016) (Archer et al., 2011), where these factors may impact the 
activity of antimicrobial agents. Biofilm embedded bacteria possess many advantages over 
31 | Chapter I: Introduction 
 
planktonic bacteria, including the ability to evade multiple clearance mechanisms produced 
by the host and synthetic sources. Biofilm embedded bacteria are resistant to clearance 
strategies by antimicrobial agents, shear stress, host phagocytic elimination and host radical 
and protease defences (Archer et al., 2011). This has been demonstrated in the literature, 
whereby P.aeruginosa planktonic and young biofilm cells were susceptible to killing by 
Tobramycin and Piperacillin, resulting in total eradication. In contrast, older P.aeruginosa 
biofilm cells were reduced to approximately 20% of the total population and regrowth of the 
organism occurred following antibiotic therapy (Anwar et al., 1992). This demonstrates the 
reduced susceptibility of biofilm embedded bacteria to antimicrobial agents. 
Biofilm-associated infections result in chronic disease and the progression of a biofilm is now 
recognised as a major mediator in infection. The high intrinsic and inducible resistance of 
biofilms to antimicrobials contributes towards their resilience, and consequently, the 
prevention and management of biofilm- associated infections represents a serious 
therapeutic challenge (Nanvazadeh et al., 2013). In this context, experimental models could 
be established to investigate the potential anti-biofilm activity of antimicrobial agents, as the 
majority of research groups investigate this in vitro, which is perhaps not truly representative 
of the pathophysiological processes involved in biofilm formation in chronic disease. 
 
1.1.3 Staphylococcus aureus 
 
S.aureus is a non-motile, gram-positive coccus bacterium, that forms distinctive irregular 
grape-like clusters. S.aureus is a commensal bacterium, which grows on the skin and nasal 
mucus membrane, and in the human population, 20-25% have become persistently colonised 
(Archer et al., 2011). However, S.aureus is also a leading cause of infection in humans, causing 
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a wide array of diseases, ranging from minor skin and soft tissue infections, to the more life-
threatening, septicaemia, endocarditis, toxic shock syndrome and pneumonia (Diep et al., 
2006) (Hu, 2013). 
Methicillin was introduced to the clinic in 1959 to treat S.aureus infections (Stapleton and 
Taylor, 2007). Two years later however, in the United Kingdom, it was reported that isolates 
of S.aureus had acquired resistance to Methicillin (Enright et al., 2002). Methicillin-resistant 
Staphylococcus aureus (MRSA) is now one of the most common pathogens implicated in both 
hospital and community-acquired infections (Hu, 2013) (Enright et al., 2002) (Diep et al., 
2006); frequently associated with infections in health care facilities, sports facilities, clinics 
and the community, and in patients presenting to the intensive care unit (Green et al., 2012). 
Formerly, MRSA infections were acquired exclusively in hospitals. Prior exposure of patients 
to healthcare associated risk factors, such as previous antibiotic therapy, surgery, admission 
to an intensive care unit and exposure to an MRSA colonised patient, increased the likelihood 
of MRSA colonisation (Chambers, 2001). However, the prevalence of MRSA infections has 
dramatically increased due to the emergence of community-acquired strains of MRSA in 
healthy individuals (Diep et al., 2006). Colonisation of the lower respiratory tract by S.aureus 
and MRSA can occur in chronic pulmonary diseases, such as COPD (Defres et al., 2009), or due 
to breaches in natural defences, such as endotracheal intubation (Defres et al., 2009). The 
most commonly reported MRSA infections in patients include septic shock (56%), pneumonia 
(32%), endocarditis (19%), bacteraemia (10%) and cellulitis (1%) (Green et al., 2012), and 
these infections are now associated with significant increases in length of hospital stay, cost 
of treatment and mortality rate (Klevens et al., 2007) (Archer et al., 2011) (Green et al., 2012). 
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1.2 Antibiotic Resistance 
 
1.2.1 An Introduction to Antibiotic Resistance 
 
 
During the era of antibiotic discovery (1940-1960), more than 15 different classes of 
antibiotics were developed and produced (Hu et al., 2010) (Martens and Demain, 2017). 
These antibiotics typically target multiplying bacteria (Hu, 2007), yet are inefficient at killing 
non-multiplying bacteria or persister cells (Hu et al., 2010) (Martens and Demain, 2017) thus 
resulting in only the partial clearance of the total bacterial population (Figure 1.2). A more 
prolonged duration of antibiotic therapy is therefore often required to control bacterial 
infections, increasing the possibility of emergence of resistance (Hu et al., 2010). The reduced 
efficacy of current antibiotics in combination with a steady decline in the discovery of novel 
compounds (Martens and Demain, 2017) has exacerbated the emergence of antibiotic 
resistance. Inappropriate antibiotic use by humans is a significant driver of this problem, for 
example misuse and overuse of antibiotics, poor management of childhood and hospital-




















As a result of a significant increase in resistance, infectious disease is now the second leading 
cause of mortality in the world, with drug-resistant bacteria killing ~25,000 people per year in 
Europe (Martens and Demain, 2017). Some infections that were previously susceptible to 
antibiotics, such as Neisseria gonorrhoeae with penicillin, are now entirely resistant 
(Laxminarayan, 2014). This exemplifies the critical requirement for a novel approach towards 
antibiotic discovery and use, in addition to the conservation of current antimicrobials. 
Colistin remains the last line of defence against many gram-negative bacteria, due to their 
resistance to multiple antimicrobial agents. However, as a likely consequence of increased 
Colistin use, Colistin-resistant bacteria have now been reported (Giani et al., 2015). This 
research reports a large nosocomial outbreak of 93 bloodstream infections with Colistin-
resistant Klebsiella pneumoniae (K.pneumonaie). This clearly highlights the critical 
requirement for novel antimicrobial agents in the clinic, which show efficacy against multiple 
drug resistant bacteria.  
Figure adapted from: 
http://www.ukpharmsci.org/2012resourcepack/PDFPresentations/TCS1_1540_Prof_Anthony_Coates.pdf: 
Prof Anthony Coates, St George’s University of London, Antibiotic Discovery 
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1.2.2 Mechanisms of Antibiotic Resistance 
 
P.aeruginosa is a versatile and adaptable microorganism, able to evade the activity of 
antimicrobial agents. The emergence of mutator variants in chronic infections further 
increases its adaptability and development of resistance to antimicrobials (Cabot et al., 2016). 
P.aeruginosa exhibits the highest rates of resistance towards fluoroquinolones, with 
resistance to ciprofloxacin ranging from 33-34% of all isolates (Flamm et al., 2004), in 
comparison to Aminoglycoside and β-lactam antibiotics (Tobramycin: 12-16%, Ceftazidime: 
12-15%) (Flamm et al., 2004). Multidrug resistant strains of P.aeruginosa represent a more 
serious therapeutic challenge, displaying resistance to three or more classes of antibiotics 
(Flamm et al., 2004). Recent research has reported that 24.9% of P.aeruginosa strains, 
isolated from wounds, blood and respiratory tracts of patients, displayed multidrug resistance 
(Flamm et al., 2004), highlighting the ongoing concern for isolates exhibiting antimicrobial 
resistance. 
During the course of chronic pulmonary infection in patients with CF, P.aeruginosa strains 
develop mutants that differ both phenotypically and genotypically to the initial infecting 
strain (Bragonzi et al., 2009). The major resistance mechanism in chronic P.aeruginosa 
infections, such as CF, is the production of high levels of β-lactamase (Campbell et al., 1997) 
(Zaidenstein et al., 2018). β-lactamases are cephalosporinase enzymes, which are encoded by 
an inducible AmpC gene and are responsible for the metabolism of β-lactam antibiotics. In 
wild type P.aeruginosa strains, AmpC cephalosporinase is expressed at low levels, however 
the pathway is induced following exposure to β-lactam antibiotics (Cabot et al., 2016). 
Mutation to constitutive high level β-lactamase production occurs spontaneously and this 
mediates resistance to β-lactam antibiotics (Colom et al., 1995). The genetic events 
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underlying the overproduction of the enzyme in resistant clinical isolates have not been 
elucidated, however it is reported that the enhancement of β-lactamase levels may occur 
either through the acquisition of a secondary β-lactamase, amplification of the gene encoding 
the chromosomal β-lactamase or mutations in the regulatory genes that control the 
expression of the β-lactamase gene (Campbell et al., 1997) (Colom et al., 1995). 
The outer membrane of P.aeruginosa contains water filled protein channels, called porins 
(Bajaj et al., 2017). These channels play an important role in the transportation of nutrients, 
ions, vitamins and proteins through biological membranes (Bajaj et al., 2017) (Ochs et al., 
1999). Additionally, certain classes of hydrophilic antibiotics are transported across the 
membrane via porins, for example OprD is responsible for the transportation of carbapenems, 
including Imipenem (Ochs et al., 1999). Research has reported that two predominant types 
of imipenem-resistant mutants are observed in the clinic, both involving the porin channel, 
OrpD (Ochs et al., 1999). Firstly, OrpD-mediated resistance occurs as a result of deletions in 
the OrpD coding region and the upstream promoter region. Secondly, bacteria displaying 
multiple antibiotic resistance to both imipenem, quinolones and chloramphenicol show a 
marked reduction in the expression of OprD in the outer membrane (Ochs et al., 1999) (Cabot 
et al., 2016). A loss of function and inactivation of the membrane porin channels prevent 
antimicrobial agents from crossing bacterial membranes and further contribute to the 
complexity and concern about antimicrobial resistance. In addition to the production of 
inducible AmpC cephalosporinases and the reduced permeability of the outer membrane, 
P.aeruginosa expresses constitutive and inducible efflux pumps which further contribute to 
the genetic antibiotic resistance machinery of P.aeruginosa (Cabot et al., 2016). 
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Similarly, S.aureus has the ability to rapidly develop resistance towards antimicrobial agents 
through the acquisition of resistance genes or through chromosomally encoded resistance 
mechanisms. Methicillin is a β-lactam antibiotic, which acts by inhibiting penicillin-binding 
proteins (PBPs). β-lactam antibiotics function to inhibit the transpeptidation domain of PBPs, 
thus interfering with the cross-linking reaction. Without the cross-linking of peptidoglycan, 
the cell wall is weakened, resulting in leakage of the bacterial cell contents and cell death 
(Stapleton and Taylor, 2007). PBPs are involved in the synthesis of a mesh-like structure, 
called peptidoglycan, which is an essential component of the Staphylococcal cell wall. There 
are four native subtypes of PBPs in S.aureus, PB1, PB2, PB3 and PB4, which are essential for 
the growth and survival of the bacteria (Pereira et al., 2007). These PBPs have different 
molecular weights; with high molecular weight PBPs possessing two protein domains, one 
involved in transpeptidation and the other involved in transglycosylation (Stapleton and 
Taylor, 2007). Furthermore, these PBPs elicit different susceptibilities to antimicrobials, most 
likely a reflection of differential PBP affinity (Georgopapadakou and Liu., 1980). 
Resistance to Methicillin in S.aureus is, in part, conferred through the expression of a foreign 
PBP, called PBP2a, which is encoded by the mecA gene (García-Álvarez et al., 2011) (Pereira 
et al., 2007). Synthesis of PBP2a is regulated and usually expressed low at basal levels, 
however synthesis is enhanced if mutations occur in the regulatory genes (Stapleton and 
Taylor, 2007).  In contrast to the native PBPs, PBP2a shows an extremely low affinity for most 
β-lactam antibiotics, consequently PBP2a can take over the transpeptidase function of cell 
wall synthesis in the presence of therapeutic levels of methicillin, which would usually inhibit 
the function of other PBPs (Pereira et al., 2007) (García-Álvarez et al., 2011).  
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The emergence of mutant forms of P.aeruginosa and S.aureus, which display reduced 
susceptibility to antimicrobial agents and possess a wide array of resistance mechanisms, 
demonstrate that a novel approach for the discovery of antibiotics is critical to allow the 
continuation of the antibiotic era. 
 
1.2.3 Antibiotic Enhancer Compounds 
 
Within a bacterial population, both multiplying and non-multiplying bacteria co-exist (Hu et 
al., 2010). Antibiotics are typically developed to target the multiplying subpopulation of 
bacteria and all commercially available antibiotics currently work via this mode of action (Hu 
et al., 2010). However, these agents are either inactive or only partially active against non-
multiplying or slow multiplying bacteria (Belley et al., 2009). Consequently, this leads to the 
partial death of the total target population, requiring repeated doses of antibiotics and in 
turn, enhancing the emergence of resistance (Hu et al., 2010). Furthermore, in some cases, it 
is not feasible to significantly enhance doses of antibiotics as a result of their toxic side effects 
(Hu et al., 2010). 
One potential strategy for eradicating bacterial infection is by targeting the non-multiplying 
population of bacteria, thereby swiftly removing the total target bacterial population and in 
turn, shortening the duration of therapy. Shortening antibiotic treatment regimens has the 
added benefit of reducing side effects for patients, reducing cost of treatment and slowing 
the emergence of antibiotic resistance (Coates and Hu, 2008). Enhancer compounds have 
been developed as a strategy to provide improved treatments for infectious diseases, which 
act by restoring sensitivity of resistant bacteria to currently commercially available antibiotics. 
Furthermore, enhancer compounds target both multiplying and non-multiplying bacteria (Hu, 
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2013). Hu and colleagues have developed such a drug, the antibiotic enhancer, HT61, a small 
quinolone derived compound as an exemplar of this novel approach.  
The activity of HT61 was tested and compared to commercially available antibiotics, including 
Amoxicillin and Levofloxacin and it was demonstrated that HT61 as a singular treatment was 
more active against non-multiplying Methicillin-susceptible Staphylococcus aureus (MSSA), 
producing a 7 log CFU/ml reduction in bacteria, when compared to currently available 
antibiotics, which failed to exhibit any activities against non-multiplying bacteria (Hu et al., 
2010). Intriguingly, HT61 was less active against multiplying S.aureus, when compared to 
commercially available antibiotics, and despite showing activity against non-multiplying 
gram-positive bacteria, had no activity against gram-negative bacteria, including P.aeruginosa 
(Hu et al., 2010). 
With the aim of restoring sensitivity to drug resistant bacteria, experiments were performed 
using HT61 in combination with commercially available antibiotics. Intriguingly, time-kill 
analysis reported an enhancement of the activity of older generation antibiotics (gentamicin, 
neomycin and chlorhexidine) when used in combination with HT61 (Hu, 2013) against MRSA 
and MSSA, eradicating the total bacterial population by 2-8 hours.  
It was elucidated that the compound acts on the bacterial cell membrane, causing cell 
depolarisation and the release of the intracellular contents of the cell, leading to bacterial 
destruction (Hubbard et al., 2017). In addition, the cell wall structure was nicked in the 
presence of high concentrations of HT61 (Hu et al., 2010), allowing greater cellular access to 
the antibiotic. Furthermore, it is postulated that HT61 by disrupting the membrane, the 
membrane-embedded enzymes that are involved in anaerobic metabolism are disrupted. 
Therefore, non-multiplying bacteria are required to activate their anaerobic metabolic 
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pathways when they are oxygen deprived and consequently become susceptible to killing by 
compounds that poison the respiratory chain (Hu, 2013). It has been reported elsewhere in 
the literature that antimicrobial combinations that display in vitro synergistic effects may be 
more effective in eradicating infections in patients, for example against Tobramycin resistant 
strains of P.aeruginosa (Chan and Zabransky, 1987). These observations have also been 
supported by other studies, which have demonstrated the enhancement of the activity of 
Doxycycline with ianthelliformisamine derivatives against resistant gram-negative bacteria 
(Pieri et al., 2014). 
These studies highlight the potential beneficial effects of using combination treatments and 




1.3.1 Platelet Development and Production 
 
The platelet is an anucleated, specialised component of the blood, which primarily functions 
as a regulator of haemostasis in response to vascular injury. It is well documented that 
circulating platelets have a characteristic discoid shape under normal resting conditions  
(Hartwig et al., 2003) and an approximate size of 1-3 µm (Machlus and Italiano, 2013). 
Platelets are present at high concentrations in the human blood, typically ranging from 1.5- 
4.0 x 108 platelets/mL, and once released into the circulation, have a typical lifespan of 8-10 
days (Thon and Italiano, 2012). Whilst the precise mechanism remains unclear, platelets 
derive from the fragmentation of megakaryocytes and (Radley and Scurfield, 1980) were the 
first to postulate that long pro-platelet extensions from megakaryocytes were linked to the 
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production and release of platelets. In order to maintain adequate platelet levels, 
approximately 1011 platelets are replenished daily from megakaryocytes residing in the bone 
marrow (Hartwig et al., 2003). 
The development and production of platelets is a complex process and can be arbitrarily 
divided into two main phases (Hartwig et al., 2003) (Machlus and Italiano, 2013). The first 
phase occurs over a period of days and requires megakaryocyte specific growth factors 
(Hartwig et al., 2003). During this phase, the cytoplasm of the megakaryocytes becomes 
enlarged and is filled with cytoskeletal proteins and platelet specific granules (Thon and 
Italiano, 2012) (Machlus and Italiano, 2013). The second phase of platelet development is 
much more rapid and is completed within hours. During the second phase, it has been 
proposed that the cytoplasm of the megakaryocyte remodels itself into multiple long, 
branching extensions, termed pro-platelets (Richardson et al., 2005) (Hartwig et al., 2003). In 
this case, platelets form at the tip of the pro-platelet extensions, extruding outwards from the 
cell body of the megakaryocyte. Prior to the release of mature platelets into the circulation, 
nascent platelets must be packaged and assembled with platelet organelles and granules 
(Machlus and Italiano, 2013). Pro-platelets function as the assembly line of platelet 
production, with the shaft of the pro-platelet serving as a track to transport the organelles 
and granules from the regions of synthesis within the megakaryocyte to the pro-platelet 
(Thon and Italiano, 2012) (Machlus and Italiano, 2013). This transportation process is 
bidirectional, culminating at the end of the pro-platelet (Thon and Italiano, 2012), where the 
platelet organelles and granules can be assembled and packaged, thus completing platelet 
maturation prior to their subsequent release (Kosaki, 2005) (Leven and Yee, 1987) (Tablin et 
al., 1990). The process of megakaryopoiesis and platelet production occurs over a time period 
of approximately 5 days in humans (Machlus and Italiano, 2013), and intriguingly, a single 
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megakaryocyte can form 10-20 pro-platelet extensions (Machlus and Italiano, 2013) and give 
rise to 1,000-3,000 platelets (Thon and Italiano, 2012). 
It remains unclear as to where this process occurs as platelets have been shown to be 
produced from megakaryocytes within the pulmonary circulation (Trowrridge et al., 1982) 
(Martin et al., 1983), which is suggestive of the occurrence of thrombopoiesis in an additional 
organ asides from the bone marrow. Indeed, the formation of pro-platelets from 
megakaryocytes isolated from humans, mice and guinea pigs has been demonstrated in vitro 
(Cramer et al., 1997) (Leven and Yee., 1987) (Tablin et al., 1990) (Radley and Haller, 1983). 
Moreover, the release of platelets from pro-platelet tips has been demonstrated using 
intravital microscopy in mice (Junt et al., 2007) and pro-platelets extending into the sinusoidal 
blood vessels of bone marrow has been observed (Zhang et al., 2012). Asides from animal 
models, in the clinic it has been reported that platelet production from megakaryocytes can 
increase by as much as 20-fold under conditions of peripheral demand and inflammation 
(Bozza et al., 2009). Significant increases in pulmonary megakaryocytes have been detected 
in patients with acute lung injury, acute respiratory distress syndrome (ARDS) and in patients 
dying from burns, and in addition, platelet life span and platelet turnover rates are altered in 
these patients  (Mandal et al., 2007). 
The experimental and clinical evidence demonstrating enhanced platelet production and 
megakaryopoiesis in the lung is suggestive of a potential role for platelets as effector cells in 
a variety of pulmonary disorders (Weyrich and Zimmerman, 2013). 
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1.3.2 Platelet Ultrastructure 
 
Platelets have a complex structure, containing a number of distinguishable structural 
elements that allow them to function as regulators of haemostasis, angiogenesis and innate 
immunity. The plasma membrane of the platelet is composed of a phospholipid bilayer, 
comprising of cholesterol, glycolipids and glycoproteins, and further contains a plethora of 
densely packed receptors that are requisite in signaling and intracellular trafficking of the 
platelet (Thon and Italiano, 2012). In addition, the plasma membrane contains membrane 
foldings, which are the entrances to a system of internal membranes called the open 
canalicular system (OCS) (Hartwig, 2013) (Bearer et al., 2002). The OCS is a network of 
membrane channels that run throughout the platelet, which has several functions. The OCS 
allows for the selective entry of external elements into the platelet and serves as a conduit 
into which platelet granules fuse and release their contents (Hartwig, 2013). Studies have 
demonstrated that following platelet activation, degranulation occurs most often into the 
OCS, with granule contents subsequently released through pores into the extracellular space 
(Stenberg et al., 1984). Furthermore, the OCS may facilitate filopodia formation and cell 
spreading following platelet adhesion to an activating surface and acts as a storage site for 
plasma membrane glycoproteins (Thon and Italiano, 2012). The dense tubular system (DTS) 
of the platelet is a closed-channel network of residual endoplasmic reticulum, which is 
involved in calcium ion (Ca2+) sequestration (Bearer et al., 2002).  
Also contained within the platelet are a vast array of different organelles, including 
mitochondria, peroxisomes, lysosomes and granules, which contain a large number of 
biologically active molecules (Bearer et al. 2002). The mediators contained within platelet 
granules are implicated in the regulation of haemostasis, inflammation and infection, and are 
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requisite in determining platelet function following activation (Smyth et al., 2009). Platelet 
granular contents are listed in Table 1.1.  
Platelets contain three main types of granule within their cytoplasm, α-granules, dense (δ) 
granules and lysosomal (λ) granules. Previous published research has demonstrated that 
thrombin stimulation of platelets results in the release of preformed mediators from platelet 
α-granules (Stenberg et al., 1984), thus highlighting that platelet activation leads to granular 
release. Platelet α-granules are the largest (approximately 0.2-0.5 μm in diameter) and most 
abundant granule (50-80 per platelet) (King and Reed, 2002) (Yun et al., 2016). The α-granules 
contain mediators requisite in platelet adhesion during vascular repair and haemostatic 
functions. The α-granules store matrix adhesive proteins (fibrinogen, fibronectin, 
thrombospondin, vitronectin and von- Willebrand Factor (vWF)), and have glycoprotein (GP) 
and platelet adherence receptors embedded in their membranes (P-selectin, GPIb-IX-V, 
integrin αIIβ3), which promote adhesion between platelets and the matrix (Hartwig, 2013) 
(Thon and Italiano, 2012).  
In contrast to α-granules, platelets contain considerably less dense granules, with 
approximately 3-9 present in human platelets (King and Reed, 2002). Dense granules are 
approximately 0.15 μm in diameter and they function primarily to enhance platelet activation 
through the secretion of additional platelet agonists. Dense-granules contain a variety of 
haemostatically active molecules, including adenosine triphosphate (ATP), adenosine 
diphosphate (ADP), serotonin and Ca2+ (Hartwig, 2013) (Yun et al., 2016), which upon platelet 
activation promote aggregation. Furthermore, they contain a large array of chemokines, 
including Macrophage Inflammatory Protein-1α (MIP-1α) and Regulated on Activation, 
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Normal T Cell expressed and Secreted (RANTES), which can amplify platelet activation and 
induce platelet and leukocyte migration (Smyth et al., 2009). 
The third type of platelet secretory granules are lysosomal granules, which contain 
glycosidases, acid proteases, and cationic proteins, including collagenase and β-
glucuronidase, which may possess bactericidal activity and aid in pathogen clearance (Yun., 
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Table 1. 1 Platelet Granular Constituents 
 Adapted from (Smyth et al., 2009) (Yeaman, 1997) (Jenne et al., 2013) 
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The cytoskeleton defines the discoid shape of the resting platelet and maintains cell integrity, 
under the shear forces generated by the blood flow (Thon and Italiano, 2012). The 
cytoskeleton is composed of a spectrin-based skeleton, a microtubule coil and a network of 
cross-linked actin filaments and supports the OCS and platelet plasma membrane (Hartwig, 
2013) (Bearer et al., 2002). Under normal resting conditions, granules are located within close 
proximity to the OCS membranes. Upon platelet activation, the α and dense-granules may 
fuse with the plasma membrane and secrete their pre-formed mediators (Table 1.1) via the 
OCS, to be delivered precisely at the site of vascular injury (Thon and Italiano, 2012). This 
process enables platelets to play important roles in the functional modulation of leukocytes 
and other circulating platelets (Smyth et al., 2009).   
 
1.4 Mechanisms of Platelet Activation 
 
Under normal physiological conditions, circulating platelets must sustain the high fluid shear 
forces generated by the blood flow over the endothelium, without becoming prematurely 
activated. Platelet activation leading to aggregation is a well-defined role of platelets in the 
regulation of haemostasis, following injury to damaged endothelium (Brass, 2010). In this 
instance, platelets must recognise vascular injury, cease motion, adhere to the vessel wall and 
aggregate to one another to form a stable platelet plug (Brass, 2010). Additionally, over 
stimulation of platelet aggregation results in the formation of platelet thrombi (Andrews and 
Berndt, 2004). This occurs when diseases or drugs interfere with the mechanisms involved in 
unwarranted platelet activation, resulting in the accumulation of platelets where it is not 
required (Brass, 2010). 
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Conversely, platelets have also been shown to play an important role in the modulation of 
the inflammatory response (Hechler and Gachet, 2015) (Pitchford, 2007) (Semple and 
Freedman, 2010) (Amison et al., 2015) (Gresele et al., 1993) (Boilard et al., 2010). Platelets 
are thought to be implicated in various autoimmune, allergic and infectious diseases, 
including asthma, COPD, rheumatoid arthritis (RA) and sepsis (Pitchford et al., 2008) (Gawaz 
et al., 1995) (Gresele et al., 1993) (Johansson et al., 2011) (Bunescu et al, 2004)(Ferroni et al., 
2000). Interestingly, in regards to platelet activation in the context of inflammation, activation 
induced by inflammatory stimuli is not associated with subsequent platelet aggregation. 
Indeed, it has been demonstrated that in patients with asthma a mild haemostatic defect is 
seen (Kowalska et al., 2000) (Brown et al., 2013). 
Quiescent platelets express a plethora of cell surface receptors, including G-Protein Coupled 
Receptors (GPCRs) (Purine receptors, Thromboxane receptors, Thrombin receptors and 
Chemokines receptors) (Brass, 2010), Ionotropic receptors (P2X1), Toll-like receptors (TLR2, 
TLR4 and TLR9) (Clark et al., 2007) (Kerrigan and Cox, 2010) (Middleton et al., 2016), integrins 
(αIIbβ3), immunoglobulin receptors (FcεRI) and glycoprotein receptors (GPVI) (Walsh et al., 
2015). Furthermore, platelets express a wide array of adhesion molecules (P-selectin, P-
selectin glycoprotein ligand-1 (PSGL-1), CD40 and CD40L (Pitchford, 2007) (Yeaman, 2010) 
(Hechler and Gachet, 2015) (Mangin et al., 2004). Platelets can become activated by a number 
of inflammatory agents, such as bacteria, viruses and chemokines, as well as in response to 
endogenous agonists, such as ADP and thrombin. Stimulation of these receptors may result 
in different products of platelet activation, such as platelet granule secretion (Stenberg et al., 
1984), platelet chemotaxis (Czapiga et al., 2005) (Kraemer et al., 2010), leukocyte recruitment 
(Pitchford et al., 2003) and pathogen recognition (Ali et al., 2017). 
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Although there are some shared intracellular signalling cascades leading to platelet granule 
secretion, it is now recognised that there is a divergence in platelet function whereby platelet 
activation is distinct following activation with inﬂammatory stimuli in comparison to 
aggregatory stimuli (Maccia et al., 1977) (Thompson et al., 1984)(Amison et al., 2018). For 
example, the purinergic ligand, ADP can activate platelets by signalling through the purinergic 
P2Y1 receptor (Gachet, 2006) (Leon et al., 2008). This receptor is mediated via stimulation of 
Gαq, which induces PLC-β activation, catalysing the production of inositol-1,4,5-triphosphate 
(IP3) and Diacyl-glycerol (DAG). IP3 triggers Ca2+ mobilisation from intracellular stores, whilst 
DAG causes the activation of PKC. This initiates platelet shape change, granule release and 
transient aggregation (Mangin et al., 2004) (Amison et al., 2018) (Fabre et al., 1999).  
Similarly, activation of the CCR4 receptor by Macrophage derived Chemokine (MDC) and 
Thymus and Activation-Regulated Chemokine (TARC), and activation of the CXCR4 receptor 
by Stromal Derived Factor 1α (SDF-1α), is mediated by Gαq intracellular pathways and induces 
a transient intracellular rise in cytosolic Ca2+ in washed platelet preparations ( Abi-Younes et 
al., 2001) (Abi-Younes et al., 2000). However, whilst stimulation of the P2Y1 receptor with ADP 
induces transient platelet aggregation with a subthreshold dose of ADP (100nm) (Fabre et al., 
1999), co-activation with SDF-1α and MDC stimulates platelet chemotaxis (Kraemer et al., 
2010) (Amison et al., 2015). This therefore highlights that there are multiple mechanisms 
controlling platelet function, which dictates the type of the response (Walsh et al., 2015).  
Further evidence supports this divergence in platelet function, since platelet activation 
induced by inflammatory stimuli can be inhibited pharmacologically, without interfering with 
platelet aggregation (Amison et al., 2015). The rho family of GTP binding proteins, commonly 
known as Rho-GTPases (including RhoA, Rac1 and cdc42), are regulators of platelet function, 
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and are important in adhesion, activation and motility of leukocytes (Amison et al., 2018). 
Rho-GTPases are involved in the amplification of the intracellular signaling pathways 
following activation of platelet cell surface receptors (Aslan and McCarty, 2013), which in turn 
moderates platelet function. It is thought that RhoA contributes towards platelet shape 
change upon activation and has been implicated in the motility of leukocytes (Aslan and 
McCarty, 2013), however RhoA activity is insufficient for full platelet aggregation in response 
to ADP (Amison et al., 2018). Furthermore, it has been suggested that Rac1 controls platelet 
lamellipodia formation and plays a minor role in platelet aggregation (Qian et al., 2012), and 
Cdc42 is associated with platelet granule secretion (Aslan and McCarty, 2013).   
(Amison et al., 2018) showed differences in the signaling of P2Y1 receptors depending on the 
stimulation present, for example low doses of ADP (0.1µM) induced inflammatory effects 
through the small GTPase RhoA, but not through induction of the canonical pathway via PLC 
(Amison et al., 2018). Conversely, high doses of ADP (10µM) induced platelet aggregation 
(Amison et al., 2018). Other GTPases, such as Rac1 are requisite for leukocyte recruitment in 
lipopolysaccharide (LPS)-induced airway inflammation (Qian et al., 2012). As the P2Y1 specific 
agonist MRS2365 binds to the same site as ADP, albeit with a much lower affinity, it is possible 
that this difference in effect on platelet function through P2Y1 is a result of biased agonism 
(Amison et al., 2018) (Amison et al., 2015). 
However, despite these specific functions of Rho-GTPases and the canonical pathway in 
platelet activation, it is now thought that there is a cross-talk amongst integrins, GPCRs and 
Rho proteins to modulate platelet function in cytoskeletal regulation, aggregation, secretion, 
thrombus formation and other cellular processes (Aslan and McCarty, 2013). 
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Platelets undergo dynamic morphological alterations upon exposure to biological stimuli or 
agonists, changing from a resting discoid shape into more rounded structures. Platelet shape 
change occurs following exposure to sub-threshold concentrations of platelet agonists, which 
cannot result in either aggregation or adhesion (Shin et al., 2017). Under normal resting 
physiological conditions, the discoid shape of the platelet is maintained through inhibition of 
actin polymerisation and sequestration of actin monomers by monomer binding proteins, 
such as profilin and thymosin-β4 (Hartwig, 1992) (Bearer et al., 2002). Platelet shape change 
occurs via reorganisation of actin filaments within the cytoskeleton. Firstly, platelets become 
rounded as actin filaments are fragmented, and spectrin networks composed of filamin A, 
Gp1b/IX and spectrin are released (Paul et al., 1999) (Shin et al., 2017) (Hartwig, 1992). The 
membranes of the platelets then protrude outwards, forming lamellipodia and filopodia, 
resulting from actin filament assembly (Winokur and Hartwig, 1995). As previously described, 
platelet activation leading to shape change is mediated via a Gαq dependent mechanism 
(Zheng et al., 2015) (Paul et al., 1999) (Gachet, 2006)(Lapetina and Siegel, 1983) (Figure 1.3). 
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Figure 1. 3 Induction of Platelet Shape Change and Granule Secretion via Gαq Coupled 
Receptors 
 
Breakdown of the cytoskeleton maintaining the discoid shape under resting conditions is 
regulated by Gelsolin and Cofilin (Hartwig, 1992) (Li et al., 2002) (Winokur and Hartwig, 1995) 
(Bearer, 1991). These are actin binding proteins that severe and cap actin filaments in the 
presence of Ca2+, and subsequently release actin monomers (Shin et al., 2017). This unlocks 
the membrane cytoskeleton and allows deformation of the membrane, allowing the 
production of new structures within the platelet (Shin et al., 2017). The actin monomers can 
then bind to Arp2/3 complex (actin related protein 2/3) stimulating actin assembly (Li et al., 
2002). In addition, actin sequestering proteins, profilin and thymosin-β4, carry actin 
monomers to the barbed end of filopodia enabling filament elongation. CapZ then recaps the 
barbed filament ends to complete assembly (Bearer, 1991). This newly formed actin 
cytoskeleton results in the final activated platelet shape- round, small structures with long, 
thin filopodia extending outwards from the platelet (Hartwig, 1992). 
Gαq coupled 
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Platelet shape change is one of the first measurable physiological responses following platelet 
activation (Lapetina and Siegel, 1983). Although, for continued platelet activation a vast 
number of signalling and adhesion molecules (Table 1.1) are released from the platelet 
granules (Smyth et al., 2009). Platelet activation results in the release of contents from dense 
granules via exocytosis. Dense granules store an array of haemostatically activate mediators, 
such as ADP, ATP and Ca2+ (King and Reed, 2002) (Jenne et al., 2013). Additional mediators are 
released from platelet dense granules, such as serotonin, which has been shown to play an 
important role in neutrophil rolling and adhesion (Duerschmied et al., 2013). 
Previous studies have demonstrated the redistribution of platelet α-granule contents 
(Fibrinogen, Platelet Factor 4) following platelet stimulation with thrombin (Stenberg et al., 
1984), demonstrating platelet α-granules release upon activation. Platelet activation inducing 
granular release is mediated through stimulation of Gαq receptors (Figure 1.3) (Gachet, 
2006). These mediators play a significant role in innate immunity, either by modulating the 
expression of platelet adhesion receptors interacting with leukocytes, or by releasing 
cytokines that affect leukocyte function (Yun et al., 2016). Platelet factor-4 (PF-4) is one of the 
most abundant proteins within α-granules and has a broad range of activities linked to innate 
immunity, such as promoting phagocytosis, respiratory burst and the secretion of cytokines 
(Kasper et al., 2007). RANTES is also found in large quantities in platelet α-granules and 
mediates monocyte recruitment (Von Hundelshausen et al., 2005). Platelets express P-
selectin, which is rapidly mobilised to the platelet surface upon activation and has a requisite 
role in the interactions between platelets, leukocytes and endothelial cells via its counter 
ligand PSGL-1 (Frenette et al., 2000). P-selectin/PSGL-1 interactions are critical mediators in 
the formation of platelet-leukocyte complexes, allowing tethering and rolling along the 
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endothelium and the subsequent recruitment of platelet-leukocyte complexes (Pitchford et 
al., 2003). 
Furthermore, platelets have been identified as the single largest source of CD40L, which 
interacts with CD40 located on neutrophils (Pitchford et al., 2017). The engagement of CD40L 
with CD40 induces a pro-inflammatory phenotype, characterised by the release of pro-
inflammatory cytokines and an increased expression of adhesion molecules (intercellular 
adhesion molecule-2 (ICAM-2), and vascular cell adhesion molecule-1 (VCAM-1)) (Vowinkel 
et al., 2007) (Danese et al., 2004). 
Platelet shape change and the secretion of mediators from platelet granules contributes to 
activation pathways and allows platelets to function as regulators of haemostasis, thrombosis 
and innate immunity.  
 
1.5 A Proposed Divergence in Platelet Function 
 
1.5.1 The Role of Platelets in Haemostasis and Thrombosis 
 
Platelets have a well-established role in haemostasis and platelet activity is primarily 
associated with the initiation of platelet activation and aggregation in response to vascular 
injury. The basic function of platelets is to bind to endothelial cells of damaged blood vessels, 
aggregate to form a stable platelet plug and prevent excessive bleeding. Similarly, the role of 
platelets in thrombosis has been well established. Thrombosis is considered to be a 
pathological process, where clot formation results from inappropriately triggered or 
dysregulated haemostasis (Kuijpers et al., 2004) (Middleton et al., 2016). In this instance, 
activated platelets aggregate at the site of the atherosclerotic plaque or endothelial cell 
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erosion, stimulating thrombus formation and promoting atherothrombotic disease (Yun et 
al., 2016) 
The haemostatic response can be characterised by three distinct phases, initiation, extension 
and stabilisation (Brass, 2010). During the initiation phase, platelets are activated by collagen 
or thrombin and adhere to the damaged vessel wall (Brass, 2010) (Kuijpers et al., 2004). 
Platelets bind to collagen fibres, which forms a complex with vWF. This complex subsequently 
interacts with exposed GPIbα on the surface of circulating platelets (Tsuji et al., 1997). The 
interaction of platelets and collagen fibres, mediated by vWF, slows platelet progression 
along the vessel and triggers inside-out activation of the integrin αIIbβ3 (Kuijpers et al., 2004). 
Platelet activation also results in the secretion of thromboxane A2 (TXA2) and ADP from dense 
granules, alongside increased expression of adhesion molecules, including P-selectin and 
PSGL-1 (Li et al., 2010).  This creates a monolayer of activated platelets along the damaged 
endothelium (Rivera et al., 2009).  
During the secondary extension phase, circulating platelets adhere to this platelet monolayer 
resulting in their activation and the further release of platelet agonists, Thrombin, ADP and 
TXA2. These all activate PLCβ via Gq resulting in an increase in cytosolic levels of Ca2+ (Li et al., 
2010) (Brass, 2010). This activates integrin αIIbβ3 via inside-out signalling, which enables 
interaction with fibrinogen and the formation of cohesive interactions between adjacent 
platelets. (Rivera et al., 2009) (Brass, 2010). Interactions between adjacent platelets and 
platelets with the endothelium are then strengthened via interactions between 
fibrinogen/fibrin or vWF with αIIbβ3, GPVI or GPIb-IX-V (Andrews and Berndt, 2004) (Li et al., 
2010). 
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The third stabilisation phase is characterised by activated platelets within the plug coming 
into close contact with one another to form a cross-linked fibrin network, preventing 
premature platelet disaggregation. This enables paracrine signalling of platelet molecules and 
occurs through outside-in signalling, predominantly mediated by integrin αIIbβ3 (Rivera et al., 
2009). This results in the formation of a haemostatic plug composed of activated platelets 
embedded within a cross-linked fibrin mesh, stable enough to withstand the shear forces 
generated by the flow of blood (Brass, 2010). 
 
1.5.2 The Role of Platelets in Inflammation 
 
1.5.2.1 The Role of Platelets in Inflammatory Disorders 
 
In addition to their roles in haemostasis and thrombosis, platelets have been described as 
important mediators in inflammatory disorders. Evidence now suggests that platelets are 
potent and versatile immune and inflammatory effector cells, with the ability to perform 
recognition and signaling functions, transfer biologic information and orchestrate complex 
physiological and pathological inflammatory responses (Middleton et al., 2016) (Middleton et 
al., 2018). Platelets have been implicated in several pro-inflammatory disorders, including 
asthma, COPD, irritable bowel disease (IBD), RA, ARDS and acute lung injury (ALI) (Pitchford 
et al., 2003) (Joseph et al., 2001) (Bunescu et al, 2004) (Gresele et al., 1993) (Vowinkel et al., 
2007) (Ortiz-Muñoz et al., 2014) (Lax et al., 2017).  
Platelets contribute to inflammatory disorders via several mechanisms. Firstly, platelets have 
been reported to directly migrate to the site of inflammation (Pitchford et al., 2003)  
(Pitchford et al., 2005), where they release pro-inflammatory mediators from their granules 
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(Table 1.1), contributing to chronic inflammatory events inducing tissue remodelling and 
altering tissue architecture (Pitchford et al., 2004) (Idzko et al, 2015). Secondly, platelets can 
directly interact with inflammatory leukocytes, ‘priming’ them for efficient migration to the 
site of inflammation. Therefore, platelets are critical links between the innate and adaptive 
immune system (Pitchford, 2007) (Middleton et al., 2016) (Bozza et al., 2009) (Semple and 
Freedman, 2010) (Langer and Chavakis, 2009) (Amison et al., 2012). 
Evidence has suggested an alteration in platelet function and character in the clinic in patients 
with allergic inflammatory diseases, including asthma, allergic rhinitis and atopic dermatitis 
(Pitchford., 2007), as measured by alterations in platelet secretion, expression of surface 
molecules, aggregation and adhesion to the endothelium (Idzko et al., 2015). In addition, 
elevated levels of platelet-derived activation markers have been detected in patients with 
asthma following allergen provocation, with increased levels of Beta-Thromboglobulin (β-TG), 
PF-4, RANTES, platelet activating factor (PAF) and P-selectin (Pitchford., 2007) (O’Sullivan et 
al., 2005) (Idzko et al., 2015). Moreover, patients with atopic asthma have also been reported 
to have a shorter platelet lifespan in the circulation (4.7 days), when compared to healthy 
individuals (8.9 days) (Taytard et al., 1986), suggestive of continuous platelet activation in this 
disease. This clearly highlights a role for platelets in the modulation of inflammatory 
disorders, which is distinct from haemostasis and thrombosis. 
 
1.5.2.1 Pulmonary Platelet Recruitment 
 
 
Platelets were previously regarded as static cells that do no move once they adhere to a 
matrix (Kraemer et al., 2010). However, once recruited from the circulation platelets possess 
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all of the molecular assets required for cell migration  (Gaertner et al., 2017). More recently, 
platelet migration towards both allergic and bacterial stimuli has been demonstrated in vitro, 
towards N-formyl-methionyl-leucyl-phenylalanine (fMLP) (Czapiga et al., 2005), LPS (Ortiz-
Muñoz et al., 2014), SDF-1α (Kraemer et al., 2010) and MDC (Kowalska et al., 2000). This 
highlights that platelets are indeed motile cells and suggests that platelet migration may be 
modulated by mediators involved in inflammation and infection. Through the use of 
experimental models, platelets have been found in extravascular lung tissue of allergic mice, 
mediated by an IgE/FcεRI-dependent mechanism (Idzko et al., 2015) (Pitchford et al., 2008). 
Similarly, intratracheal LPS administration has been shown to induce pulmonary platelet 
sequestration (Ortiz-Muñoz et al., 2014) and platelet recruitment into lung alveoli (Lax et al., 
2017). This is consistent with findings in the clinic, whereby platelets obtained from allergic 
donors have demonstrated migration in vitro when exposed to the allergen to which the 
patient was sensitised (Idzko et al., 2015). Similarly in other inflammatory diseases, platelets 
have been found extravascularly in the synovial fluid of patients with arthritis (Boilard et al., 
2010) and in ischemia and reperfusion (Kraemer et al., 2010) (Rainger et al., 2015). This 
evidence therefore suggests that mediators involved in inflammation and infection may be 
capable of inducing platelet activation and migration. 
Once recruited to inflamed tissue, platelets participate in the innate immune response and 
contribute directly to tissue remodeling in chronic inflammation. Studies have implicated a 
direct role for platelets in airway remodelling and chronic inflammation, by the release of 
platelet-derived mediators, including growth factors (transforming growth factor b (TGFB), 
vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF)) and 
matrix metalloproteinases (MMP1, MMP2, MMP3 and MMP14) (Pitchford et al., 2004). This 
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platelet activation has been shown to persist long after the initial allergen challenge, 
suggesting a potential role for platelets in chronic airway remodeling associated with 
asthmatic patients (Kowal et al., 2006). Similarly, increased platelet activation has been 
shown to correlate with changes in lung architecture, as measured by basement membrane 
thickening, myofibroblast proliferation and bronchial smooth muscle growth (Pitchford, 
2007). This is further demonstrated in studies where platelet depletion in a mouse model of 
allergic inflammation decreased epithelial thickening, smooth muscle thickening, and sub-
epithelial reticular fiber deposition (Pitchford et al., 2004). 
 
1.5.2.2 The Role of Platelets in Inflammatory Leukocyte Recruitment 
 
In addition to platelet recruitment alone, research suggests that platelets can influence 
leukocyte recruitment towards both allergic and infectious stimuli (Page and Pitchford, 2013) 
(Pitchford et al., 2017) (Kornerup et al., 2010) (Ortiz-Muñoz et al., 2014) (Lax et al., 2017). 
Activated platelets displaying adhesion molecules (CD40L, P-selectin) are able to interact with 
counter ligands expressed on leukocytes (CD40, PSGL-1) within the circulation, forming 
platelet-leukocyte complexes (Langer and Chavakis, 2009) (Page and Pitchford, 2013). These 
complexes are important for subsequent leukocyte activation, tethering, rolling and 
migration into inflamed tissue  (Kornerup et al., 2010) (Wang et al., 2007) (Lukacs et al., 2002) 
(Pitchford et al., 2005). The heightened occurrence of platelet-leukocyte complexes in 
circulating blood has been reported in a vast array of inflammatory, infectious and 
autoimmune diseases, including asthma, COPD, RA, bacteremia and sepsis (Ferroni et al., 
2000) (Gresele et al., 1993) (Pitchford et al., 2003)(Pitchford et al., 2005) (Johansson et al., 
2011) (Gawaz et al., 1995) (Russwurm et al., 2002) (Bunescu et al., 2004). The formation of 
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platelet-leukocyte complexes as seen in the clinic has also been replicated in numerous 
animal models of acute inflammation (Lukacs et al., 2002) (Pitchford et al., 2003) (Pitchford 
et al., 2005) (Tamagawa-Mineoka et al., 2009) (Bins et al., 2014) (Pan et al., 2015) (Amison et 
al., 2015), underpinning a role for platelets in leukocyte recruitment. 
The importance of platelets in the recruitment of leukocytes in the acute inflammatory 
response has been demonstrated previously in literature (Kornerup et al. 2010) (Pitchford et 
al., 2003)(Pan et al., 2015) (Amison et al., 2017) (Coyle et al., 1990). For example, recent 
observations have indicated that platelet depletion results in the abolition of allergen induced 
eosinophilia (Pitchford et al., 2003) (Amison et al., 2015), and platelet activity is important for 
LPS-induced neutrophil recruitment (Pan et al., 2015) (Riffo-Vasquez et al., 2016) (Amison et 
al., 2017). This further demonstrates platelet-facilitated leukocyte accumulation. 
P-selectin is a glycoprotein expressed by platelets, which is rapidly translocated from platelet 
α-granules to the plasma membrane of the platelet upon platelet activation (Mauler et al., 
2016). Here, P-selectin recognises its counter ligand PSGL-1, expressed on the surface of 
polymononuclear cells (PMC), initiating the interaction between platelets and leukocytes and 
increasing circulating platelet-leukocyte complexes (Joseph et al., 2001) (Kornerup et al., 
2010) (Pitchford et al., 2003) (Jawien et al., 2002). These interactions support contact-
dependent activation of leukocytes and subsequent activation of integrins (αMβ2 and α4β1) 
(Johansson and Mosher, 2013). This leads to increased adhesion of leukocytes to the vascular 
endothelium and facilitates the extravasation of leukocytes into inflamed tissue (Jawien et al. 
2002). 
Indeed, the importance of P-selectin in mediating leukocyte recruitment has been 
demonstrated experimentally using both P-selectin knockout mice and P-selectin blocking 
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agents (de Stoppelaar et al., 2015) (Mauler et al., 2016), which demonstrate platelet 
dependence of leukocyte rolling, intravascular crawling  and diapedesis in vivo (Langer and 
Chavakis, 2009) (Wang et al., 2007). This has been further confirmed through reinfusion of 
thrombocytopenic mice with platelets treated with the P-selectin blocking antibody RB40.34 
(Pitchford et al., 2005). When treated platelets were reinfused, allergen induced eosinophilia 
remained suppressed unlike vehicle treated platelets. 
P-selectin-PSGL-1 interactions tether leukocytes to the endothelium from rapidly flowing 
blood. The sequential formation and dissolution of these interactions enables the subsequent 
rolling of platelet-leukocyte complexes along the endothelium (Alon et al., 1996) This process 
does not require leukocyte activation and is mediated by endothelial derived selectins (P-
selectin, E-selectin and L-selectin). The importance of leukocyte rolling in the recruitment of 
leukocytes is highlighted by a rare congenital disorder called leukocyte adhesion deficiency II 
(LAD II), where patients cannot produce functional selectin ligands and consequently display 
defects in neutrophil rolling and recruitment, leading to severe recurrent bacterial infections 
(Langer and Chavakis, 2009).  
Whilst it is important to note that P-selectin-PSGL-1 interactions are important in leukocyte 
adhesion and recruitment to inflamed tissue, other molecules are implicated. The mediators 
involved are dependent upon both the cell types involved and the mediators expressed and 
released on the platelet surface. It has been reported that activated platelets are a rich source 
of soluble CD40L (Vowinkel et al., 2007) (Vanichakarn et al., 2008), which has been shown to 
interact with its receptor CD40 expressed on neutrophils (Vanichakarn et al., 2008). Studies 
have demonstrated that the engagement of CD40L with its receptor stimulates the release of 
pro inflammatory cytokines, chemokines and the increased expression of adhesion 
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molecules, including selectins and ICAM-2 (Vowinkel et al., 2007). This increased expression 
of adhesion molecules amplifies the signals involved in the recruitment of leukocytes to 
inflamed tissue and may contribute to the perpetuation of the inflammatory response. The 
importance of CD40-CD40L interactions has been highlighted in the literature, which 
described an attenuated recruitment of leukocytes and platelets in CD40 or CD40L knockout 
mice in a model of acute inflammation (Vowinkel et al., 2007). 
Contact dependent activation, in addition to activation of leukocytes by chemokines secreted 
from the inflamed tissue, leads to inside-out integrin activation of leukocytes (Johansson and 
Mosher, 2013). Integrin adhesion molecules and their counter ligands (ICAM-2/ Lymphocyte 
function-associated antigen 1 (LFA1) (Diacovo et al., 1994) (Kuijper et al., 1998), Very Late 
Antigen 4 (VLA4)/ VCAM-1, α4β7/ mucosal vascular addressin cell adhesion molecule 1 
(MAdCAM 1) and junctional adhesion molecules (JAM 1-3)) (Chavakis et al., 2004) (Woodfin 
et al., 2007) provide firm adhesion to the endothelium and support paracellular and 
transcellular diapedesis of platelet-leukocyte complexes to inflamed tissue. Further 
important adhesion molecules involved in leukocyte recruitment include the platelet-
endothelial cell adhesion molecule-1 (PECAM-1) (Berman and Muller, 1995) (Woodfin et al., 
2007) and endothelial cell adhesion molecule (ESAM) (Figure 1.4).  Intriguingly, the 
involvement of these interactions in mediating leukocyte recruitment has been demonstrated 
using antagonists, which was reported to significantly attenuate neutrophil recruitment into 
inflamed tissue (Chavakis et al., 2004). 
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1.5.3 The Role of Platelets in Infection 
 
1.5.3.1 The Inflammatory Response to Bacterial Infection 
 
The innate immune system and its primary cellular components, including macrophages, 
neutrophils, natural killer (NK) and dendritic cells (Figure 1.5), play a pivotal role in the 
activation of the inﬂammatory response to infection. Pulmonary bacterial infections, 
including CF, are characterised by chronic airway inflammation and consequently patients 
present to the clinic with diminished lung function (Pillarisetti et al., 2011) (Cigana et al., 
2018).  
Innate immune mechanisms detect bacterial infections through their characteristic pathogen 
associated molecular mechanisms (PAMPs), which triggers the appropriate response against 
that particular infection (Kurup and Tarleton, 2013). PAMPs are usually components of the 
bacterial cell wall, including LPS (gram-negative), lipopeptides (gram-positive), peptidoglycan, 
flagellin and bacterial DNA (Elson and Daubeuf, 2007). PAMPs are recognised by complement, 
and the complement components C3b and iC3b (Frank and Fries, 1991) (Gaboriaud et al., 
2003) subsequently label the particles in a process termed opsonisation. Phagocytes are then 
able to recognise opsonised bacterial components by the expression of complement (C1q and 
C3) and Fc receptors  (Frank and Fries, 1991) (Van Amersfoort et al., 2003). In addition, 
phagocytes express pattern recognition receptors (PRRs) (TLRs, NOD-like receptors (NLRs), 
RIG-1 like receptors (RLRs), C type lectin receptors (CLRs)) on their cell surface, which enables 
the recognition and phagocytosis of opsonised bacteria. The bacterial epitopes may then be 
presented on the cell surface via MHC class II to initiate the adaptive immune response. 
Pathogens or immunogenic particles initiate the release of an array of pro-inflammatory 
mediators from macrophages, including tumour necrosis factor (TNF-α), interleukin (IL) 1β 
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and IL-6, and induce vascular and physiological changes (Kawakami et al., 1983) (Broug-Holub 
et al., 1997) (Huang et al., 2008) (Bhakdi et al., 1991). Neutrophils respond to these 
inflammatory stimuli by intravascular aggregation, adhering to the endothelium and 
migrating towards the inflammatory source (Bray et al., 1981) (Schiffmann et al., 1975) 
(Gaertner et al., 2017). Neutrophils further augment the inflammatory cascade by the 
production of additional inflammatory mediators, including leukotriene-β4, PAF and TNFα 
(Camussi and Tetta, 1989). Once activated, neutrophils express CD14, CD11/CD18, 
complement and Fc receptors, enabling phagocytosis of either bacterial fragments or whole 
bacteria (Van Amersfoort et al., 2003) (Gaertner et al., 2017).  
Neutrophils produce and secrete microbicidal agents from internal granules, including oxygen 
free radicals and lysozyme, which facilitate their role in host defence (Chatham and Blackburn, 
1993). In addition to their more traditional role in phagocytosis, activation of neutrophils 
causes the release of dense web-like structures of DNA, called neutrophil extracellular traps 
(NETs). These NETs contain proteolytic activity that can trap and destroy invading 
microorganisms (Caudrillier et al., 2012) (Clark et al., 2007) (McDonald et al., 2012). 
The innate immune response leads to the activation of the acquired immune system. It is 
reported that IL-12 is a key modulator of immune function (Wolf et al., 1994). Antigen 
presenting cells present bacterial epitopes to naive T-cells, resulting in the activation of T-cells 
and the differentiation of naïve T-cells into Th1 cells (Figure 1.5). This leads to the production 
of pro-inflammatory cytokines, including interferon gamma (IFN-γ) (Wolf et al., 1994) (Cooper 
et al., 1995) (O’Sullivan et al., 1995), which promotes cell mediated immunity directed 
towards intracellular pathogens (Wurster et al., 2002). Exposure to allergen induces IL-4 
production and causes activation of the transcription factor STAT6, which promotes Th2 cell 
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differentiation (Kaplan et al., 1996) (Figure 1.5). Th2 cells produce IL-4, IL-5 and IL-13, which 
activate mast cells and eosinophils (Wurster et al., 2002) to mediate allergic reactions, asthma 
and anti-parasitic infections. A summary of the innate and acquired immune responses to 
bacterial infection is shown in Figure 1.5. 
 
 
Figure 1. 5 The Innate and Acquired Immune Responses to Infection 
 
(Sherwood and Toliver-Kinsky, 2004) 
 
 
1.5.3.2 Platelet Activation and Thrombocytopenia in Infectious Diseases 
 
Asides from their well-established role in haemostasis, recently a role for platelets in the 
regulation of the immune response has become increasingly more apparent. Platelets are the 
first and most abundant inflammatory cell type recruited in response to injury or infection 
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(Kerrigan, 2015) (Gaertner et al., 2017). Furthermore, platelets interact with various 
inflammatory cells and regulate adhesion and extravasation (Pitchford et al., 2003) (Smyth et 
al., 2009) (Hurley et al., 2016) (Ortiz-Muñoz et al., 2014) (Kornerup et al., 2010) (Amison et 
al., 2017), suggesting a role for platelets in orchestrating the immune response to infection. 
The involvement of platelets in the regulation of the immune response to infection was 
initially identified in 1901, whereby platelets were observed to ‘clump’ in response to Vibrio 
cholerae in rabbits (Levaditi, 1901). This has since been validated in the clinic, whereby 
increases in the expression of platelet activation markers in patients with numerous infectious 
diseases has been documented (Gawaz et al., 1995) (Gawaz et al., 1997) (Ogura et al., 2001) 
(O’Sullivan et al., 2005) (Papapanagiotou et al., 2009). It has been demonstrated that CF 
patients have increased circulating activated platelets when compared to healthy individuals, 
as determined by increases in platelet-monocyte and platelet-neutrophil complexes, and 
platelet P-selectin surface expression, (O’Sullivan et al., 2005). Similarly, platelet activation 
has been detected in patients presenting to the clinic with sepsis (Gawaz et al., 1995) (Gawaz 
et al., 1997) (Ogura et al., 2001). In these patients, circulating platelet-neutrophil complexes 
are increased in early stage sepsis, yet decrease following multiple organ dysfunction, 
suggesting the platelet-neutrophil complexes migrate towards the damaged organs 
(Russwurm et al., 2002) (Peters et al., 2003) (Gawaz et al., 1997). This finding is consistent in 
animal models of bacterial induced sepsis, indicating that platelet-neutrophil complexes 
decrease during late stage sepsis (Hurley et al., 2016). Similarly in other bacterial infections, 
including periodontitis, platelet activation has been shown to correlate with the severity of 
disease  (Papapanagiotou et al., 2009).  
68 | Chapter I: Introduction 
 
Indeed, the finding of platelet activation in response to bacterial infection  has been replicated 
in numerous experimental models of pulmonary infection, as measured by increases in 
platelet granular secretion and platelet-neutrophil complex formation  (Youssefian et al., 
2002) (Hurley et al., 2016) (Gawaz et al., 1995) (Ogura et al., 2001) (de Stoppelaar, 2014)(de 
Stoppelaar et al., 2015). Gram-positive species of bacteria (S.aureus and Streptococcus 
pyogenes (S.pyogenes)) have been shown to induce platelet activation, as measured by 
elevated P-selectin surface expression and fibrinogen release (Youssefian et al., 2002), in 
addition to increased platelet-neutrophil complex formation and the accumulation of platelet 
aggregates (Hurley et al., 2016). Similarly, gram-negative species of bacteria have been shown 
to induce platelet activation in a model of gram-negative pneumonia derived sepsis, whereby 
K.pneumoniae induced PF-4 secretion from platelet granules (de Stoppelaar, 2014). These 
findings clearly suggest a role for platelets in response to bacterial infection. 
Thrombocytopenia is a common finding in patients admitted to the intensive care unit with 
sepsis (de Stoppelaar, 2014) (Shannon, 2015) (Greco et al., 2017) and this is associated with 
a poor prognosis and worsened outcome (Xiang et al., 2013) (Yeaman, 2014) (Claushuis et al., 
2016). Studies have reported that the level of thrombocytopenia correlates to illness severity. 
For example, findings by (Hui et al., 2011) have demonstrated that the occurrence of 
thrombocytopenia during critical illness appeared to increase the risk of death and was often 
correlated to sepsis and organ dysfunction in patients admitted to the intense care unit. 
Furthermore, additional studies have demonstrated that patients with thrombocytopenia 
presented more commonly with severe sepsis and 30-day mortality was significantly elevated 
(Gafter-Gvili et al., 2011). Other studies have suggested that thrombocytopenia can also be 
used as an independent predictor of organ damage and mortality in critically ill patients 
(Hurley et al, 2016). 
69 | Chapter I: Introduction 
 
There are several proposed mechanisms to elucidate infection induced thrombocytopenia. 
Firstly, bacteria induces platelet activation and activated platelets have shown shortened 
survival (4.7 days) in comparison to platelets from healthy individuals (8.9 days) (Taytard et 
al., 1986) in atopic asthma. Furthermore, platelet activation induced by interactions with 
bacteria causes platelet granular secretion, irreversible platelet aggregation (Youssefian et al., 
2002) (Clawson and White, 1971) and increased platelet accumulation at the site of infection 
(Hurley et al., 2016) (Kerrigan and Cox, 2010) (Yeaman, 2014). Reports have suggested that 
bacterial components, such as peptidoglycan and their secreted toxins can induce platelet 
apoptosis and cytotoxic effects (Kraemer et al., 2012), further contributing to the observed 
thrombocytopenia during bacterial infection. Other plausible mechanisms which induce 
thrombocytopenia during infection are the enhancement of platelet phagocytosis by 
macrophages (Guo et al., 2009) and the sequestration of platelets in the spleen (Aster, 1966). 
Animal models of experimentally induced thrombocytopenia have been developed to further 
investigate the protective role of platelets in host defence against infection. In these models, 
experimentally induced thrombocytopenia has been associated with worsened infection in 
rabbits and mice, as measured by enhanced mortality and bacterial load and the exacerbation 
of sepsis and organ failure (Sullam et al., 1993) (Xiang et al., 2013) (de Stoppelaar, 2014)(van 
den Boogaard et al., 2015) (Ali et al., 2017). The depletion of circulating platelets has been 
shown to dramatically impair host defence against infection, increasing mortality in LPS 
induced endotoxemia (Xiang et al., 2013) and K.pneumonaie (de Stoppelaar, 2014), 
Streptococcus pneumoniae (S.pneumoniae) and Escherichia coli (E.coli) derived sepsis models 
(van den Boogaard et al., 2015) (Xiang et al., 2013). Thrombocytopenia has been associated 
with a higher bacterial burden in a rabbit model of Streptococcal endocarditis (Sullam et al., 
1993) and has been shown to exacerbate bacterial sepsis and organ failure in numerous other 
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models (Xiang et al., 2013) (Van den Boogaard et al., 2015) (de Stoppelaar, 2014). Intriguingly, 
the protective effect of platelets have been restored upon platelet reinfusion, improving 
survival and protection against septic shock (Xiang et al., 2013). These data implicate a role 
for platelets in the protection against infection and suggest that platelet transfusion may be 
an effective method of treating severely septic patients.  
 
1.5.3.3 Platelet-Bacteria Interactions 
 
Platelets express an array of constitutive and inducible receptors that allow them to sense 
PAMPs and respond to signals of infection (Kurup and Tarleton, 2013) (Figure 1.6). Platelets 
are able to interact with bacteria via three main mechanisms: Direct binding, whereby a 
bacterial surface protein binds to a platelet surface receptor (Kerrigan et al., 2002) (Miajlovic 
et al., 2010), indirect binding, mediated by a protein that can bind to both platelets and 
bacteria (e.g. fibrinogen) (Loughman et al., 2005) (Siauw et al., 2006), or the binding of 
platelets to bacterial secretory product (e.g. cysteine proteinases) (Ståhl et al., 2006) 
(Lourbakos et al., 2001). The sequence of events involved in platelet-bacteria interactions 
involves four subsequent steps: contact, platelet shape change, early aggregation and 
irreversible aggregation (Clawson and White, 1971a). 
Bacteria display considerable variation in their ability to interact with platelets, with the 
subsequent effect on platelet function determined by the receptors involved in bacterial 
recognition and both the species and concentration of bacteria present  (Dewitte et al., 2017) 
(Yeaman, 1997a). For example, S.aureus and S.pyogenes have been shown to induce rapid 
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and complete platelet aggregation, whilst E.coli induces platelet aggregation much less 
rapidly (Clawson and White, 1971b) (Clawson and White, 1971a). 
Similarly, the bacteria to platelet ratio has a direct correlation with the velocity and extent 
with which platelet aggregation occurs (Bayer et al., 1995) (Yeaman et al., 1992). Platelet 
aggregation induced by bacteria is an ‘all or nothing’ response, whereby a sub-threshold 
concentration of bacteria does not induce platelet aggregation (Arman et al., 2014). Unlike 
with classical platelets agonists, following interaction there is a distinct pause or ‘lag’ prior to 
platelet aggregation induced by bacteria, with a higher concentration of bacteria shortening 
the lag time to aggregation (Arman et al., 2014). A short lag time is indicative of a direct 
interaction between platelets and bacteria, yet a long lag time is indicative of an indirect 
interaction (Kerrigan, 2015). Literature has reported that some bacteria, including 
Helicobacter pylori (H.pylori),  can induce platelet aggregation with a short lag time of 2-5 
minutes (Byrne et al., 2003) (Kerrigan et al., 2002), whilst other bacteria, including 
Streptococcus gordonii (S.gordonii), can induce platelet aggregation with a long lag time of 
12-18 minutes (Loughman et al., 2005) (Kerrigan et al., 2007).  
 
1.5.3.3.1 Toll-Like Receptors  
 
Murine and human platelets constitutively express low levels of TLR2, TLR4 and TLR9 on their 
surface (Andonegui et al., 2005) (Cognasse et al., 2005) (Aslam et al., 2016), suggesting that 
platelets can detect and bind infectious agents (Figure 1.6). The expression of these TLRs is 
significantly increased upon platelet activation (Scott and Owens, 2008). Studies have 
indicated that PAMPs are detected via TLRs (Takeuchi et al., 1999) and this is a pivotal 
component of the immune response to infection. Indeed, it has been demonstrated that LPS 
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from gram-negative bacteria evokes platelet activation and secretion by a TLR4-mediated 
process, whilst the platelet response to LPS was diminished using platelets isolated from TLR4 
knockout mice (Zhang et al., 2009). Furthermore, engagement of TLR4 by LPS has been shown 
to induce platelet degranulation, enhancing ATP release and P-selectin expression, in addition 
to inducing the secretion of cytokines, microbicidal proteins and kinocidins (Zhang et al., 
2009) (Cognasse et al., 2008). Conversely, additional studies reported that LPS did not induce 
platelet aggregation, nor the expression of the activation marker P-selectin (Ward et al., 
2005). It is therefore evident that the ability of platelet TLR4 to induce aggregation in response 
to LPS remains controversial and requires further investigation. 
Evidence has reported that the actions of LPS on platelet activation mediated by TLR4 may in 
fact be indirect. It has been suggested that LPS induced platelet activation by TLR4 primes 
platelets for efficient neutrophil binding and activation (Clark et al., 2007), leading to NETosis 
and the subsequent trapping of bacteria within the vasculature.  
Platelet TLR2 also plays a significant role in the recognition of PAMPs associated with gram- 
positive bacteria, including lipoproteins (Takeuchi et al., 1999). Gram-positive bacteria, 
including S.pneumoniae, have been shown to induce platelet aggregation and dense granule 
secretion in a TLR2-dependent manner (Keane et al., 2010). This was further demonstrated 
using blocking agents, whereby pre-treatment of platelets with an inhibitory monoclonal 
antibody against TLR2 antibody abolished bacterial-induced platelet secretion and 
aggregation (Keane et al., 2010). These data highlight the importance of TLR2 and TLR4 in 
platelet interactions with gram-positive and gram-negative bacteria respectively. They 
further suggest that platelets possess the capacity to augment the antimicrobial function of 
other immune cells.  
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1.5.3.3.2 FcγRIIa receptors 
 
Platelets express a large number of functional FcγRIIa receptors (400-2000 per platelet)  
(Karas et al., 1982), which are thought to be involved in platelet interactions with bacteria 
(Dewitte et al., 2017) (Figure 1.6). FcγRIIa is a low affinity receptor that binds to IgG (Karas et 
al., 1982) and plays a significant role in linking the innate and adaptive immune systems. The 
platelet FcγRIIa receptor can recognise immune complexes and other IgG coated targets 
(Middleton et al., 2016) (Arman et al., 2014), providing direct mechanisms for immune 
interaction and effector activities. Subsequent receptor stimulation triggers Ca2+ mobilisation, 
platelet activation and the release of platelet derived mediators (PF-4, P-selectin), which 
further amplifies the platelet response to bacteria (Arman et al., 2014). Furthermore, it has 
been suggested that IgG immune complexes that bind to FcγRIIa can be internalised by 
platelets (Worth et al., 2006). A number of reports suggest that the binding of bacteria to 
FcγRIIa is mediated via an indirect mechanism, whereby bacterial proteins use IgG to cross-
link to platelet FcγRIIa (Tilley et al., 2013) (Naito et al., 2006). Bacteria-induced platelet 
aggregation is generally inhibited by antibodies that target the FcγRIIa receptor, with the 
blockade of FcγRIIa preventing aggregation induced by numerous bacterial species (Kerrigan 
et al., 2002) (Shannon et al., 2007) (Byrne et al., 2003). It has also been suggested that the 
activation of other platelet receptors by bacteria often requires the simultaneous 
involvement of the FcγRIIa receptor for an effective platelet response (Hamzeh-Cognasse et 
al., 2015). This suggests a direct link between the FcγRIIa receptor and the mechanisms of 
platelet aggregation induced by bacteria. Platelets are the richest source of FcγRIIa, therefore 
they play a pivotal role in the ability of platelets to interact with bacteria and in their 
subsequent antibacterial response (Hamzeh-Cognasse et al., 2015). 
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1.5.3.3.3 Integrin αIIbβ3 
 
Integrin αIIbβ3 (GPIIbIIIa) is expressed exclusively on platelets and megakaryocytes and 
primarily acts as a fibrinogen receptor (Bennett, 2005). αIIbβ3 facilitates the bridging of 
fibrinogen and cross-linking of platelets in haemostasis, although this platelet receptor has 
also been implicated in mediating the interactions between platelets and bacteria (Dewitte 
et al., 2017) (Deppermann et al., 2016) (Figure 1.6). The binding sites of ligands, including 
fibrinogen, to this receptor is thought to be mediated by the recognition of an arginine-
glycine-aspartate (RGD) peptide sequence  (Kerrigan, 2015). A number of bacteria have also 
been shown to express surface proteins that can bind directly to αIIbβ3, independent of 
fibrinogen (Kerrigan, 2015). A common feature of these interactions is the presence of regions 
rich with RGD repeats in the bacterial protein mediating the binding (Kerrigan, 2015). For 
example, S.aureus expresses iron-regulated surface determinant (Isd) proteins, which have 
been shown to directly bind to platelet αIIbβ3 in the absence of fibrinogen (Arman et al., 2014). 
Furthermore, platelet adhesion and aggregation induced by S.aureus were significantly 
attenuated following incubation with either an anti- αIIbβ3 antibody, Tirofiban, an RGD-
sequence inhibitor or using a strain defective in the expression of IsdB (Miajlovic et al., 2010). 
Bacteria are also capable of indirect binding to platelet αIIbβ3 using a plasma protein, such as 
fibrinogen, to bridge itself to the platelet (Deppermann and Kubes, 2016). Different species 
of bacteria express different proteins which enable binding to the plasma protein. For 
example, S.aureus expresses clumping factor B (ClfB), fibronectin-binding protein A (FnBPA), 
fibronectin-binding protein B (FnBPB) and clumping factor A (ClfA) (Arman et al., 2014). These 
bacterial proteins are characterised by an RGD-sequence and a C-terminal containing a 
leucine-proline-x-threonine-glycine (LPxTG) motif, which anchors the protein to the cell wall 
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of the bacteria (Kerrigan, 2015) (Signas et al., 1989). Following binding to fibrinogen, the 
bacteria is then cross-linked to the platelet via αIIbβ3. In order to induce full platelet 
aggregation by indirect binding, a co-stimulus is required, which is provided by the bacteria 




GPIbα is a membrane glycoprotein expressed exclusively on platelets and megakaryocytes 
(Lopez, 1994). Although it primarily functions as the platelet receptor for vWF, a number of 
different species of bacteria have been shown to express serine-rich repeats (SRR), which can 
bind directly to platelet GPIbα (Arman et al., 2014). For example, Streptococcus sanguinis  
(S.sanguinis) and S.aureus express the SRR proteins termed SrpA and SraP respectively, which 
can bind directly to GPIbα (Plummer et al., 2005) (Siboo et al., 2005) (Figure 1.6). In the same 
way that fibrinogen acts as a bridge between bacteria and platelets when indirectly binding 
to αIIbβ3, vWF may be used as an intermediary to facilitate the interactions between bacteria 
and platelet GPIbα. For example, protein A (SpA) from S.aureus binds to vWF for indirect 
adhesion to platelets (O’Seaghdha et al., 2006), and similarly vWF is used by H.pylori to 
interact with platelets (Byrne et al., 2003). The involvement of this receptor in mediating the 
interaction with bacteria has been underpinned clinically, whereby platelets obtained from 
patients lacking expression of GPIbα in Bernard Soulier Syndrome fail to aggregate in 
response to H.pylori (Byrne et al., 2003). 
  

















































Figure 1. 6 A Summary of Direct and Indirect Interactions Between Platelets (TLR, FcγRIIa, 


































































































































































The complement receptor gC1q-R is expressed at low levels on platelets under normal resting 
conditions, however it becomes upregulated upon platelet activation (Peerschke et al., 2003). 
Complement proteins interact with bacteria through both the classical and alternative 
complement pathways (Hamzeh-Cognasse et al., 2015) (Figure 1.7). The classical pathway is 
initiated following the formation of immune complexes, after IgG or IgM bind to bacteria 
(Sarma and Ward, 2011). The C1 complex, consisting of C1q, C1r and C1s molecules, then 
binds to the immune complex inducing the activation of C1s and C1r. C1s then subsequently 
cleaves C4 and C2 to form the C3 convertase, C4bC2a. C4bC2a further cleaves C3 to release 
C3a and C3b. C3b acts to amplify complement activation and is involved in phagocytosis. 
Furthermore, C3b complexes with the C3 convertases to form the C5 convertases, C3bBbC3b 
and C4bC2aC3b. The C5 convertases cleave C5 to form C5a and C5b. The membrane attack 
complex (C5b-9) is then initiated by C6 and C7 binding to C5b, followed by the binding of C8 
and C9 binding. This complex forms a pore in cell membranes and results in cell lysis (Sarma 
and Ward, 2011) (Figure 1.7). 
The alternative pathway is initiated by carbohydrates, lipids and proteins on non-self surfaces 
(Figure 1.7) (Sarma and Ward, 2011). C3 is hydrolysed to form C3b, which binds to bacteria. 
Factor B is then recruited to C3b, followed by Factor D, which cleaves Factor B to form the C3 
convertase C3bBb (Sarma and Ward, 2011). 
Bacteria coated with the complement factor C1q are able to interact with and bind to platelet 
gC1q-R (Hamzeh-Cognasse et al., 2015), where it has been shown that SpA from S.aureus can 
bind directly to platelet gC1q-R (Nguyen et al., 2000). 














Figure 1. 7 An Overview of the Main Components and Actions of Complement 
 
Platelet aggregation induced by ClfA and ClfB from S.aureus are also thought to be mediated 
by complement, since its inactivation by heating the sera or removing complement proteins 
using zymosan has been shown to inhibit platelet activation and aggregation (Loughman et 
al., 2005) (Miajlovic et al., 2007). Consequently, this implicates the complement receptor 
gC1q-R in mediating the interactions between platelets and bacteria (Figure 1.6).  
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These data suggest that platelets possess a vast array of cell surface receptors, which facilitate 
their interactions with bacteria (Figure 1.6). It is evident that different bacterial species have 
different mechanisms by which they interact with platelets and vary in their ability to adhere 
to and aggregate platelets. However, the overall resulting effect on platelet function induced 
by bacteria is determined by the magnitude of stimulation and the duration of contact 
between the platelets and bacteria (Yeaman and Bayer, 1999). 
 
 
1.5.3.4 Platelet Purinergic Receptors in Inflammation and Infection 
 
Platelets express a family of receptors, which are activated by the purines, ADP, ATP, uridine 
5′-diphosphoglucose (UDP) and uridine 5′-triphosphoglucose (UTP) (Scrivens and Dickenson, 
2006) (Chambers et al., 2000). 4 receptor subtypes are known to be expressed on the platelet 
surface, 3 from the G-protein coupled receptor family, P2Y1, P2Y12 and P2Y14 and 1 from the 
ionotropic P2X family, P2X1 (Storey et al., 2002) (Dovlatova et al., 2008) (Figure 1.8). The P2X1 
receptor is a ligand gated ion channel, which is activated by endogenous ATP, resulting in the 
rapid influx of Ca2+ ions (Murugappan and Kunapuli, 2006). In contrast, the P2Y1 receptor 
subtype is stimulated by endogenous ADP triggering activation of the Gαq/ phospholipase C 
pathway (Gachet, 2006). Similarly, the P2Y12 receptor is activated by endogenous ADP and is 
coupled to Gi. Signalling via this G-protein negatively regulates the membrane bound adenylyl 
cyclase (Kauffenstein et al., 2001). P2Y14 receptors are thought to be coupled to Gi and are 
activated by uridine diphosphate (UDP) and UDP-glucose (Dovlatova et al., 2008), although 
signalling downstream of the P2Y14 receptor remains to be elucidated in platelets. 
The role of platelet purinergic receptors in platelet aggregation (P2X1, P2Y1, P2Y12) has been 
well documented (Gachet, 2006) (Léon et al., 2003) (Storey et al., 2000), however more 
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recently the implication of these receptors and their purine ligands in inflammatory processes 
has become much more apparent (Storey et al., 2002) (Leon et al., 2008) (Klinkhardt et al., 
2002) (Amison et al., 2018c) (Amison et al., 2015). Various cell types involved in innate 
immunity and inflammation express the purinergic P2 receptor subtype, which have been 
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Asides from the ability of platelet purinergic receptors to modulate platelet function in the 
context of haemostasis, stimulation of the platelet purinergic receptors, by ADP or ATP has 
been shown to induce platelet activation, resulting in aggregation, granule secretion, 
adhesion molecule upregulation and interactions with inflammatory cells (Fabre et al., 1999) 
(Léon et al., 2003) (Storey et al., 2000) (Cattaneo et al., 2004) (Hechler et al., 2003). Indeed, a 
number of studies have demonstrated the ability of purinergic receptor stimulation to induce 
increases in P-selectin expression, platelet-leukocyte complex formation and in contributing 
to leukocyte activation and recruitment (Léon et al., 2003) (Storey et al., 2002) (Amison et al., 
2017) (Amison et al., 2015). This is suggestive of the ability of platelet purinergic receptors to 
modulate platelet function that is relevant to inflammation. 
ADP induced activation of platelet P2Y1 receptors triggers the activation of PLCβ via Gq 
(Gachet, 2006), leading to the generation of the second messengers IP3 and DAG from PIP2 
(Figure 1.8). Elevated levels of IP3 result in calcium mobilisation and release from intracellular 
stores (Lian et al., 2005). Ca2+ promotes rearrangement of the actin cytoskeleton to induce 
platelet shape change. Furthermore, DAG triggers PKC activation, which in combination with 
elevated levels of intracellular Ca2+, results in the secretion of platelet granules (Walker and 
Watson, 1993). Indeed, the inhibition of P2Y1 has been shown to reduce platelet activation 
and inflammation in a number of studies. For example, pulmonary neutrophil recruitment 
induced by intranasal LPS administration was inhibited in mice following administration of a 
P2Y1 antagonist, MRS2500 (Amison et al., 2017), whilst blockade of P2Y1 also reduced P-
selectin expression and the incidence of circulating platelet-leukocyte complexes (Léon et al., 
2003) (Amison et al., 2015). 
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The platelet P2Y12 receptor is coupled to Gi, with activation of the G-protein negatively 
regulating adenylyl cyclase. Under normal resting conditions, adenylyl cyclase catalyses the 
production of cyclic adenosine monophosphate (cAMP), which locks the platelet integrin 
αIIbβ3 in an inactive conformation preventing platelet aggregation (Kauffenstein et al., 2001). 
However, upon P2Y12 receptor activation and subsequent inhibition of adenylyl cyclase, the 
decrease in intracellular cAMP levels removes this ‘break’ on the platelet integrin αIIbβ3 
activation, thus enabling platelet aggregation (Kauffenstein et al., 2001) (Gachet, 2006). 
Furthermore, activation of the platelet P2Y12 receptors amplifies platelet aggregation, since 
its activation also stimulates the secretion of platelet dense granules resulting in the local 
generation of thrombin and TXA2 (Storey et al., 2000). 
The P2Y12 receptor is an attractive therapeutic target for anti-thrombotic agents and its 
antagonism has demonstrated clear anti-thrombotic effects, decreasing P-selectin expression 
and platelet aggregation induced by a variety of stimuli (Storey et al., 2002) (Léon et al., 2003) 
(Kauffenstein et al., 2001). 
In the context of inflammation, literature has shown mixed actions of the platelet P2Y12 
receptor. Some groups have highlighted that antagonism of the platelet P2Y12 receptor, using 
Clopidogrel, has demonstrated attenuation of circulating inflammatory mediators, decreased 
exposure of P-selectin and CD40L and diminished formation of platelet-leukocyte complexes 
(Gachet, 2012) (Cattaneo, 2015) (Steinhubl et al., 2007) (Liverani et al., 2016). Recent findings 
also implicate the P2Y12 receptor in acute inflammation in sepsis, where platelets play an 
important role by enhancing pulmonary infiltration of neutrophils, exacerbating tissue 
damage (Asaduzzaman et al., 2009) (de Stoppelaar et al., 2015). Whilst, other published 
literature has demonstrated that LPS induced systemic inflammation becomes more severe 
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in the absence of P2Y12 receptors (Liverani et al., 2014) and P2Y12 antagonism using 
Clopidogrel was shown to potentiate inflammation in a rat model of peptidoglycan-
polysaccharide induced arthritis (Garcia et al., 2011). 
In contrast, literature using a murine model of allergic airway inflammation has suggested 
that the antagonism of P2Y12 had no significant effect in pulmonary leukocyte recruitment, 
yet significantly reduces bleeding time and ex vivo platelet aggregation to ADP (Amison et al., 
2017). This would indicate a dichotomy in platelet activation during inflammation when 
compared to purinergic receptor involvement in haemostatic processes, however the 
conflicting results in the literature show a clear need to further investigate the role of the 
P2Y12 receptor in inflammatory conditions. 
More recently, platelets have also been shown to express the purinergic P2Y14 receptor on 
their surface (Dovlatova et al., 2008), which is activated by UDP glucose and related sugar 
nucleotides (Scrivens and Dickenson, 2006). It has been suggested that the P2Y14 receptor is 
coupled to Gi proteins (Moore et al., 2003) (Dovlatova et al., 2008), since UDP-glucose 
stimulated signalling was completely blocked following pre-treatment of human embryonic 
kidney (HEK) 293 cells with pertussis toxin (Chambers et al., 2000). Furthermore, UDP glucose 
has been shown to stimulate significant increases in intracellular Ca2+ in a variety of cell lines, 
which again was sensitive to pertussis toxin (Scrivens and Dickenson, 2006). This is further 
suggestive of the P2Y14 receptor coupling to Gi proteins.  
The physiological function of P2Y14 remains unknown at present, however the P2Y14 receptor 
appears to be redundant in platelet aggregation unlike the other platelet P2 receptors 
(Amison et al., 2017) (Dovlatova et al., 2008). This receptor subtype has demonstrated an 
ability to mediate cell migration in other cell types, including stem cells (Lee et al., 2003), in 
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addition to stimulating pro-inflammatory cytokine release (IL-8), inducing dendritic cell 
maturation (Scrivens and Dickenson, 2006) and inhibiting T-lymphocyte proliferation 
(Scrivens and Dickenson, 2005), clearly indicating an involvement of the P2Y14 receptor in 
modulating inflammatory processes. Moreover, the expression of P2Y14 has been shown to 
increase in rat brain and spleen following provocation with LPS (Moore et al., 2003). Others 
(Amison et al., 2017) have demonstrated that P2Y14 receptor activation affects platelet 
function by stimulating platelet-induced neutrophil chemotaxis in vitro and in mediating 
pulmonary neutrophil recruitment in mice, in response  to LPS challenge (Amison et al., 2017). 
In these studies, administration of a P2Y14 antagonist significantly inhibited pulmonary 
neutrophil recruitment induced by intranasal LPS, whilst the haemostatic responses (platelet 
aggregation and bleeding times) remained unaltered. 
The P2X1 receptor is an ATP-gated, non-selective cation channel (Gachet, 2006). Studying the 
involvement of P2X1 in platelet activation has proved difficult due to rapid desensitisation of 
the receptor following stimulation. However, this can be prevented through the hydrolysis of 
excess ATP using Apyrase (Mahaut-Smith et al., 2011) (Sun et al., 1998). ATP stimulation of 
the P2X1 receptor has been shown to increase cellular permeability to Ca2+ (Sun et al., 1998), 
resulting in significant increases in intracellular Ca2+ levels following activation (Mahaut-Smith 
et al., 2011). The influx of Ca2+ can trigger reversible platelet shape change, movement of 
secretory granules without secretion and low level inside-out activation of αIIbβ3 integrin 
(Mahaut-Smith et al., 2011) (Toth-Zsamboki et al., 2003). Furthermore, it has been reported 
that activation of the P2X1 receptor with ATP plays an important role in facilitating neutrophil 
chemotaxis (Lecut et al., 2009).  
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In other studies, it was shown that inhibition of the P2X1 receptors in a model of  LPS-induced 
inflammation had no impact on pulmonary neutrophil recruitment (Amison et al., 2017). 
Interestingly, these studies demonstrated that antagonism of the P2X1 receptor significantly 
increased bleeding times and ex vivo platelet aggregation in response to ADP. This further 
highlights a potential dichotomy in platelet activation during inflammation versus 
haemostasis. 
It is evident that purinergic receptor signalling can mediate inflammatory processes, 
therefore it is reasonable to suggest that these receptors are likely to be activated in response 
to infection. In the lung, it is reported that purinergic receptors regulate the rate of mucus 
clearance (Homolya et al., 2000), surfactant secretion (Rice et al., 1995) and pulmonary 
vasodilation (Hamada et al., 1998). Whilst these receptors are also important in the 
modulation of inflammation, including the release of cytokines and leukocyte chemotaxis and 
adhesion (Geary et al., 2005) 
A role for purinergic receptors in response to infection with P.aeruginosa has also been 
detailed. These studies have demonstrated that pulmonary P.aeruginosa infection of P2Y1 
and P2Y2 deficient mice significantly decreased survival when compared to wild type mice 
(Geary et al., 2005). It is thought that the mechanism for the impaired survival of mice in these 
studies was related to an attenuation of the inflammatory cascade and impaired alveolar wall 
integrity (Geary et al., 2005). 
Finally, additional studies have indicated that purinergic receptor signalling via P2X7 is 
involved in modulating infectious processes in bacterial Chlamydia infections, protozoal 
infections, including Leishmania and Toxoplasma, and viral infections, including hepatitis B 
and C (Swartz et al., 2015) (Miller et al., 2011). However, this receptor is not expressed on the 
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platelet surface, suggesting that whilst platelet P2 receptors are involved in this process, their 
effects are not solely related to platelets. 
 
1.5.3.5 Effects of Bacteria on Platelet Function 
 
The consequences of the interactions between platelets and bacteria significantly influence 
the balance between infection and immunity. It has recently been described that platelets are 
involved in the earliest detection of microbial pathogens (Gaertner et al., 2017) (Kerrigan, 
2015) and possess structures and functions of host defence effector cells. Numerous reports 
have suggested that platelets possess both direct antimicrobial functions, acting as a source 
of an array of antimicrobial peptides (Yang et al., 2015) (Yeaman, 2010) (Krijgsveld et al., 2000) 
(Tang et al., 2002) (Kraemer et al., 2011) (Dewitte et al., 2017) (Ali et al., 2017) and directly 
internalising bacteria (Youssefian et al., 2002), and also indirect antimicrobial functions by 
enhancing the immune functions of other cells, for example enhancing NET formation from 
neutrophils and the phagocytic capacity of macrophages (Clark et al., 2007) (Caudrillier et al., 
2012) (Yeaman, 1997) (Ali et al., 2017) (Figure 1.9).   











Figure 1. 9 An Overview of the Direct and Indirect Antimicrobial Functions of Platelets 
 
The release of antimicrobial proteins (PF-4, RANTES, connective tissue activating peptide 3 
(CTAP-3), platelet basic protein (PBP), thymosin β-4 (Tβ-4), fibrinopeptide B (FP-B), and 
fibrinopeptide A (FP-A)) from both human and rabbit platelet α-granules has been 
demonstrated in vitro, following stimulation with thrombin (Krijgsveld et al., 2000) (Figure 
1.9). This releasate, termed platelet microbicidal proteins (PMPs), are reportedly involved in 
the clearance of pathogens including viridans streptococci, S.aureus, E.coli and Candida 
albicans  (Krijgsveld et al., 2000) (Tang et al., 2002) (Yeaman, 1997a). Furthermore, platelets 
have been shown to release a subset of PMPs, termed kinocidins, which directly kill pathogens 
and mediate leukocyte chemotaxis (Yount and Yeaman, 2006) (Yount et al., 2007). Thus 
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demonstrating that platelet-derived microbicidal proteins and kinocidins are capable of 
orchestrating the immune response to infection. 
Kinocidins are classified according to their chemokine nomenclature, for example the CXC 
chemokines, including PF-4, PBP, CTAP-3 and neutrophil activating peptide 2 (NAP-2), are 
termed α- kinocidins due to their CXC-chemokine motif. In contrast, β- kinocidins, including 
RANTES, contain a CC-chemokine motif (Yeaman, 2010) (Yeaman et al., 1997) (Krijgsveld et 
al., 2000). Mature PMPs and kinocidins are subject to further cleavage after their release from 
platelets and their products also possess strong antimicrobial activity. For example, the N-
terminal of the kinocidins PF-4 is cleaved to give rise to CTAP-III, β-TG and NAP-2 (Yeaman, 
2014), generating additional antimicrobial peptides. 
PMPs and kinocidins are rapidly released from platelets into the blood stream in response to 
bacterial invasion via a sequential process. Firstly, bacteria induced platelet activation results 
in platelet degranulation and the release of PMPs, kinocidins and ADP/ATP (Trier et al., 2008) 
(Figure 1.9). Studies have suggested that PMPs and kinocidins are released if the platelet- 
bacteria (S.aureus) ratio is above 10:1, highlighting the importance of platelet recognition and 
interactions with bacteria (Trier et al., 2008). The ADP/ATP released from platelets 
subsequently activates platelet purinergic receptors (P2X1 and P2Y12) on adjacent platelets, 
further amplifying the release of PMPs and kinocidins from successive platelets (Yeaman, 
2010) (Figure 1.9). The association between purinergic receptors and PMPs/kinocidins has 
been underpinned using Apyrase and P2X1 and P2Y12 receptor antagonists, whereby the 
release of PMPs from platelets was diminished (Trier et al., 2008). 
Studies have indicated that human derived PF-4 and RANTES display antimicrobial activity 
against E. coli and S.aureus (Y. Tang et al., 2002). Similarly, the levels of PMPs and kinocidins 
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released from human platelets have been reported to increase dramatically (4-6 fold) in an 
infectious setting in vivo (Lorenz and Brauer, 1988) (Mezzano et al., 1992). In this instance, 
plasma levels of PF-4 increased in septicaemia (Lorenz and Brauer, 1988) and other bacterial 
infections, including Streptococcal nephritis (Mezzano et al., 1992). Furthermore, research 
has indicated that platelet antimicrobial peptides are detectable within human wounds and 
blister fluid (Tang et al., 2002), demonstrating that platelets can play a protective role in 
preventing and limiting infection. Intriguingly, in patients with inherited platelet disorders, 
including Wiscott–Aldrich Syndrome, May–Hegglin Anomaly and Gray-Platelet Syndrome, 
where there is an abnormality in platelet function, a strong correlation exists between 
morbidity and mortality due to S.aureus and other infections (Yeaman, 2010). This study 
suggests that normal platelet function and a threshold platelet count is an important barrier 
to infection. This protective role of platelets in infection has highlighted the potential 
beneficial effect of platelet transfusions in infection and sepsis (Yeaman, 2010).  
Additional studies have also demonstrated the antimicrobial activity of platelet rich plasma 
(PRP) and other additional plasma preparations in periodontal disease (Yang et al., 2015) 
(Drago et al., 2013). These studies showed that PRP interfered with Porphyromonas gingivalis 
and Aggregatibacter actinomycetemcomitans attachment (Yang et al., 2015) and inhibited 
the growth of Enterococcus faecalis, Candida albicans, Streptococcus agalactiae and 
Streptococcus oralis isolated from the oral cavity (Drago et al., 2013).  
In vitro studies exposing rabbit derived PMPs to bacterial cells have revealed that PMPs target 
and disrupt bacterial cytoplasmic membranes (Yeaman, 1997) (Figure 1.9), resulting in 
ultrastructural damage and subsequent bactericidal and bacteriolytic effects. PMPs have also 
been shown to potentiate the antimicrobial effects of conventional antibiotics against 
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infection with S.aureus (Asensi and Fierer, 1991) (Figure 1.9), for example β-lysin and 
ampicillin interact synergistically in vitro to inhibit Listeria monocytogenes, thus 
demonstrating a potential therapeutic use of PMPs in patients with bacterial infections.  
In addition to the release of PMPs and kinocidins, platelets contribute to other host defence 
effector functions. Platelets have been shown to release free radicals, such as superoxide 
anion, hydrogen peroxide and hydroxyl radicals, when stimulated by certain bacteria 
(Yeaman, 2010) (Figure 1.9). Moreover, studies have shown that platelets interact with 
components of the complement system to mediate complement fixation. For example, 
platelets are capable of regulating the generation of the membrane attack complex (Polley et 
al., 1981) (Zimmerman and Kolb, 1976) (Figure 1.9). Complement receptors expressed on the 
platelet surface subsequently bind to bacteria exhibiting this complex, which triggers platelet 
activation and degranulation (Polley and Nachman, 1983). Furthermore, platelet proteases 
can cleave C5 to C5a, therefore providing a positive chemotactic stimuli for the recruitment 
of macrophages and neutrophils (Weksler and Coupal, 1973) (Figure 1.9).  
Platelet migration and scanning of the vascular surface for invading pathogens precedes the 
collection and internalisation of deposited bacteria, clearing pathogens from the blood 
stream (Gaertner et al., 2017) (Youssefian et al., 2002). Studies performed by (Youssefian et 
al., 2002) demonstrated the engulfment of S.aureus by platelets that displayed classical signs 
of activation, including GPIb, P-selectin expression and fibrinogen release. It was proposed 
that the engulfing vacuole was formed by plasma membrane invagination following platelet 
activation. GPIb was not detected within the engulfing vacuole, suggested that its clearance 
from the platelet plasma membrane facilitates platelet shape change and initiates the 
contractile events required for bacteria internalisation. These studies also demonstrated the 
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fusion of platelet α-granules with the engulfing vacuole, resulting in the interaction of bacteria 
with the granular secretory products (Youssefian et al., 2002). Other research has proposed 
that platelets function as ‘covercytes,’ with platelet pseudopods surrounding bacteria until 
the organism is enclosed in a vacuole consisting of extracellular space surrounded by plasma 
membrane (White, 2005) (Figure 1.9). 
In addition to platelets possessing direct antimicrobial functions, it has been suggested that 
platelets potentiate the antimicrobial mechanisms of leukocytes (Tang et al., 2002) (Clark et 
al., 2007) (Ali et al., 2017) (Caudrillier et al., 2012). It has been suggested that the interaction 
between platelets with monocytes and neutrophils provides a plausible mechanism by which 
platelets participate in antimicrobial defence. A wide array of platelet secretory products, 
including PF-4, PAF, PDGF, act as positive chemotactic stimuli for monocytes and neutrophils 
(Nachman and Weksler, 1972). Studies using experimental models have demonstrated that 
injection of PF-4 and PDGF rapidly induces neutrophil infiltration (Nachman and Weksler, 
1972). Additionally, research performed by (Ali et al., 2017) suggested an indirect role of 
platelets in pathogen clearance through potentiation of phagocytic and killing capacity of 
macrophages (Ali et al., 2017) (Figure 1.9). In these studies, it was observed that activated 
platelets and their secreted products enhanced phagocytosis and restricted intracellular 
growth of S.aureus by macrophages. It was proposed that this process was mediated by 
platelet derived IL-1β, since its inhibition from platelets blocked phagocytosis and permitted 
S.aureus survival (Ali et al., 2017).  
Other studies have suggested that PMPs that are active under mildly acidic conditions may 
augment the antimicrobial effect of leukocytes. It has been described that the ability of 
neutrophils to kill bacteria through non-oxidative mechanisms may be regulated by pH, 
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following engulfment by phagolysomes. Therefore, the acidic platelet (pH 5.5) releasate may 
amplify the direct antimicrobial mechanisms of neutrophils (Shafer et al., 1986) (Tang et al., 
2002). 
As previously described, emerging evidence has suggested that activated platelets induced 
the formation of NETS in ALI and sepsis (Caudrillier et al., 2012) (Clark et al., 2007) (Figure 
1.9), further implicating platelets in the indirect mediation of the immune response to 
infection.  These studies reported that under extreme conditions, such as severe sepsis, 
platelets via TLR4 function as a barometer for systemic infection. Bacteria induced platelet 
activation subsequently resulted in their rapid binding to sequestered neutrophils and 
induced the formation of NETS to ensnare bacteria in the circulation (Clark et al., 2007). The 
bacterial trapping capacity of these neutrophils is greatly augmented in the presence of 
platelets, with high concentration of LPS unable to induce NET formation directly, without the 
presence of platelets (Clark et al., 2007).  Furthermore, the production of reactive oxygen 
species correlates to NET formation and interfering with platelet TXA2 and MEK signalling 
significantly decreases NET formation (Caudrillier et al., 2012). 
In summary, these studies provide evidence for platelets playing a key role in host defence 
against infection, mediated by both direct and indirect mechanisms. Platelets are the earliest 
and most abundant cell type present at sites of infection and can bind directly and indirectly 
to numerous microbial pathogens. Platelets can collect, bundle and internalise bacteria and 
release PMPs and kinocidins to facilitate microbial killing. They can also enhance the immune 
functions of other effector cells by NET formation and phagocytosis. Furthermore, 
thrombocytopenia has been shown to increase the susceptibility to infection (Yeaman, 1997). 
Therefore, the roles of platelets in infection towards P.aeruginosa and MRSA will be assessed 
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both in terms of their impact on inflammatory cell recruitment and direct interactions 
between platelets and bacteria.  
 
1.6 Aims and Objectives 
 
 
1) To assess the inflammatory components in the response to infection and the 
involvement of platelets in this response.  
 
Neutrophil infiltration and inflammation are thought to contribute significantly to the 
pathophysiologic features of sepsis, CF and other bacterial infections. A murine model of 
pulmonary infection with S.aureus and P.aeruginosa will be established to investigate the 
inflammatory response induced by pulmonary bacterial infection. 
To assess whether infection is associated with increased markers of platelet activation, 
measurements of platelet accumulation, granule secretion and the formation of platelet-
neutrophil complexes will be quantified.  
 
2) To validate a model of pulmonary infection in animals experimentally depleted of 
circulating platelets to assess their role in the regulation of the infectious 
phenotype. 
 
Thrombocytopenia is a common feature in patients with sepsis, which is associated with a 
poor prognosis and worsened outcome. Similarly, numerous animal models have 
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demonstrated that thrombocytopenia dramatically impairs host defence. Therefore, the aims 
are: 
1) To investigate whether experimentally induced platelet depletion in a murine model of 
pulmonary infection with S.aureus and P.aeruginosa is associated with a worsened 
phenotype.  
2) To confirm whether the removal of circulating platelets enhances bacterial survival and 
subsequent mortality rates.  
3) To determine whether thrombocytopenia amplifies increased permeability of alveolar and 
endothelial barriers in infection and permits the usual localised pulmonary infection to 
become systemic.  
 
3) Identify platelet signalling mechanisms involved in the regulation of the host 
response to P.aeruginosa and MRSA infection. 
 
Extending from the objects listed above, the involvement of TLR4 and purinergic receptors 
will be assessed on the bacterial and inflammatory parameters in a model of pulmonary 
infection with P.aeruginosa and MRSA. 
 
4) To determine whether a novel antibiotic enhancer compound attenuates bacterial 
infection with drug-resistant strains of P.aeruginosa and S.aureus. 
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The reduced efficacy of current antibiotics in combination with a steady decline in the 
discovery of novel compounds have exacerbated the emergence of antibiotic resistance. One 
possible approach to provide improved treatment for infectious diseases is the use of 
enhancer compounds, which act by restoring sensitivity of resistant bacteria to currently 
available antibiotics. A novel antibiotic enhancer compound, HT61 will be utilised in a murine 
model of pulmonary infection with S.aureus and P.aeruginosa to determine whether there is 
any synergism associated using combination treatment with the conventional antibiotics, 
Tobramycin and Vancomycin.
















Materials and Methods   
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2.1 Materials 
     
ABC Vectastain kit     Vector Laboratories, CA, USA. 
AB183345 (anti-CD42b)    Abcam plc, Cambridgeshire, UK. 
AB68672 (Anti-Neutrophil Elastase Antibody) Abcam plc, Cambridgeshire, UK. 
Acid alcohol differentiation solution   Sigma-Aldrich LTD, Dorset, UK 
Acid Citrate-Dextrose     Sigma-Aldrich LTD, Dorset, UK. 
ADP          Sigma-Aldrich LTD, Dorset, UK. 
Anti-GPIbα antibody #R300     Emfret Analytics, Wurzburg, Germany. 
Apyrase      Sigma-Aldrich LTD, Dorset, UK. 
ARC-66096      Tocris Bioscience, Bristol, UK 
BA1000 (Biotinylated Goat Anti-Rabbit Secondary 
Antibody)      Vector Laboratories, CA, USA. 
BD Falcon 24 well companion plate   Beckton Dickinson, Plymouth, UK. 
BD Falcon Transparent 3μM PET insert  Beckton Dickinson, Plymouth, UK. 
GelRed  Nucleic Acid Stain    VWR International, Leicestershire, UK. 
Bovine serum albumin    Sigma-Aldrich LTD, Dorset, UK. 
Calcium      Sigma-Aldrich LTD, Dorset, UK. 
Dimethyl sulfoxide     Sigma-Aldrich LTD, Dorset, UK. 
DNA Ladder #15615-016    Invitrogen, Paisley, UK 
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DPX mounting medium    Thermo Fisher, Loughborough, UK. 
EC8+ blood analyser cartridges    Point of Care Testing ltd, London, UK. 
Eosin       Thermo Fisher, Loughborough, UK.  
Evans Blue Dye     Sigma-Aldrich LTD, Dorset, UK. 
FITC mouse anti-human CD41a #555466  BD Biosciences, Oxford, UK. 
FITC mouse anti-rat IgG2b #553900   BD Biosciences, Oxford, UK. 
FITC mouse IgG1 κ isotype control #555909  BD Biosciences, Oxford, UK. 
FITC rat anti-mouse CD41 #553848   BD Biosciences, Oxford, UK. 
Flow count flurospheres    Beckman Coulter Inc, 
Buckinghamshire, UK. 
MRS2500      Tocris Bioscience, Bristol, UK 
Murine Stromal cell derived factor 1    PeproTech EC, Ltd, London, UK. 
NF279 Tocris Bioscience, Bristol, UK 
Noble Agar Scientific Laboratory Supplies, 
Nottingham, UK. 
Formaldehyde      Thermo Fisher, Loughborough, UK. 
Formamide       Sigma-Aldrich LTD, Dorset, UK. 
Glucose      Thermo Fisher, Loughborough, UK  
Haemotoxlyin      Sigma-Aldrich LTD, Dorset, UK 
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Heparin Sodium     Sigma-Aldrich LTD, Dorset, UK 
HEPES       Sigma-Aldrich LTD, Dorset, UK. 
Histoclear      National Diagnostics, Nottingham, UK. 
HT61       Helperby Therapeutics, London, UK. 
Hydrogen Peroxide Sigma-Aldrich LTD, Dorset, UK  
100% Industrial methylated spirit                                 Fisher Scientific, Loughborough, UK. 
Isoflurane      Animal Care Ltd, York, UK. 
i-STAT blood analyser     Abaxis, Union City, CA, USA 
(VetScan iSTAT 1 analyser 300A) 
LIVE/DEAD BacLight Bacterial Viability #L7012 Thermo Fisher, Loughborough, UK. 
Magnesium Chloride     Sigma-Aldrich LTD, Dorset, UK. 
Mineral oil      Sigma Aldrich, Dorset, UK. 
Mouse IgG isotype control #00751   Bioxcell, New Hampshire, USA. 
Murine IL-6 Duoset ELISA, DY453   Bio-techne, Oxfordshire, UK. 
Murine KC Duoset ELISA, DY406   Bio-techne, Oxfordshire, UK. 
Murine PF-4 Duoset ELISA, DY595   Bio-techne, Oxfordshire, UK. 
Murine RANTES Duoset ELISA, DY478  Bio-techne, Oxfordshire, UK.  
Paraplast      Sigma-Aldrich LTD, Dorset, UK. 
PCR Ready Mix Reaction Kit, R2648 20RXN  Sigma-Aldrich LTD, Dorset, UK.  
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PE rat anti-mouse Ly6g #551461   BD Biosciences, Oxford, UK. 
PE rat IgG1 κ Isotype control #551979  BD Biosciences, Oxford, UK. 
Phosphate buffered saline    Oxoid, Hampshire, UK. 
Potassium Chloride     Sigma-Aldrich LTD, Dorset, UK.  
PPTN Mesylate     Sigma-Aldrich LTD, Dorset, UK 
Prostaglandin E1     Sigma-Aldrich LTD, Dorset, UK. 
Rat anti-mouse CD62P FITC #561923   BD Biosciences, Oxford, UK. 
RPMI 1640 media     Sigma-Aldrich LTD, Dorset, UK. 
0.9% Saline      Baxter Healthcare Ltd, UK. 
Shandon™ Kwik-Diff™ staining kit    Thermo Fisher, Loughborough, UK. 
Sodium Chloride     Thermo Fisher, Loughborough, UK. 
Sodium Dihydrogen Phosphate Dodecahydrate Thermo Fisher, Loughborough, UK 
Sodium Hydrogen Carbonate    Sigma-Aldrich LTD, Dorset, UK.  
Sodium Hydroxide                                                            Sigma-Aldrich LTD, Dorset, UK. 
Stromatol      Mascia Brunelli, Italy. 
Tobramycin      Cayman Chemical Company, Mi, USA. 
Thrombin receptor activating peptide  Tocris Bioscience, Bristol, UK   
Tri-sodium citrate      Fisons Scientific Equipment, UK. 
Trypticase soy broth     Oxoid, Hampshire, UK . 
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Turks solution      Merck KGaA, Germany. 
Tween 20      Thermo Fisher, Loughborough, UK. 
Urethane      Sigma-Aldrich LTD, Dorset, UK. 
Vancomycin      Sigma-Aldrich LTD, Dorset, UK. 
Xylene       Sigma-Aldrich LTD, Dorset, UK.  
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2.2  Animals 
 
All animal experiments were approved by and conducted in accordance with the guidelines 
of the Animals (Scientific Procedures) Act (ASPA) 1986 (United Kingdom) with local ethical 
approval of King’s College London, or according to protocols approved by San Raffaele 
Scientific Institute (Milan, Italy) Institutional Animal Care and Use Committee (IACUC) and 
adhered strictly to the Italian Ministry of Health guidelines for the use and care of 
experimental animals. Animals were housed under standard conditions of 22±2oC and a 12:12 
light: dark cycle. All animals were provided with food and water ad libitum and wood shavings, 
shredded paper and cardboard tubes were provided for environmental enrichment. All 
animals were provided with a minimum acclimatisation period of seven days upon arrival.  
Male, C57/Bl6J mice (20-25g, 8 weeks) were sourced from Envigo Laboratories 
(Cambridgeshire, UK). All animals were sacrificed through intra-peritoneal (i.p.) injection of 
0.3mL 25% weight per volume (w/v) urethane to induce terminal anaesthesia.  
 
2.3 Bacterial Strains 
 
Three strains of the gram-negative bacterium P.aeruginosa were used in this study; RP73, a 
multi-drug resistant non-mucoid clinical strain, isolated 17.5 years after the onset of infection 
in a CF patient (Bragonzi et al., 2006), PAO1, the fully sequenced laboratory reference strain 
(Bragonzi et al., 2006) and NN2, a Tobramycin Resistant CF isolate, collected at the onset of 
chronic colonisation. (Bragonzi et al., 2006). A single strain of the gram-positive bacterium 
MRSA was used, USA300, which was isolated from a patient in 2000 and is the predominant 
cause of community acquired infections (Diep et al., 2006). Bacterial strains were kindly 
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provided by Dr. A. Bragonzi (Infection and Cystic Fibrosis Unit, San Raffaele Scientific Institute, 
Milan, Italy). 
 
2.4 Bacterial Culture Preparation 
 
48 hours prior to use, primary overnight cultures (ONC) for all strains were prepared by 
inoculating trypticase soy agar (TSA) plates (1.5% w/v agar and 3% w/v trypticase soy broth 
(TSB) in deionised water) with a stock cryo bead for 24 hours at 37oC (Gallenkamp Hotbox size 
2). 24 hours prior to use, secondary overnight cultures were prepared, inoculating 20mL TSB 
(3% w/v TSB in deionised water) with 2-3 colonies. Cultures were incubated for 16 hours at 
37oC, under shaking at 120 rotations per minute (rpm) (Sciquip mini incu shake). 
 
2.5  In vivo Animal Studies 
 
2.5.1 Preparation of Bacterial Embedded Agar Beads 
 
The infectious and inflammatory profiles associated with bacterial infection were studied 
using a murine model of chronic pulmonary infection. Using a modified version of the method 
described by Facchini et al (Facchini et al., 2014), bacterial embedded agar beads were 
prepared in vitro, followed by direct instillation into the lungs. Bacterial ONCs were 
centrifuged at 2800 g (Heraeus Labofuge 400R) for 20 minutes at 4oC. The pellet was 
resuspended in 1mL phosphate buffered saline (PBS). The bacteria were embedded into agar 
beads by mixing 1mL ONC with 9mL molten 1.5% w/v noble agar. This was then added into 
warmed mineral oil previously heated to 50oC under stirring conditions using a IKA C-MAG 
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HS7 stir plate (speed setting 3 on plate, 6 minutes). The preparation was then cooled by slowly 
spinning (speed setting 1) on a stir plate, on ice for 35 minutes and subsequently centrifuged 
at 2,800 g for 30 minutes to remove any remaining mineral oil. The preparation was washed 
in sterile PBS and centrifuged at 2,800 g for 10 minutes, the supernatant was then discarded 
and the remaining pellet resuspended in sterile PBS to achieve a final volume of 20mL. A 
colony forming units (CFU) determination was performed on the bead slurry by homogenising 
a 3mL aliquot of the beads (Ultra Turrax T2, IKA WERKE). 1 in 10 serial dilutions (in saline) 
were performed using a 96 well plate and appropriate dilutions were plated onto TSA plates. 
The bead slurry was diluted with sterile PBS to obtain the desired CFU of either 2x107 cfu/mL, 
2x106 cfu/mL or 2x105 cfu/mL, to achieve a final dose of either 1x106, 1x105 or 1x104 
cfu/mouse. As a control, sterile, PBS embedded agar beads were prepared using the same 
protocol. 
 
2.5.2 Establishing a Model of Pulmonary Infection with P.aeruginosa and MRSA 
 
To define the optimum conditions for pulmonary infection with P.aeruginosa and MRSA, male 
C57/Bl6J mice were exposed to 3 different infection protocols. The infection protocols used 
3 different inoculum levels with different bacterial strains (Figure 2.1). Mice were 
anesthetized with inhaled 3% isoflurane using an adaptable combination system with on-
board oxygen concentrator rig (Burtons Vetinary). Animals were then inoculated with 50μL of 
either 2x107 cfu/mL, 2x106 cfu/mL or 2x105 cfu/mL bacteria, strains P.aeruginosa RP73, PAO1, 
NN2 or MRSA USA300, via oropharyngeal (o.a.) dosing, achieving a final dose of 1x106, 1x105 
or 1x104 cfu/mouse. Sham control mice were inoculated with sterile PBS embedded agar 
beads via the o.a. route. Animals were weighed and assessed daily for signs of pain and 
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distress using the Body Condition Score (BCS), grading the animals from 5-1 (1: emaciated, 2: 
under conditioned, 3: well-conditioned, 4: over conditioned, 5: obese). Parameters assessed 
included animals showing reluctance to move, abnormal hunched posture, piloerection, 
dehydration detectable by skin tenting, lethargy and vocalisation on handling suggestive of 
pain. Animals that lost more than 20% of their body weight or received a BCS of less than 2 









Figure 2.1 Protocol for Inducing Pulmonary Bacterial Infection in Mice 
 
 
2.5.3 Whole Blood Platelet Quantification and Plasma Isolation 
 
48 hours post infection (h.p.i), mice were terminally anaesthetised with 0.3mL 25% w/v 
Urethane via i.p. injection. Once suitably anaesthetised, 0.5-1mL blood was collected via 
cardiac puncture from animals anaesthetised with 0.3mL Urethane. Upon collection, blood 
was mixed with Acid Citrate Dextrose (ACD) at a ratio of 1-part ACD to 9-parts blood. For 
platelet quantification, whole blood was diluted in Stromatol (1:100) and quantified using an 
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improved Neubauer haemocytometer under a x40 objective and Leica DM 2000 LED upright 
microscope. The absolute platelet count was used to calculate the number of platelets/mL.  
For plasma isolation, remaining whole blood was spun at 1700 g (Eppendorf centrifuge 5417R) 
for 10 minutes, and the supernatant collected and stored at -80oC. 
 
2.5.4 Bronchoalveolar Lavage 
 
The trachea was exposed by blunt dissection and a small incision made. A 22-gauge cannula 
was inserted into the trachea and 3 aliquots of 0.5mL sterile PBS were injected into the lung. 
The resulting fluid was withdrawn using a 1mL syringe. 
 
2.5.5 Total Leukocyte Quantification 
 
Bronchoalveolar lavage (BAL) fluid was used to quantify total leukocytes. Each BAL sample 
was diluted 1:1 in Turk’s solution. The total cell counts were then quantified using an 
improved Neubauer haemocytometer under a x20 objective and Leica DM 2000 LED upright 
microscope. 
 
2.5.6 Differential Leukocyte Quantification 
 
Cytospin slides (thermo scientific) were set up and a 100µL aliquot of each BAL sample was 
added. Samples were spun at 1000 rpm for 1 minute under slow acceleration (Shandon 
Cytospin 3) and allowed to air dry. Slides were subsequently stained using a Shandon™ Kwik-
Diff™ staining kit and cover slipped using DPX mounting medium. Differential leukocyte 
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counts were quantified by counting 200 cells from a representative area of each slide, defined 
as 50 cells per field of view, and the percentage of neutrophils, lymphocytes, macrophages 
and eosinophils was determined. The total leukocyte count and the percentages of each cell 
type were used to determine the number of individual inflammatory leukocytes present in 
each BAL sample. 
 
2.5.7 Colony Forming Unit Determination 
 
48 h.p.i, lungs were aseptically removed and homogenized in 2mL sterile saline. Lung 
homogenates were serially diluted (in saline) using a 96 well plate and appropriate dilutions 
were plated onto TSA plates. Bacterial colonies were manually counted and the total 
pulmonary CFU was calculated.   
 
2.5.8 The Effect of Tobramycin on Pulmonary Infection with P.aeruginosa 
 
The optimum inoculum for pulmonary infection with P.aeruginosa was determined to be 
1x106 cfu/mouse, producing an infection and inflammatory profile analogous to the clinical 
setting. Therefore, experiments were performed to validate the murine model of pulmonary 
infection with P.aeruginosa, using a single dose of 0.2mL/ mouse of either vehicle (saline) 
Tobramycin at either 10, 50, 100, 200 or 300 mg/kg, at 24 h.p.i, via i.p. injection. Tobramycin 
doses for each P.aeruginosa strain are listed in Table 2.1. At 48 h.p.i, blood was taken, a BAL 
was performed and lungs were aseptically removed and processed as described in sections 
2.5.3, 2.5.4 and 2.5.7 respectively. 









Table 2. 1 Tobramycin Doses for the Murine Model of Pulmonary Infection with 
P.aeruginosa 
 
2.5.9 The Effect of Vancomycin on Pulmonary Infection with MRSA 
 
The optimum inoculum for pulmonary infection with MRSA, strain USA300, was determined 
to be 1x106 cfu/mouse. Experiments were performed to validate the murine model of 
pulmonary infection with MRSA, strain USA300, using a single dose of 0.2mL/ mouse of either 
vehicle (saline) or Vancomycin at either 50, 100 or 200 mg/kg, initiated at 24 h.p.i, via i.p. 
injection. At 48 h.p.i, blood was taken, a BAL was performed and lungs were aseptically 
removed and processed as described in sections 2.5.3, 2.5.4 and 2.5.7 respectively. 
 
2.6  The Effect of Thrombocytopenia in a Murine Model of Pulmonary Infection with 
P.aeruginosa and MRSA 
 
2.6.1 Establishing a Murine Model of Platelet Depletion 
 
To investigate the role of platelets in the regulation of pulmonary infection, the depletion of 
circulating platelets was induced in a murine model of pulmonary infection with P.aeruginosa 
strain RP73. These experiments were performed with the assistance of collaborators at the   
Bacterial Strain Tobramycin Dose (mg/kg) 
P.aeruginosa RP73 50, 100, 300 
P.aeruginosa PAO1 10, 50, 100 
P.aeruginosa NN2 50, 100, 200 
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Infections and Cystic Fibrosis Unit, Division of Immunology, Transplantation and Infectious 
Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. Male C57/Bl6 mice were 
anaesthetised and inoculated with P. a. strain RP73 embedded agar beads, at either 1x106, 
1x105 or 1x104 cfu/mouse as previously described in section 2.5.2. In other separate 
experiments, mice were infected with 1 x 105 cfu/mouse MRSA strain USA300. Sham control 
mice were inoculated with sterile PBS embedded agar beads. 24 hours prior to infection, 
platelet depletion was induced via intra-muscular (i.m.) injection with 50μL 1mg/kg of an anti-
GPIbα platelet depleting antibody (in saline). Control mice were administered with 50μL IgG 
control antibody (i.m.) in saline. The following protocol (Figure 2.2) was used to investigate 










Figure 2. 2 A Protocol for Platelet Depletion: To Investigate the Effect of Platelet Depletion 
in a Murine Model of Pulmonary Bacterial Infection 
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24 h.p.i, platelet numbers were enumerated in whole blood, as described in section 2.5.3, to 
ensure adequate platelet depletion of ≥85%. A BAL of the lungs was performed and lungs 
were aseptically removed and processed as described in sections 2.5.4 and 2.5.7 respectively. 
Any incidence of mortality in mice depleted of platelets or in mice with normal circulating 
platelet levels was recorded.  
 
2.6.2 The Effect of Platelet Depletion on Pulmonary Haemorrhage 
 
In order to investigate whether administration of the platelet depleting anti-GPlbα antibody 
has any effect on pulmonary haemorrhage following infection with P.aeruginosa strain RP73, 
haemoglobin levels present in BAL fluid were quantified following administration of either the 
IgG control or anti-GPlbα antibodies. A 100μL aliquot of BAL fluid was taken and the 
absorbance was measured using a Spectramax 340PC microplate reader at 410nm, to detect 
haemoglobin. 
In additional separate experiments, images of individual BAL fluid samples were taken to 
qualitatively analyse the haemoglobin levels present in BAL fluid, to determine whether 
administration of the platelet depleting anti-GPlbα antibody has any effect on pulmonary 
haemorrhage following infection with MRSA strain USA300. 
 
2.6.3 Spleen and Kidney Harvest for Microbiological Analysis 
 
To investigate whether experimentally induced platelet depletion had any effect on bacterial 
dissemination from the lungs to other peripheral organs, the kidney and spleen were removed 
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and homogenized in 2mL sterile saline. Homogenates were serially diluted using a 96 well 
plate and appropriate dilutions were plated onto TSA plates. Bacterial colonies were manually 
counted and the total kidney and spleen cfu were calculated. 
 
2.6.4 Evaluation of Biochemical Markers of Metabolic Acidosis 
 
Throughout experimentally induced platelet depletion experiments, core body temperature 
was monitored using rectal probe thermometry (Homeothermic Monitor, Harvard 
Apparatus). 
24 hours following infection with 1x105 cfu/mouse P.aeruginosa strain RP73, blood was 
collected, under anaesthesia, via cardiac puncture into heparin (100 units/mL) coated 
syringes. 65µl blood was transferred to EC8+ blood analyser cartridges and processed using a 
handheld i-STAT blood analyser (Abaxis VetScan iSTAT 1 analyser 300A) to quantify a panel of 
biochemical markers of metabolic acidosis used to detect organ dysfunction, including pH, 
urea, base excess, bicarbonate ions, pCO2 and anion gaps. 
In separate experiments, naïve mice were administered either 50µL of the IgG control or 
platelet depleting anti- GPIbα antibody. At 24 hours post treatment, the effects of platelet 
depletion on biochemical markers of metabolic acidosis were analysed as described above. 
 
2.6.5 The Effect of Thrombocytopenia on Pulmonary Alveolar Integrity 
 
Experiments were performed to investigate the effect of thrombocytopenia on pulmonary 
alveolar integrity, following infection with P.aeruginosa strain RP73. Thrombocytopenic mice 
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were infected with 1x105 cfu/mouse as described in sections 2.5.2 and 2.6.1. 23 h.p.i 100μL 
0.5% Evans Blue dye was administered via intra-venous (i.v.) injection. 24 h.p.i the right lobe 
of the lung was removed, weighed and added to 500μL Formamide. This was incubated at 
65oC for 24 hours to extract the dye. At the same time point, the left lobe of the lung was 
removed and weighed to determine the ‘wet weight’. This was subsequently incubated for 24 
hours at 65oC. 24 hours post incubation, the left lobe lung samples were weighed, to 
determine the ‘dry lung weight’. The right lobe lung samples were centrifuged at 1700 g for 5 
minutes to remove remaining tissue fragments and absorbance values measured at 620nm 
(Jenway 6300 spectrophotometer). A standard curve was used to calculate nanograms (ng) 
Evans Blue dye per mg lung tissue for each sample. 
 
2.7  Mechanisms of Platelet Involvement in Infection 
 
2.7.1 The Role of Platelet TLR4 in the Regulation of Pulmonary Infection 
 
To investigate the role of platelet Toll- like receptor 4 (TLR4) in infection, male TLR4 knockout 
mice (Riffo-Vasquez et al., 2012) and C57/BI6J wild type mice were infected with 1x105 
cfu/mouse as described in section 2.5.2 and sham control mice were inoculated with sterile 
PBS embedded agar beads. 24 h.p.i, a BAL of the lungs was performed as described in section 
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2.7.1.1 Polymerase Chain Reaction Analysis of Murine TLR4 cDNA 
 
A mutation inducing loss of function was used to generate TLR4 knockout mice. DNA was 
extracted from tail clips of TLR4 knockout and C57/BI6J wild type mice. Tails clips were 
immersed in lysis buffer (100nM TRIS, 5mM EDTA, 0.4% SDS, 200nM NaCL, pH 8) and 
Proteinase K (diluted 1 in 100). Samples were subsequently heated overnight at 55oC. The 
lysate was then centrifuged at 5,000 g for 1 minute in order to remove the insoluble fraction. 
Polymerase Chain Reaction (PCR) reaction mixture was then added to samples (components 
indicated in Table 2.2) and left at room temperature for approximately 10 minutes.  TLR4 and 









Table 2.2 Reaction Mixture Components and Final Concentrations Used 
 
 
Table 2.3 TLR4 Knockout and Wild Type Primers using for DNA Amplification 
 
Amount Component Final Concentration 
25µl Ready Mix  
0.5µl Forward Primer 0.1-0.5μM 
0.5µl Reverse Primer 0.1-0.5µM 
1µl Template DNA (typically 10ng) 200pg/μL 
23µl Denucleated water  
50µl Total Volume  
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The DNA present in each sample was subsequently amplified in a thermal cycler using 25 
cycles of the protocol indicated in Table 2.4, Following DNA amplification, samples were 
placed on a hold cycle at 4oC.  
 
Cycling Parameter Temperature (oC) Time (mins) 
Denature Template 94 1 
Anneal Primers 55 2 
Extension 72 3 
 
 
Table 2.4 Cycling Parameters Used for DNA Amplification.  
 
Molten agarose gel solution was prepared (1.5% agarose in 1x TAE buffer- 40mM Tris, 20mM 
Acetate and 1mM EDTA pH 8), and heated until dissolved. GelRed stain was added into the 
molten gel solution (1:10,000) and mixed thoroughly. The gel was then allowed cooled, to 
solidify. Following the DNA amplification process, the samples or standard ladder were loaded 
onto the agarose gel. The gel was subsequently run at 100 volts for 30 minutes. The stained 
gel was viewed using a standard trans illuminator at 302nm and the gel was then imaged 
using an ethidium bromide filter. 
 
2.7.2 The Role of Platelet Purinergic Receptors in the Regulation of Pulmonary Infection 
 
The purine hydrolysing enzyme, Apyrase, was used to investigate the role of purines and 
purinergic receptors in the regulation of pulmonary infection. 30 minutes prior to infection, 
mice were treated with either vehicle (saline) or 100 units/mL Apyrase (0.1mL/mouse), via 
i.v. injection.  
Additional separate experiments were performed to further investigate the role of specific 
platelet purinergic receptors (P2Y1, P2Y12, P2X1 and P2Y14). 30 minutes prior to infection, mice 
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were administered a single dose (0.1mL/mouse) of either vehicle control (saline), a P2Y1 
antagonist, MRS2500 (3mg/kg), a P2Y12 antagonist, AR-C66096 (3mg/kg), a P2X1 antagonist, 
NF-279 (3mg/kg) or a P2Y14 antagonist, PPTN Mesylate (10mg/kg), via i.v. injection. A second 
dose of PPTN was administered at 6 h.p.i. 
After drug treatments, mice were infected with 1x105 cfu/mouse P.aeruginosa strain RP73, 
as described in section 2.5.2. Sham control mice were inoculated with sterile PBS embedded 
agar beads. At 24 h.p.i, blood was taken, a BAL was performed and lungs were aseptically 
removed and processed as described in sections 2.5.3, 2.5.4 and 2.5.7 respectively. 
To investigate the effect of platelet purinergic receptors on bacterial dissemination from the 
lungs to the peripheral organs, the kidney and spleen were removed, as described in section 
2.6.3.  
 
2.8  Histological Analysis of Lung Tissue 
 
2.8.1 Analysis of Infection Induced Pulmonary Neutrophil Recruitment 
 
Lungs from sham and 1x106 cfu/mouse P.aeruginosa strain RP73 infected mice, prepared as 
described in section 2.5.2, were inflated (0.5mL) and subsequently fixed in 20mL 10% 
Formaldehyde (in deionised water) for 24 hours. Lung tissue samples were paraffin fixed using 
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Reagent Time (minutes) 

















Table 2. 5 Protocol to Prepare Lung Tissues from Mice Infected with P.aeruginosa 
 
Tissue samples were subsequently embedded into paraffin wax blocks and allowed to cool 
for 1 hour on a cold plate. Lungs were then sectioned, using a microtome (Microtom 
Heidelberg HM330), to 6µm slices onto superfrost plus slides and allowed to dry overnight. 
Sections were dewaxed in dewax xylene for 5 minutes and rehydrated in xylene and 
decreasing concentrations of ethanol for 1 minute at each concentration (100%, 90%, 70%, 
tap water). To block endogenous peroxidase activity, sections were immersed in 3% hydrogen 
peroxide in ethanol for 10 minutes and then washed 3 times with tap water. For antigen 
retrieval, a sodium citrate buffer (2.94g Tri-sodium citrate, 1L deionised water, 500μl tween 
20) was prepared in a pressure cooker (Nordic ware) at pH 6.0 with 0.1M Sodium Hydroxide 
(NaOH). The sodium citrate buffer was heated on full power in a microwave (Kenwood) for 
10-15 minutes, until the solution was at 100oC. The rack of microscope slides was then placed 
into the buffer and the lid of the pressure cooker was tightened. The pressure cooker was 
heated in the microwave for a further 5 minutes. Once the pressure had equalised, the 
pressure cooker was placed under cold tap water to remove the retrieval buffer and to cool 
the slides. The remaining tap water was shaken off the slides and a ring was drawn around 
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each lung section using a hydrophobic pap pen.  To block non-specific binding, 50μL 1% bovine 
serum albumin (BSA) blocking buffer (in PBS) was added to each lung section for 10 minutes, 
before blotting dry. Slides were stained for neutrophils using 50μL of an Abcam AB6872 anti-
neutrophil elastase primary antibody (1:100 in 1% BSA in PBS) or 1% BSA in PBS for control 
sections and incubated for 2 hours at room temperature in a humidified chamber. The 
primary antibody was removed by washing sections 3 times in PBS, using a plastic squeeze 
dispensing wash bottle. 50μL of a secondary mouse-adsorbed biotinylated anti-rat rabbit 
secondary antibody (1:200 in 1% BSA in PBS) was added to sections for 1 hour. During this 
time, streptavidin (1:200 in 1% BSA in PBS) and biotinylated Horse Radish Peroxidase (HRP), 
(1:200 in 1% BSA in PBS) from an ABC Vectastrain kit, were mixed to form a complex. After 1 
hour, the secondary antibody was removed by washing in PBS. The streptavidin + biotinylated 
(HRP) was added to sections for 1 hour at room temperature, before washing. A 
Diaminobenzidine (DAB) developing buffer was prepared (20mL DAB developing buffer 10x 
stock (1M TRIS pH 7.6), 180mL deionised water, 200μL 30% hydrogen peroxide and 1mL 
50mg/mL DAB stock), and slides were developed in the DAB solution for 10 minutes before 
washing slides in tap water. Slides were counterstained with haematoxylin Gill’s number 1 for 
30 seconds, washed in tap water and immersed in acid alcohol differentiation solution for 10 
seconds. Slides were then washed in tap water before dehydrating in increasing 
concentrations of ethanol (70%, 90%, 100%) and xylene, each for one minute. Following 
dehydration, slides were coverslipped using DPX mounting medium. Representative images 
of infected and control lung sections were captured using a Leica DM 2000 LED upright 
microscope, under a x40 objective.   
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2.8.2 Histological Analysis of Pulmonary Tissue with Haematoxylin and Eosin (H&E) 
 
Experiments were performed to visualise the pulmonary inflammatory cell infiltrate following 
infection. Lungs from either sham control or infected (1x106 cfu/mL P.aeruginosa strain RP73) 
mice, as described in section 2.5.2, were formalin fixed, processed and embedded into 
paraffin wax blocks as described in section 2.8.1. Lungs were dehydrated in xylene and 
ethanol, as described in section 2.8.1 and immersed into tap water for 5 minutes. Slides were 
immersed in eosin for 10 seconds and subsequently washed in tap water 3 times. Slides were 
immersed in acid alcohol differentiation solution for 10 seconds, followed by washing in tap 
water. Samples were then immersed in haematoxylin Gill’s number 1 for 30 seconds, followed 
by washing in tap water. Slides were immersed in acid alcohol differentiation solution a 
second time, dehydrated using ethanol and xylene, and coverslipped, as described in section 
2.8.1. Representative images of infected and control lung sections were captured using a Leica 
DM 2000 LED upright microscope, under a x40 objective.  
 
2.9  Evaluation of Inflammatory and Platelet Activation Markers Following Infection 
 
Experiments were performed to investigate whether inflammatory markers, IL-6 and the 
chemokine receptor ligand KC (CXCL1), and platelet activation markers, PF-4 and RANTES, 
were significantly elevated following pulmonary bacterial infection. Plasma and BAL samples 
were taken from sham control, P.aeruginosa (RP73, PAO1 and NN2) and MRSA (USA300) 
infected mice, as described in 2.5.3 and 2.5.4. Murine IL-6, KC, PF-4 and RANTES in samples 
were measured using mouse Duoset enzyme linked immunosorbent assay (ELISA) kits, 
according to manufacturer’s instructions (Table 2.6). 100μL of the capture antibody (in PBS 
(Table 2.6) was added to each well in a 96 well ELISA microplate and incubated overnight at 
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room temperature. Wells were washed three times with 400μL wash buffer (0.05% Tween 20 
in PBS, pH 7.2-7.4) and blotted dry to remove any remaining wash buffer. Plates were blocked 
by adding 300μL of reagent diluent (1% BSA in PBS, pH 7.2-7.4) to each well, for 1 hour at 
room temperature. The plates were then washed again, as described previously. A seven-
point standard curve of recombinant IL-6, KC, PF-4 and RANTES was prepared using 2-fold 
serial dilutions (in reagent diluent, Table 2.6), 100μL of sample or standard (diluted in reagent 
diluent) was added to wells and incubated for 2 hours at room temperature. Wells were 
washed again and 100μL of detection antibody (in reagent diluent, Table 2.6) was added to 
each well for 2 hours at room temperature. Wells were washed and 100μL of streptavidin- 
HRP (diluted in reagent diluent according to vial instructions) was added to each well for 20 
minutes at room temperature, avoiding direct light. Plates were washed a final time and 
100μL of substrate solution (1:1 mix of hydrogen peroxide and tetramethylbenzine) was 
added to each well for 20 minutes at room temperature, avoiding direct light. 50μL stop 
solution (2N H2SO4) was added to each well, whilst tapping gently to ensure thorough mixing. 






Table 2. 6 The Concentrations of Capture and Detection Antibodies and 7-point Standards: 













IL-6 2 1000 - 15.6 150 
KC 2 1000 - 15.6 50 
PF-4 2 2000 - 31.3 100 
RANTES 2 2000 - 31.3 12.5 
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2.10 The Use of a Murine Model of Pulmonary Infection for Therapeutic Analysis 
 
2.10.1 The Effect of HT61 Against Pulmonary Infection with P.aeruginosa and MRSA 
 
Mice were anesthetised with inhaled isoflurane and inoculated with 1x106 cfu/mouse 
bacterial embedded agar beads as described in section 2.5.2. Sham control mice were 
inoculated with sterile PBS embedded agar beads. 24 h.p.i, mice were administered with 
either 0.2mL/ mouse vehicle control (0.1% Dimethyl sulfoxide (DMSO)) or with a single dose 
of a small quinolone derived compound, HT61 at either 0.1, 1, 5 or 10 mg/kg HT61, via i.p. 
injection. HT61 doses for each bacterial strain are listed in Table 2.7. 
 
Bacterial Strain HT61 Dose (mg/kg) 
P.aeruginosa RP73 0.1, 1, 5 
P.aeruginosa PAO1 0.1, 1, 5 
P.aeruginosa NN2 0.1, 1, 5 
MRSA USA300 0.1, 1, 10 
 
Table 2.7 HT61 Doses Used in the Murine Model of Pulmonary Infection with P.aeruginosa 
and MRSA 
 
48 h.p.i, a BAL was performed and lungs were removed and processed, as described in 
sections 2.5.4 and 2.5.7 respectively.  
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2.10.2 The Effect of HT61 and Tobramycin/ Vancomycin Combination Treatment Against 
Pulmonary Infection with P.aeruginosa and MRSA 
 
Experiments were performed to investigate whether combination therapies of HT61 with 
Tobramycin had any further effects on pulmonary bacterial load. Mice were anesthetised with 
inhaled isoflurane and inoculated with 1x106 cfu/mouse bacterial embedded agar beads as 
described in 2.5.2. Sham control mice were inoculated with sterile PBS embedded agar beads. 
24 h.p.i, mice were treated with either 0.2mL/ mouse vehicle (0.1% DMSO), 50, 100, 200 or 
300 mg/kg Tobramycin (for P.aeruginosa strains), 100 mg/kg Vancomycin (for MRSA), 1 mg/kg 
HT61 (for all bacterial strains) or combination treatment, all administered via i.p. injection. 
Singular and combination treatment doses for each bacterial strain are listed in Table 2.8. 
 
















P.aeruginosa RP73 100, 300 X 1 100 T 1 
P.aeruginosa PAO1 50 X 1 50 T 1 
P.aeruginosa NN2 100, 200 X 1 100 T 1 
MRSA USA300 X 100 1 50 V 1 
 
 
Table 2. 8 Singular and Combination Treatment Doses for the Murine Model of Pulmonary 
Infection with P.aeruginosa and MRSA 
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48 h.p.i, a BAL was performed and lungs were removed and processed, as described in 
sections 2.5.4 and 2.5.7 respectively.  
 
2.11 The Role of Platelets in the Regulation of Pulmonary Infection 
 
2.11.1 Pulmonary Platelet Recruitment Following Infection with P.aeruginosa Strain RP73 
 
Experiments were performed to determine whether platelets are recruited to the lung 
following bacterial infection. Lungs from sham control and 1x106 cfu/mouse P.aeruginosa 
strain RP73 infected mice, were formalin fixed, processed and embedded into paraffin wax 
blocks as described previously (2.8.1). To assess platelet recruitment into different anatomical 
regions of the lung, sections were stained for platelets using a platelet specific anti-CD42b 
primary antibody (1:500), a Vector Laboratories BA100 biotinylated anti- rabbit secondary 
antibody (1:200), and an ABC Vectastain kit, as described in section 2.8.1. 
 
2.12 In vitro Experiments 
 
2.12.1 Murine Blood Collection 
 
Male C57/BI6J mice were terminally anaesthetised with 0.3mL 25% w/v Urethane, via i.p. 
injection. 1mL citrated blood was collected via cardiac puncture, mixing with ACD at a ratio of 
1-part ACD to 9-parts blood. 
  
124 | Chapter II: Materials and Methods 
 
2.12.2 Murine Platelet Isolation 
 
Platelet rich plasma (PRP) was collected from citrated blood by centrifugation at 100 g for 10 
minutes at 23oC. Blood was then centrifuged again at 120 g for 5 minutes at 23oC and the 
remaining PRP collected. Prostaglandin E1 (PGE1) (5μL 2.5mM) was added to the PRP, which 
was then centrifuged again at 900 g for 6 minutes. The resulting platelet pellet was 
resuspended in 200μL Tyrode’s buffer (0.14M Sodium Chloride (NaCl), 0.003M Potassium 
Chloride (KCl), 0.0003M Sodium Dihydrogen Phosphate Dodecahydrate (Na2HPO4.12H2O), 
0.01M Sodium Hydrogen Carbonate (NaHCO3), 0.02M HEPES, 0.001M Magnesium Chloride 
(MgCl2) and 0.005M Glucose, pH 7.3). Platelets were subsequently stained in Stromatol 
(1:100) and quantified on a Neubauer haemocytometer, under a x40 objective, using a Leica 
D 2000 led upright microscope. Platelets were diluted to a final working concentration of 
either 1x106, 1x107 or 1x108 platelets/mL in Tyrodes buffer and treated with 2mM Ca2+ prior 
to use.  
 
2.12.3 The Effect of Platelets on Growth of P.aeruginosa strain RP73 in vitro 
 
Co-culture experiments were performed to investigate whether platelets can have a direct 
effect on bacterial growth.  ONCs of P.aeruginosa strain RP73 were prepared, as described in 
2.4, and diluted to a final working concentration of 1x106 cfu/mL in TSB (OD600 0.0031). 
Murine platelets were isolated, as described in section 2.12.2, and diluted to a final working 
concentration of 1x106 platelets/mL in Tyrodes buffer. Platelets and bacteria were cultured 
at a volumetric ratio of 1:1, at 37oC, under shaking conditions at 120rpm. For CFU 
quantification, 20μL aliquots of the culture were taken periodically every 2 hours from 0 to 8 
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hours and 10-fold serial dilutions (in saline) were performed and plated onto TSA plates for 
24 hours at 37oC.  
 
2.12.4 Platelet Bacterial Killing Assays 
 
To further investigate whether platelets have a direct killing effect on bacteria, co-culture 
experiments were performed as described in 2.12.3, using a LIVE/DEAD BacLight Bacterial 
Viability Kit, according to manufacturer’s instructions. For these experiments, murine 
platelets were diluted to a final working concentration of either 1x106, 1x107 or 1x108 
platelets/mL in Tyrodes buffer. A culture with no platelets was prepared as a negative control. 
At each time point (0, 2, 4, 6 and 8 hours), 150μL aliquots were taken and centrifuged at 1700 
g for 10 minutes and resuspended in 150μL deionised water. 100μL of each sample was added 
to black 96 well plates. 50μL 2.5uM SYTO9 (in deionised water) was added to each well, 
incubated for 15 minutes on ice and read at 488/20nm excitation, 528/20nm emission on a 
fluorescent plate reader (Synergy HT Bio-Tek). Samples were then counterstained using 50μL 
15uM Propidium Iodide (PI) (in deionised water) for 15 minutes, and plates were read again 
at 488/20nm excitation, 645/20nm emission. 
Other separate experiments were performed to ensure platelets remained viable throughout 
the duration of the co-culture experiments. At each time point (0, 2, 4, 6,8), 3 aliquots (50µL) 
of the 1x107 platelet-bacteria co-culture were taken and stimulated with either vehicle control 
(saline), 100µM ADP or 10µM thrombin receptor activating peptide (TRAP) for 30 minutes at 
room temperature. After incubation, 1µL anti-CD41 Phycoerythrin (PE) and 1µL anti- CD62P 
Fluorescein Isothiocyanate (FITC) antibodies were added to each sample, and these were left 
to incubate for an additional 15 minutes at room temperature. Following incubation 500µL 
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PBS was added to each sample. CD62P events were quantified and analysed on a Beckman 
Coulter Cytomics FC 500 flow cytometer. Data was collected using FITC and PE fluorescent 
wavelengths at 515nm and 580nm respectively. Live gating was used to specifically identify 
CD62P positive events on cells positive for CD41, using forward and side scatter analysing 
10,000 events. Events staining positive for both CD41 and CD62P were considered to 
represent P-selectin expressing platelets.  
 
2.13 Ex vivo Animal Studies 
 
 
2.13.1 Analysis of Platelet-Leukocyte Complexes Formation ex vivo 
 
Male C57BIJ6 mice were anesthetised with inhaled isoflurane and inoculated with either 
sham or 1x106 cfu/mouse P.aeruginosa RP73 bacterial embedded agar beads as described in 
section 2.5.2. 24 h.p.i, citrated blood was isolated via cardiac puncture. 2μL murine whole 
blood was treated with saturating concentrations of the platelet specific antibody, CD41-FITC 
(1:10 in saline) and the neutrophil specific antibody Ly6G-PE. Blood samples were incubated 
with the antibodies for 30 minutes, in the dark at room temperature. After the incubation 
period, 500μL lysis buffer (0.015M NH4Cl, 0.001M KHCO3, 0.00001M EDTA) was used to lyse 
erythrocytes. Platelet-leukocyte complexes were quantified and analysed on a Beckman 
Coulter Cytomics FC 500 flow cytometer as described in section 2.13.1. Live gating was used 
to specifically identify CD41 expressing platelets and Ly6G expressing neutrophils, using 
forward and side scatter analysing 10,000 events. Events positive for both CD41 and LY6G 
were considered to represent platelet-neutrophil complexes. 
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2.14 Human in vitro Studies 
 
2.14.1 Human Platelet Isolation 
 
Human citrated venous blood (20 mL) was isolated from the antecubital vein of healthy 
volunteers (who had not taken anti-platelet drugs for 10 days prior to donation), at a ratio of 
1-part ACD: 9-parts blood. Blood was centrifuged at 120 g for 20 minutes at 25oC and the 
resulting PRP was collected. PGE1 was added to the PRP in excess (1:1000 into PRP) and 
centrifuged at 1300 g for 10 minutes at 25oC. The supernatant or platelet poor plasma (PPP) 
was aspirated and the remaining platelet pellet resuspended in 1mL RPMI 1640 media. 10μL 
2.5mM PGE1 (1:100) was added to the platelet suspension and the final volume was made up 
to 10mL in RPMI 1640. The platelet suspension was centrifuged again at 1300 g for 10 minutes 
at 25oC, before the supernatant was aspirated and the platelet pellet resuspended in 1mL 
RPMI 1640. Platelets were stained with Stromatol (1:100) and quantified using an improved 
Neubauer haemocytometer under a x40 objective and Leica DM 2000 LED upright microscope 
and diluted to a final working concentration of 1x108 platelets/mL. Platelets were left for 45-
60 minutes at 37oC, to allow the PGE1 to degrade prior to use. Platelets were then treated 
with 2mM Ca2+ for functional experiments and stimulated with 100nM ADP for chemotaxis 
experiments. 
 
2.14.2 Bacteria Induced Platelet Chemotaxis in vitro 
 
Wells on a BD Falcon 24 well companion plate were blocked for 1 hour using 1mL RMPI 1640 
media + 1% BSA per well. After 1 hour, the blocking buffer was aspirated and individual wells 
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were washed using 1mL RPMI 1640 media. Cell culture inserts (BD Falcon transparent 3μm 
PET membrane for 24 well plate) were added to individual wells and 600μL P.aeruginosa 
strain RP73 was added to the bottom chamber at varying concentrations (1x106, 1x105, 1x104 
cfu/mL in RPMI 1640 media). 600μL 1μg/mL stromal cell derived factor 1α (SDF-1α) was added 
as a positive chemotactic control and 600μL RPMI 1640 media was added as a negative 
control. 250μL of washed platelets, isolated from human whole blood (ADP stimulated 
(100nM)) were added on top of the transwell inserts (Figure 2.3) and incubated for 90 
minutes at 37oC. After the incubation period, 50μL media from each of the bottom chambers 
was incubated with 2μL platelet specific CD41-FITC (1:10 in saline) antibody, for 30 minutes 
at room temperature in the dark. After 30 minutes, 500μL PBS and 50μL flow count 
flurospheres (Beckman Coulter) were added to 50μL of each sample. Flow count 
fluorospheres are a suspension of fluorospheres used to directly determine absolute counts 
on the flow cytometer. Samples were subsequently analysed and the platelets were 
quantified using a Beckman Coulter Cytomics FC 500 flow cytometer. Those that stained 
positively for the CD41 antigen were used as a measure of platelet migration.  
  
















2.15 Statistical Analysis 
 
Total lung CFU is expressed as log cfu. Total lung cfu and total and differential cell counts from 
BAL fluid taken from in vivo infection studies, and blood samples (circulating platelets and 
flow cytometry analysis) were expressed as mean ± standard error of the mean (SEM). A 
Sharipo-Wilk normality test was performed to confirm that values came from a Gaussian 
distribution of data. A parametric one-way analysis of variance (ANOVA), followed by a 
Bonferroni’s multiple comparison post hoc test were used for comparisons of data sets. For 
immunohistochemistry and ELISA experiments, data were expressed as mean ± SEM and 
analysed using an unpaired Two-Tailed T-test. Survival curves were analysed using a Mantel-
Cox test. For chemotaxis experiments, data was expressed as a chemotactic index (CI) ± SEM. 
Data was analysed using a one-way ANOVA, followed by a Bonferroni’s multiple comparison 
test between groups.  All data was analysed by GraphPad Prism 6.0 and significant differences 
Chemoattractant 
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were accepted if p<0.05 was observed between individual groups, when compared to either 
sham or vehicle control groups.   
 













Chapter III: Results I 
 
 
Establishment and Validation of a 
Murine Model of Pulmonary Infection 
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3.1 Establishing a Murine Model of Pulmonary Infection with P.aeruginosa and MRSA 
 
3.1.1 Establishing a Murine Model of Pulmonary Infection with P.aeruginosa strain RP73 
 
Initial titration studies were performed to determine the optimum inoculum to establish a 
murine model of pulmonary infection with the multidrug resistant clinical strain of 
P.aeruginosa, RP73. Mice were exposed to 3 different concentrations (1x104, 1x105 or 1x106 
cfu/mouse) of bacterial embedded agar beads and infection and inflammatory parameters 
were subsequently analysed. 
Murine pulmonary infection was established with all 3 tested inoculum levels, with a 
significant increase in pulmonary bacterial load observed at 48 h.p.i when compared to sham 
controls (104: 3.94±0.20 log cfu, 105: 4.25±0.57 log cfu and 106: 4.76±0.17 log cfu, versus 
sham: 0.0±0.0 log cfu, p<0.0001, Figure 3.1A).  
Infection with 1x106 cfu/mouse P.aeruginosa strain RP73 induced a significant increase in 
pulmonary total leukocyte recruitment when compared to sham controls (106: 
12.47±1.19x105 cells/mL versus sham: 1.43±0.16x105 cells/mL, p<0.0001, Figure 3.1B). This 
increase in total pulmonary leukocyte recruitment was characterised by a significant increase 
in neutrophils (106: 10.18±1.50x105 cells/mL versus sham: 0.04±0.01x105 cells/mL, p<0.0001, 
Figure 3.1C). In contrast, pulmonary infection with either 1x104 or 1x105 cfu/mL P.aeruginosa 
strain RP73 did not demonstrate any significant increase in either total leukocyte recruitment 
(104: 3.95±0.76x105 cells/mL and 105: 4.33±0.36x105 cells/mL, versus sham: 1.43±0.16x105 
cells/mL, Figure 3.1B) or neutrophil recruitment (104: 2.38±0.85x105 cells/mL, 105: 
2.84±0.53x105 cells/mL, versus sham: 0.04±0.01x105 cells/mL, Figure 3.1B) to the lungs, when 
compared to sham controls. No significant changes were observed with either macrophage 
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(104: 1.56±0.10x105 cells/mL, 105: 1.49±1.20x105 cells/mL and 106: 2.29±0.45x105 cells/mL, 
versus sham: 1.40±0.17x105 cells/mL, Figure 3.1D) or lymphocyte (104: 0.0±0.0x105 cells/mL, 
105: 0.0±10.0x105 cells/mL and 106: 0.0±0.0x105 cells/mL, versus sham: 0.0±0.0x105 cells/mL) 
numbers at any tested inoculum.  


















Figure 3.1 Effects of P.aeruginosa strain RP73 on Bacterial and Inflammatory Parameters 
of Pulmonary Infection 
 
Mice were infected (o.a) with either sham or 1x104, 1x105, 1x106 cfu/mouse RP73 
embedded agar beads. A BAL of the lungs was performed for inflammatory cell 
quantification and lungs were aseptically removed, homogenised and plated for 
quantification of bacterial load at 48 h.p.i. (A) Pulmonary Bacterial Load, (B) Total Cells, (C) 
Neutrophils and (D) Macrophages, one-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, **** p<0.0001 versus sham, n=3-4, data are presented as 
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3.1.1.1 Histological Analysis of Pulmonary Tissue Following Infection with P.aeruginosa strain RP73 
 
Lung samples collected 24 h.p.i were stained with H&E to determine whether infection with 
P.aeruginosa strain RP73 had any significant effect on inflammatory cell recruitment, lung 
architecture and alveolar integrity.  
Lung histopathology indicated gross differences in both the inflammatory cell type present 
and the density and distribution of cells, between P.aeruginosa infected and sham control 
animals. The H&E stain of P.aeruginosa infected animals indicated intra-alveolar 
inflammation and neutrophil accumulation (Figure 3.2 iv-vi). Infection with P.aeruginosa 
induced alveolar damage and loss of alveolar integrity. In addition, representative images 
suggested evidence of haemorrhaging in the lungs and basement membrane thickening 
following infection (Figure 3.2 iv-vi). Lung sections of sham control animals however showed 
preservation of normal lung architecture and little or no neutrophil recruitment. The 
predominant cell type in the lung parenchyma of sham control mice was macrophages, with 
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Figure 3.2 Effects of P.aeruginosa strain RP73 on Inflammatory Cell Recruitment, Lung 
Architecture and Alveolar Integrity 
 
  
i ii iii 








Mice were infected (o.a) with either sham or 1x106 cfu/mouse RP73 embedded agar 
beads. At 24 h.p.i, lungs were removed, fixed in 10% formaldehyde and embedded into 
paraffin wax blocks. Tissue sections were stained with a Haematoxylin and Eosin stain. 
Representative images of lung parenchyma at x40 magnification from H&E stained lungs 
from (i-iii) sham control and (iv-vi) 1x106 cfu/mL P.aeruginosa strain RP73 infected 
animals. 
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3.1.1.2 An Investigation into P.aeruginosa Strain RP73 Infection Induced Neutrophil Recruitment 
 
Lung samples collected 24 h.p.i were stained with an anti-neutrophil elastase antibody to 
provide further evidence of neutrophil recruitment to the lungs post infection. 
Representative images of P.aeruginosa strain RP73 infected tissue sections indicated 
neutrophil accumulation and an increase in neutrophil recruitment into the airway lumen and 
alveolar spaces when compared to sham controls. Following quantification, a significant 
increase in neutrophil recruitment to the lungs was observed following infection with 
P.aeruginosa strain RP73 when compared to sham controls, as measured by the number of 
neutrophil elastase positive events per mm2 of lung tissue (1x106 cfu/mL P.aeruginosa strain 
RP73: 39456±448.2 neutrophil elastase positive events/mm2, versus sham: 2962±580.8 
neutrophil elastase positive events/mm2, Figure 3.3A). The percentage area of neutrophil 
elastase staining was also significantly increased following infection with P.aeruginosa strain 
RP73 when compared to sham controls (1x106 cfu/mL P.aeruginosa strain RP73: 8.99±1.5%, 
versus sham: 0.47±0.20%, Figure 3.3B), further highlighting infection induced neutrophil 
recruitment to the lungs. 
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Mice were infected (o.a) with either sham or 1x106 cfu/mouse RP73 embedded agar 
beads. At 24 h.p.i, lungs were removed, fixed in 10% formaldehyde and embedded into 
paraffin wax blocks. Tissue sections were stained with an anti-neutrophil elastase 
antibody and analysed for quantification of (A) Neutrophil Elastase positive events per 
mm2 and (B) Percentage area of neutrophil elastase. (C) Representative images of lung 
parenchyma at x40 magnification from (i) sham control and (iii) 1x106 cfu/mL RP73 
infected animals, (ii) and (iv) no addition of primary anti-neutrophil elastase antibody 
controls. Unpaired two-tailed t-test, **p<0.01 versus sham, n=3, data are presented as 
mean ± SEM. 
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3.1.2 Establishing a Murine Model of Pulmonary Infection with P.aeruginosa strain PAO1 
 
Having established a murine model of pulmonary infection with P.aeruginosa strain RP73, 
experiments were performed to characterise additional gram-negative P.aeruginosa strains 
in the model. Mice were infected with 2 different concentrations (1x105 or 1x106 cfu/mouse) 
of the laboratory reference strain, PAO1 embedded into agar beads and infection and 
inflammatory parameters were subsequently analysed. 
The data obtained was comparable to that observed following infection with P.aeruginosa 
strain RP73, whereby infection was established with both tested inoculum levels. A significant 
increase in pulmonary bacterial load was observed at 48 h.p.i, when compared to sham 
controls (105: 4.87±0.30 log cfu and 106: 5.91±0.17 log cfu, versus sham: 0.0±0.0 log cfu, 
p<0.0001, Figure 3.4A). 
Infection with 1x106 cfu/mouse P.aeruginosa strain PAO1 induced significant recruitment of 
both total pulmonary leukocytes (106: 31.77±3.09x105 cells/mL versus sham: 1.82±0.23x105 
cells/mL, p<0.0001, Figure 3.4B) and neutrophils (106: 29.57±3.12x105 cells/mL versus sham: 
0.02±0.01x105 cells/mL, p<0.0001, Figure 3.4C) to the lungs. Conversely, pulmonary infection 
with 1x105 cfu/mL P.aeruginosa strain PAO1 had no significant increase in total leukocyte 
recruitment (105: 4.46±0.53x105 cells/mL, versus sham: 1.82±0.23x105 cells/mL, Figure 3.4B) 
or neutrophil recruitment (105: 1.91±0.46x105 cells/mL, versus sham: 0.01±0.01x105 cells/mL, 
Figure 3.4C) to the lungs, when compared to sham controls.  
Pulmonary infection with P.aeruginosa strain PAO1 had no significant effect on the 
recruitment of macrophages (105: 2.55±0.16x105 cells/mL and 106: 2.20±0.19x105 cells/mL, 
versus sham: 1.79±0.23x105 cells/mL, Figure 3.4D) or lymphocytes (105: 0.0±10.0x105 cells/mL 
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and 106: 0.0±0.0x105 cells/mL, versus sham: 0.0±0.0x105 cells/mL) to the lungs, with no 













Figure 3.4 Effects of P.aeruginosa strain PAO1 on Bacterial and Inflammatory Parameters 
of Pulmonary Infection 
 
Mice were infected (o.a) with either sham, 1x105 or 1x106 cfu/mouse PAO1 embedded 
agar beads. A BAL of the lungs was performed for inflammatory cell quantification and 
lungs were aseptically removed, homogenised and plated for quantification of bacterial 
load at 48 h.p.i. (A) Pulmonary Bacterial Load, (B) Total Cells, (C) Neutrophils and (D) 
Macrophages. One-way ANOVA and Bonferroni’s multiple comparisons post hoc test, **** 
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3.1.3 Establishing a Murine Model of Pulmonary Infection with P.aeruginosa strain NN2 
 
Titration experiments were performed to characterise a Tobramycin resistant clinical isolate 
strain of P.aeruginosa in the murine model of pulmonary infection. Mice were infected with 
3 different concentrations (1x104, 1x105 or 1x106 cfu/mouse) of P.aeruginosa strain NN2 
embedded into agar beads and infection and inflammatory parameters were subsequently 
analysed. 
Infection with 1x104, 1x105 and 1x106 cfu/mouse induced a significant increase in pulmonary 
bacterial load at 48 h.p.i, when compared to sham controls (104: 1.35±0.57 log cfu, 105: 
4.20±0.19 log cfu and 106: 6.41±0.05 log cfu, versus sham: 0.0±0.0 log cfu, p<0.0001, Figure 
3.5A). In this strain, unlike RP73 and PAO1, a 0.41 log cfu increase was observed from the 
initial 1x106 cfu/mouse inoculum. 
Infection with both 1x105 cfu/mouse and 1x106 cfu/mouse induced significant recruitment of 
both total leukocytes (105: 32.05±2.86x105 cells/mL, p<0.01 and 106: 76.9±8.65x105 cells/mL, 
p<0.0001, versus sham: 2.74±0.51x105 cells/mL, Figure 3.5B) and neutrophils (105: 
28.25±3.34x105 cells/mL, p<0.01 and 106: 74.15±8.77x105 cells/mL, p<0.0001, versus sham: 
0.0±0.0x105 cells/mL, Figure 3.5C) to the lungs. However, no significant effects were observed 
on total leukocyte recruitment (104: 8.06±0.99x105 cells/mL, versus sham: 2.74±0.51x105 
cells/mL, Figure 3.5B) or neutrophil recruitment to the lungs (104: 3.80±0.91x105 cells/mL, 
versus sham: 0.0±0.0x105 cells/mL, Figure 3.5C), following infection with 1x104 cfu/mouse, 
when compared to sham controls. 
Pulmonary infection with P.aeruginosa strain NN2 had no significant effect on the recruitment 
of macrophages (104: 4.28±0.30x105 cells/mL, 105: 3.81±0.98x105 cells/mL and 106: 
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2.76±1.61x105 cells/mL, versus sham: 2.74±0.51x105 cells/mL, Figure 3.5D) or lymphocytes to 
the lungs (104: 0.0±0.0x105 cells/mL, 105: 0.0±10.0x105 cells/mL and 106: 0.0±0.0x105 cells/mL, 
versus sham: 0.0±0.0x105 cells/mL), with no significant increase observed at any tested 













Figure 3.5 Effects of P.aeruginosa strain NN2 on Bacterial and Inflammatory Parameters of 
Pulmonary Infection 
Mice were infected (o.a) with either sham or 1x104, 1x105, 1x106 cfu/mouse NN2 
embedded agar beads. A BAL of the lungs was performed for inflammatory cell 
quantification and lungs were aseptically removed, homogenised and plated for 
quantification of bacterial load at 48 h.p.i. (A) Pulmonary Bacterial Load, (B) Total Cells, 
(C) Neutrophils and (D) Macrophages. one-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, ** p<0.01, **** p<0.0001 versus sham, n=4, data are 
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3.1.4 Establishing a Murine Model of Pulmonary Infection with MRSA strain USA300 
 
Having established a murine model of pulmonary infection with the gram-negative bacterium, 
P.aeruginosa, additional experiments were performed to validate the model using a gram-
positive bacterium, MRSA. Strain USA300 was used throughout this investigation, which is 
commonly associated with community acquired infections. Mice were infected with 3 
different concentrations (1x104, 1x105 or 1x106 cfu/mouse) of USA300 embedded into agar 
beads and infection and inflammatory parameters were subsequently analysed. 
Infection with 1x104, 1x105 and 1x106 cfu/mouse induced a significant dose-dependent 
increase in pulmonary bacterial load recovered at 48 h.p.i compared to sham controls (104: 
4.53±0.07 log cfu, 105: 4.86±0.03 log cfu and 106: 5.89±0.35 log cfu, versus sham: 0.0±0.0 log 
cfu, p<0.0001, Figure 3.6A).  
MRSA, strain USA300, at any tested inoculum had no significant increase in total leukocyte 
recruitment to the lungs when compared to sham controls (104: 11.69±8.63x105 cells/mL, 105: 
14.53±9.38x105 cells/mL and 106: 26.13±12.57x105 cells/mL, versus sham: 1.24±0.13x105 
cells/mL, Figure 3.6B). However, infection with 1x106 cfu/mouse significantly increased 
pulmonary neutrophil recruitment when compared to sham controls animals (106: 
21.62±13.11x105 cells/mL, versus sham: 0.0±0.0x105 cells/mL, p<0.01, Figure 3.6B). 
Conversely, infection with 1x104 cfu/mouse and 1x105 cfu/mouse had no significant effect on 
neutrophil recruitment to the lungs when compared to sham controls (104: 1.05±0.53x105 
cells/mL and 105: 4.33±2.68x105 cells/mL, versus sham: 0.0±0.0x105 cells/mL, Figure 3.6B). 
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Pulmonary infection with MRSA strain USA300 had no significant effect on the recruitment of 
macrophages (104: 10.64±8.10x105 cells/mL, 105: 10.20±6.70x105 cells/mL and 106: 
4.51±0.61x105 cells/mL, versus sham: 1.23±0.13x105 cells/mL, Figure 3.6D) or lymphocytes to 
the lungs (104: 0.0±0.0x105 cells/mL, 105: 0.0±10.0x105 cells/mL and 106: 0.0±0.0x105 cells/mL, 
versus sham: 0.0±0.0x105 cells/mL), with no significant increase observed at any tested 
concentration, when compared to sham controls. 
  
















Mice were infected (o.a) with either sham or 1x104, 1x105, 1x106 cfu/mouse MRSA 
embedded agar bead. A BAL of the lungs was performed for inflammatory cell 
quantification and lungs were aseptically removed, homogenised and plated for 
quantification of bacterial load at 48 h.p.i. (A) Pulmonary Bacterial Load, (B) Total Cells, 
(C) Neutrophils and (D) Macrophages. One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, ** p<0.01, **** p<0.0001 versus sham, n=4, data are 
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3.2 Investigating the Effects of Infection on Inflammatory Markers in BAL Fluid and Blood 
Plasma 
 
3.2.1 Quantification of IL-6 Levels in BAL Fluid Following Infection with P.aeruginosa or MRSA 
 
IL-6 is a pro inflammatory cytokine produced transiently by activated macrophages, 
monocytes and T cells, in response to infection and tissue injuries (Tanaka et al., 2014). IL-6 
may be used as an early marker of infection and has been used to predict mortality in critically 
ill patients with organ dysfunction (Takahashi et al., 2016). We therefore sought to investigate 
how infection with P.aeruginosa and MRSA influenced the concentration of IL-6 in a murine 
model of infection. 
The concentration of IL-6 present in BAL fluid samples was significantly elevated following 
infection with 1x106 cfu/mouse P.aeruginosa strain RP73 (RP73: 315.20±39.76 pg/mL, versus 
sham: 1.41±6.61 pg/mL, Figure 3.7A, p<0.0001), PAO1 (PAO1: 299.1±48.47 pg/mL, versus 
sham: -3.40±1.85 pg/mL, Figure 3.7B, p<0.0001) and NN2 (NN2: 477.1±48.62 pg/mL, versus 
sham: -4.95±0.85 pg/mL, Figure 3.7C, p<0.0001), when compared to sham controls. For PAO1 
and NN2, the concentration of IL-6 present in the BAL fluid samples taken from sham controls 
was below the limit of detection.  
Infection with 1x106 cfu/mouse MRSA strain USA300 induced a significant increase in the 
concentration of IL-6 in BAL fluid samples, when compared to sham controls (MRSA: 
83.61±16.22 pg/mL, versus sham: -4.23±0.38 pg/mL, Figure 3.7D, p<0.0001). The 
concentration of IL-6 present in the BAL fluid samples taken from sham controls was below 
the limit of detection. 
 
 



















Figure 3.7 Effects of Infection with P.aeruginosa and MRSA on IL-6 Levels in BAL Fluid 
 
  
Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain RP73, 
PAO1 or NN2 or MRSA strain USA300 embedded agar beads. At 48 h.p.i, a BAL of the lungs 
was performed. The concentration of IL-6 present in BAL fluid was measured using a 
murine IL-6 Duoset ELISA, DY453. (A) RP73, (B) PAO1, (C) NN2, (D) USA300, unpaired two-
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3.2.2 Quantification of IL-6 Levels in Blood Plasma Following Infection with P.aeruginosa or 
MRSA 
 
Infection with P.aeruginosa and MRSA induced a significant increase in the concentration of 
IL-6 at the site of infection in BAL fluid. Therefore, we sought to investigate whether infection 
with P.aeruginosa and MRSA would have a significant effect on the concentration of IL-6 in 
blood plasma. 
The concentration of IL-6 present in plasma was significantly elevated following infection with 
1x106 cfu/mouse P.aeruginosa strain RP73 (RP73: 49.69±11.08 pg/mL, versus sham: -
6.15±2.68 pg/mL, Figure 3.8A, p<0.0001), PAO1 (PAO1: 35.07±19.41 pg/mL, versus sham: -
3.53±4.36 pg/mL, Figure 3.8B, p<0.05) and NN2 (NN2: 289.30±80.89 pg/mL, versus sham: -
5.19±1.33 pg/mL, Figure 3.8C, p<0.01), when compared to sham controls. For all 3 of these 
P.aeruginosa strains, the concentration of IL-6 present in the plasma taken from sham 
controls was below the limit of detection. Although infection with all 3 strains of P.aeruginosa 
significantly increased the concentration of IL-6 in the plasma, the increase in the 
concentration of IL-6 in BAL fluid was greater at the site of the infection. 
Infection with 1x106 cfu/mouse MRSA strain USA300 had no significant effect on the 
concentration of IL-6 in plasma, when compared to sham controls (MRSA: -1.69±2.41 pg/mL, 



























Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain RP73, 
PAO1 or NN2 or MRSA strain USA300 embedded agar beads. At 48 h.p.i, blood was taken 
via cardiac puncture and plasma was isolated. The concentration of IL-6 present in plasma 
was measured using a murine IL-6 Duoset ELISA, DY453. (A) RP73, (B) PAO1, (C) NN2, (D) 
USA300, unpaired two-tailed t-test, *p<0.05, **p<0.01, ****p<0.0001 versus sham, n=8-
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3.2.3 Quantification of KC Levels in BAL Fluid Following Infection with P.aeruginosa or MRSA 
 
The murine chemokine KC (the murine analogue of human IL-8) plays a pivotal role in host 
defence against infection, by recruiting and activating circulating neutrophils to the site of 
infection, to participate in bacterial killing (Sawant et al., 2016). This has been demonstrated 
in several animal models, whereby KC has been shown to play a dual role in the host immune 
response by recruiting peripheral neutrophils and activating neutrophils to fight against 
infection, by the release of proteases and reactive oxygen species (Sawant et al., 2016). My 
earlier studies previously demonstrated infection induced pulmonary neutrophil recruitment 
and in this part of my work I investigated whether the concentration of KC was significantly 
elevated in response to bacterial infection.  
As observed with the inflammatory marker IL-6, the concentration of KC present in BAL fluid 
was significantly elevated following infection with 1x106 cfu/mouse P.aeruginosa strain RP73 
(RP73: 208.60±35.77 pg/mL, versus sham: 8.94±6.23 pg/mL, Figure 3.9A, p<0.0001) PAO1 
(PAO1: 201.10±65.54 pg/mL, versus sham: 12.81±6.48 pg/mL, Figure 3.9B, p<0.01) and NN2 
(NN2: 356.00±53.59 pg/mL, versus sham: 26.39±8.12 pg/mL, Figure 3.9C, p<0.0001), when 
compared to sham controls. 
Infection with 1x106 cfu/mouse MRSA strain USA300 also induced a significant increase in the 
concentration of KC in BAL fluid samples, when compared to sham controls (MRSA: 























Figure 3.9 Effects of Infection with P.aeruginosa and MRSA on KC levels in Bal Fluid 
 
  
Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain RP73, 
PAO1 or NN2 or MRSA strain USA300 embedded agar beads. At 48 h.p.i, a BAL of the lungs 
was performed. The concentration of KC present in BAL fluid was measured using a murine 
KC Duoset ELISA, DY406. (A) RP73, (B) PAO1, (C) NN2, (D) USA300, unpaired two-tailed t-
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3.2.4 Quantification of KC Levels in Blood Plasma Following Infection with P.aeruginosa or 
MRSA 
 
Infection with P.aeruginosa and MRSA induced a significant increase in the concentration of 
KC at the site of infection in BAL fluid. Therefore, we sought to investigate whether infection 
with P.aeruginosa and MRSA would have a significant effect on the concentration of KC in 
blood plasma. 
The concentration of KC present in blood plasma was significantly elevated following infection 
with 1x106 cfu/mouse P.aeruginosa strain RP73 (RP73: 207.60±20.78 pg/mL, versus sham: 
59.71±9.36 pg/mL, Figure 3.10A, p<0.0001) PAO1 (PAO1: 202.20±47.24 pg/mL, versus sham: 
71.13±8.76 pg/mL, Figure 3.10B, p<0.01) and NN2 (NN2: 481.1±115.60 pg/mL, versus sham: 
88.48±14.02 pg/mL, Figure 3.10C, p<0.01) when compared to sham controls. 
Similar to the data obtained for the concentration of IL-6 in plasma, infection with 1x106 
cfu/mouse MRSA strain USA300 had no significant effect on the concentration of KC in 
plasma, when compared to sham controls (MRSA: 124.90±18.04 pg/mL, versus sham: 
107.0±12.46 pg/mL, Figure 3.10D).  
 




























Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain RP73, 
PAO1 or NN2 or MRSA strain USA300 embedded agar beads. At 48 h.p.i, blood was taken 
via cardiac puncture and plasma was isolated. The concentration of KC present in plasma 
was measured using a murine KC Duoset ELISA, DY406. (A) RP73, (B) PAO1, (C) NN2, (D) 
USA300, unpaired two-tailed t-test, **p<0.01, ****p<0.0001 versus sham, n=8-22, data 
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3.3 Validation of the Murine Model of Pulmonary Infection with P.aeruginosa and MRSA, 
using Tobramycin and Vancomycin 
 
3.3.1 Validation: Assessing the Ability of Tobramycin to Reduce Bacterial Load Post Infection 
with P.aeruginosa strain RP73 
 
Having established the optimum inoculum for pulmonary infection with 3 different strains of 
the gram-negative bacterium, P.aeruginosa, additional experiments were performed to 
validate the model with the conventional antibiotic, Tobramycin. Mice were infected with 
1x106 cfu/mouse P.aeruginosa strain RP73 (a multidrug resistant strain) and the effects of 
Tobramycin (either 50, 100, or 300 mg/kg/day, i.p.) on infection and inflammatory 
parameters were subsequently analysed. 
Infection with RP73 induced a significant increase in pulmonary bacterial load in vehicle 
treated mice when compared to sham controls (5.91±0.03 log cfu, versus sham: 0.0±0.0 log 
cfu, p<0.0001, Figure 3.11A). Following treatment with Tobramycin, a dose-dependent 
reduction in pulmonary bacterial load was observed. However, only 300 mg/kg Tobramycin 
produced a significant reduction in pulmonary bacterial load when compared to vehicle 
controls (50 mg/kg: 6.13±0.04 log cfu, 100 mg/kg: 5.85±0.03 and 300 mg/kg: 4.62±0.16 log 
cfu, p<0.0001, versus vehicle: 5.91±0.03 log cfu, Figure 3.11A).  
Infection with RP73 induced a significant increase in both total leukocyte (24.13±4.26x105 
cells/mL, versus sham: 1.28±0.25x105 cells/mL, p<0.001, Figure 3.11B) and neutrophil 
recruitment (22.32±3.69x105 cells/mL, versus sham: 0.02±0.02x105 cells/mL, p<0.0001, Figure 
3.11C) to the lungs, when compared to sham controls. No tested dose of Tobramycin had any 
significant effect on pulmonary total leukocyte recruitment when compared to vehicle 
controls (50 mg/kg: 24.58±2.43x105 cells/mL, 100 mg/kg: 28.53±4.98x105 cells/mL and 300 
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mg/kg: 24.32±0.87x105 cells/mL versus vehicle: 24.13±4.26x105 cells/mL, Figure 3.11B). 
Similarly, no significant effects of Tobramycin were observed on neutrophil (50 mg/kg: 
24.06±2.45x105 cells/mL, 100 mg/kg: 27.04±4.41x105 cells/mL and 300 mg/kg: 
22.77±1.04x105 cells/mL, versus vehicle: 22.32±3.69x105 cells/mL, Figure 3.11C), macrophage 
(50 mg/kg: 0.51±0.32x105 cells/mL, 100 mg/kg: 1.49±0.88x105 cells/mL and 300 mg/kg: 
1.54±0.60x105 cells/mL, versus vehicle: 1.80±0.77x105 cells/mL, Figure 3.11D) and 
lymphocyte (50 mg/kg: 0.0±0.0x105 cells/mL, 100 mg/kg: 0.0±10.0x105 cells/mL and 300 
mg/kg: 0.0±0.0x105 cells/mL, versus vehicle: 0.0±0.0x105 cells/mL) recruitment to the lungs, 
when compared to vehicle controls. 
  


















Mice were infected (o.a) with either sham or 1x106 cfu/mouse RP73 embedded agar 
beads. At 24 h.p.i mice were treated with a single dose of either vehicle, 50, 100, 300 
mg/kg Tobramycin (200μL, i.p). A BAL of the lungs was performed for inflammatory cell 
quantification and lungs were aseptically removed, homogenised and plated for 
quantification of bacterial load at 48 h.p.i. (A) Pulmonary Bacterial Load, (B) Total Cells (C) 
Neutrophils and (D) Macrophages. One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, *** p< 0.0001 versus sham, #### p<0.0001 versus vehicle, n=4-
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3.3.2 Validation: Assessing the Ability of Tobramycin to Reduce Bacterial Load Post Infection 
with P.aeruginosa strain PAO1 
 
Similar to RP73, experiments were performed to validate the murine model of pulmonary 
infection with PAO1 using Tobramycin. Mice were infected with 1x106 cfu/mouse 
P.aeruginosa strain PAO1 (a Tobramycin susceptible strain), and the effects of Tobramycin 
(either 10, 50, or 100 mg/kg/day) on infection and inflammatory parameters were 
subsequently analysed. 
PAO1 infection induced a significant increase in pulmonary bacterial load in vehicle treated 
mice, when compared to sham controls (5.91±0.17 log cfu, versus sham: 0.0±0.0 log cfu, 
p<0.0001, Figure 3.12A). Tobramycin treatment induced a dose-dependent reduction in 
pulmonary bacterial load, with a significant reduction in pulmonary bacterial load observed 
following treatment with 50mg/kg and 100mg/kg Tobramycin (50 mg/kg: 4.97±0.06 log cfu, 
p<0.01 and 100 mg/kg: 4.74±0.31 log cfu, p<0.0001, versus vehicle 5.91±0.17 log cfu, Figure 
3.12A), when compared to vehicle controls. 
Infection with 1x106 cfu/mouse P.aeruginosa PAO1 also induced a significant increase in total 
leukocyte (31.77±3.09x105 cells/mL, versus sham: 1.82±0.23x105 cells/mL, p<0.0001) and 
neutrophil recruitment (29.57±3.12x105 cells/mL, versus sham: 0.02±0.01x105 cells/mL, 
p<0.0001) to the lungs, when compared to sham controls. Tobramycin treatment at any 
tested dose had no significant effect on total leukocyte recruitment when compared to 
vehicle controls (10 mg/kg: 33.3±4.18x105 cells/mL, 50 mg/kg: 27.2±3.49x105 cells/mL and 
100 mg/kg: 24.93±3.43x105 cells/mL versus vehicle: 31.77±3.09x105 cells/mL, Figure 3.12B). 
Data suggested a trend depicting a decrease in total leukocytes and neutrophil recruitment 
to the lungs following Tobramycin treatment, although this data did not reach statistical 
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significance. Similarly, no tested Tobramycin dose had any significant effect on neutrophil (10 
mg/kg: 30.52±4.83x105 cells/mL, 50 mg/kg: 21.93±3.68x105 cells/mL and 100 mg/kg: 
19.22±2.07x105 cells/mL, versus vehicle: 22.32±3.69x105 cells/mL, Figure 3.12C) macrophage 
(10 mg/kg: 3.05±0.60x105  cells/mL, 50 mg/kg: 5.27±0.63x105  cells/mL and 100 mg/kg: 
5.72±1.41x105  cells/mL, versus vehicle: 2.20±0.19x105  cells/mL, Figure 3.12D) or lymphocyte 
(10 mg/kg: 0.0±0.0x105 cells/mL, 50 mg/kg: 0.0±10.0x105 cells/mL and 100 mg/kg: 
0.0±0.0x105 cells/mL, versus vehicle: 0.0±0.0x105 cells/mL) recruitment to the lungs, when 
compared to vehicle controls. 
  














Figure 3.12 Effects of Tobramycin Following Infection with P.aeruginosa strain PAO1 
  
Mice were infected (o.a) with either sham sterile or 1x106 cfu/mouse PAO1 embedded 
agar beads. At 24 h.p.i mice were treated with a single dose of either vehicle, 10, 50, 100 
mg/kg Tobramycin (200μL, i.p.). A BAL of the lungs was performed for inflammatory cell 
quantification and lungs were aseptically removed, homogenised and plated for 
quantification of bacterial load at 48 h.p.i. (A) Pulmonary Bacterial Load, (B) Total Cells (C) 
Neutrophils and (D) Macrophages. One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, **** p<0.0001 versus sham, ## p<0.01, #### p<0.0001 versus 
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3.3.3 Validation: Assessing the Ability of Tobramycin to Reduce Bacterial Load Post Infection 
with P.aeruginosa strain NN2 
 
Experiments were performed to validate a murine model of pulmonary infection with 
P.aeruginosa strain NN2 using Tobramycin. Mice were infected with 1x106 cfu/mouse 
P.aeruginosa strain NN2 (a Tobramycin resistant strain) and the effects of Tobramycin (either 
50, 100 or 200 mg/kg/day) on infection and inflammatory parameters were subsequently 
analysed. 
Infection with NN2 induced a significant increase in pulmonary bacterial load in vehicle 
treated mice, when compared to sham controls (6.65±0.08 log cfu, versus sham: 0.0±0.0 log 
cfu, p<0.0001, Figure 3.13A). Tobramycin treatment at 50 mg/kg induced a significant 
reduction in pulmonary bacterial load when compared to vehicle controls (6.13±0.22 log cfu, 
versus vehicle control: 6.65±0.08 log cfu, Figure 3.13A). However, no effect on pulmonary 
bacterial load was observed following treatment with 100 and 200 mg/kg Tobramycin when 
compared to vehicle controls (100 mg/kg: 6.73±0.14 log cfu and 200 mg/kg: 6.89±0.09 log cfu, 
versus vehicle control: 6.65±0.08 log cfu, Figure 3.13A). 
Infection with 1x106 cfu/mouse P.aeruginosa NN2, induced a significant increase in 
pulmonary total leukocytes (49.0±10.88x105 cells/mL, versus sham: 1.41±0.32x105 cells/mL, 
p<0.05, Figure 3.13B) and neutrophil recruitment when compared to sham controls 
(48.08±10.9x105 cells/mL, versus sham: 0.01±0.00x105 cells/mL, p<0.01, Figure 3.13B). No 
tested doses of Tobramycin had any significant effect on pulmonary total leukocyte 
recruitment (50 mg/kg: 51.38±16.14x105 cells/mL, 100: 27.69±5.81x105 cells/mL and 200 
mg/kg: 46.93±5.34x105 cells/mL, versus vehicle control: 49.00±10.88x105 cells/mL, Figure 
3.13B), or pulmonary neutrophil recruitment (50 mg/kg: 46.77±15.03x105 cells/mL, 100 
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mg/kg: 24.43±5.07x105 cells/mL and 200 mg/kg: 42.23±4.81x105 cells/mL, versus vehicle 
control: 48.08±10.90x105 cells/mL, Figure 3.13C), when compared to vehicle controls. In 
contrast, every tested dose of Tobramycin appeared to increase macrophage recruitment to 
the lungs, however this was only significant at 50 and 200 mg/kg, when compared to vehicle 
controls (50 mg/kg: 4.61±1.12x105 cells/mL, p<0.05, 100 mg/kg: 3.14±0.81x105 cells/mL and 
200 mg/kg: 4.69±0.55x105 cells/mL, p<0.05, versus vehicle, Figure 3.13D). No tested 
Tobramycin dose had any significant effect on lymphocyte recruitment to the lungs, when 
compared to vehicle controls (50 mg/kg: 0.0±0.0x105 cells/mL, 100 mg/kg: 0.0±10.0x105 


















Figure 3.13 Effects of Tobramycin Following Infection with P.aeruginosa strain NN2 
  
Mice were infected (o.a) with either sham or 1x106 cfu/mouse NN2 embedded agar beads. 
At 24 h.p.i mice were treated with a single dose of either vehicle, 50, 100, 200 mg/kg 
Tobramycin (200μL, i.p.). A BAL of the lungs was performed for inflammatory cell 
quantification and lungs were aseptically removed, homogenised and plated for 
quantification of bacterial load at 48 h.p.i.  (A) Pulmonary Bacterial Load, (B) Total Cells 
(C) Neutrophils and (D) Macrophages. One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, *p<0.05, ** p<0.01, **** p<0.0001 versus sham, #p<0.01 
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3.3.4 Validation: Assessing the Ability of Tobramycin to Reduce Bacterial Load Post Infection 
with MRSA strain USA300 
 
Having validated the P.aeruginosa murine models of pulmonary infection with Tobramycin, 
additional experiments were performed to validate the murine model of pulmonary infection 
with MRSA strain USA300 using the conventional antibiotic Vancomycin. Mice were infected 
with 1x106 cfu/mouse MRSA strain USA300, and the effects of Vancomycin (either 50, 100 or 
200 mg/kg/day) on infection and inflammatory parameters were subsequently analysed. 
Infection with MRSA induced a significant increase in pulmonary bacterial load in vehicle 
treated mice when compared to sham controls (4.27±0.27 log cfu, versus sham: 0.0±0.0 log 
cfu, p<0.0001, Figure 3.14A). Vancomycin treatment appeared to induce a dose-dependent 
reduction in pulmonary bacterial load when compared to vehicle controls. However, 
significance was only observed using 200 mg/kg Vancomycin (50 mg/kg: 3.40 ±0.11 log cfu, 
100 mg/kg: 3.52±0.25 log cfu and 200 mg/kg 2.72±0.33 log cfu, p<0.05, versus vehicle control: 
4.27±0.27 log cfu, Figure 3.14A). 
Infection with 1x106 cfu/mouse MRSA strain USA300, had no significant increase in 
pulmonary total leukocytes when compared to sham controls (3.30 x 105 ± 0.29 cells/mL, 
versus sham: 1.56 x 105 ± 0.33 cells/mL, Figure 3.14B). However, pulmonary neutrophil 
recruitment was significantly increased in infected animals when compared to sham controls 
(0.86±0.12x105 cells/mL, versus sham: 0.00±0.00x105 cells/mL, p<0.001, Figure 3.14C). No 
tested dose of Vancomycin had any significant effect on pulmonary total leukocyte 
recruitment (50 mg/kg: 3.69±0.27x105 cells/mL, 100 mg/kg: 4.62±1.24x105 cells/mL and 200 
mg/kg: 3.27±0.07x105 cells/mL, versus vehicle control: 3.30±0.07x105 cells/mL, Figure 3.14B) 
or pulmonary neutrophil recruitment (50 mg/kg: 1.17±0.11x105 cells/mL, 100 mg/kg: 
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0.75±0.21x105 cells/mL and 200 mg/kg: 0.49±0.15x105 cells/mL, versus vehicle control: 
0.86±0.12x105 cells/mL, Figure 3.14C) when compared to vehicle controls. Similarly, no tested 
dose of Vancomycin had any significant effect on pulmonary macrophage (50 mg/kg: 
2.58±0.35x105 cells/mL, 100 mg/kg: 2.52±0.20x105 cells/mL and 200 mg/kg: 2.77±0.10x105 
cells/mL, versus vehicle: 2.48±0.35x105 cells/mL, Figure 3.14D) and lymphocyte recruitment 
when compared to vehicle controls (50 mg/kg: 0.0±0.0x105 cells/mL, 100 mg/kg: 0.0±10.0x105 
cells/mL and 200 mg/kg: 0.0±0.0x105 cells/mL, versus vehicle: 0.0±0.0x105 cells/mL). 
  




















Figure 3.14 Effects of Vancomycin Following Infection with MRSA strain USA300 
 
Mice were infected (o.a) with either sham or 1x106 cfu/mouse USA300 embedded agar 
beads. At 24 h.p.i mice were treated with a single dose of either vehicle, 50, 100, 200 
mg/kg Vancomycin (200μL, i.p.). A BAL of the lungs was performed for inflammatory cell 
quantification and lungs were aseptically removed, homogenised and plated for 
quantification of bacterial load at 48 h.p.i. (A) Pulmonary Bacterial Load, (B) Total Cells (C) 
Neutrophils and (D) Macrophages. One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, ***p<0.001, **** p<0.0001 versus sham, ### p<0.001 versus 
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The Role of Platelets in the Regulation 
of Pulmonary Infection   
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4.1 Investigating Infection Induced Thrombocytopenia 
 
Thrombocytopenia is a common finding in patients admitted to the intensive care unit (de 
Stoppelaar, 2014) and patients that present to the clinic with sepsis often present with 
thrombocytopenia (Xiang et al., 2013). This is associated with poor prognosis and increased 
mortality in comparison to patients with normal circulating platelet levels (Venkata et al., 
2013). Therefore, we sought to investigate the effect of infection on thrombocytopenia in a 
murine model of pulmonary infection with P.aeruginosa and MRSA.  
Infection with 1x106 cfu/mouse P.aeruginosa strain RP73 induced a significant decrease of 
approximately 12% in circulating platelet numbers at 48 h.p.i. when compared to sham 
controls (RP73: 6.11±0.21x108 platelets/mL, versus sham: 6.99±0.30x108 platelets/mL, 12.6% 
decrease, p<0.05, Figure 4.1A). Similarly, infection with 1x106 cfu/mouse P.aeruginosa strain 
PAO1 (PAO1: 5.80±0.18x108 platelets/mL, versus sham: 6.63±0.18x108 platelets/mL, 12.7% 
decrease, p<0.01, Figure 4.1B) and NN2 (NN2: 6.65±0.24x108 platelets/mL, versus sham: 
6.65±0.24x108 platelets/mL, 13.7% decrease, p<0.05, Figure 4.1C) significantly reduced 
circulating platelet numbers, by 12.7% and 13.7% respectively, when compared to sham 
controls. For the MRSA strain USA300, a significant decrease in circulating platelet numbers 
was observed at 48 h.p.i, with infection reducing platelet numbers by 14.7%, when compared 
to sham controls (MRSA: 6.36±0.28x108 platelets/mL, versus sham: 7.76±0.29x108 

























Figure 4.1 Effects of Infection with P.aeruginosa and MRSA on Circulating Platelet Levels 
  
Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain (A) 
RP73, (B) PAO1, (C) NN2 or (D) MRSA strain USA300 embedded agar beads. 48 h.p.i. blood 
was collected via cardiac puncture and platelets were quantified using an improved 
Neubauer haemocytometer under a x40 objective. Unpaired two-tailed t-test, * p<0.05, 
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4.2  Investigating P.aeruginosa strain RP73 Infection Induced Pulmonary Platelet 
Recruitment 
 
Platelet recruitment towards bacterial products (LPS) has been demonstrated previously  
(Ortiz-Muñoz et al., 2014), therefore we investigated whether platelet migration to the lungs 
accounts for the decreased circulating platelet numbers we observed. Lung samples from 
sham and P.aeruginosa strain RP73 infected animals were collected at 48 h.p.i. and stained 
with a platelet-specific anti-CD42b antibody. The histological images collected showed 
evidence of platelet accumulation in the lung tissue following infection with RP73, when 
compared to sham controls (Figure 4.2Ciii). Regions that stained positively for CD42b 
appeared to be present in the airways, located within close proximity to bacteria and in 
extravascular regions of lung tissue. Conversely, in sham controls, histological images 
demonstrated far fewer CD42b positively stained events (Figure 4.2Ci). Tissue samples of 
both sham and infected mice were stained with only secondary antibody to rule out non-
specific binding, thus acting as a negative control (Figure 4.2Cii and iv). 
The staining was quantified to determine whether there was a significant difference in the 
number of CD42b positive events per mm2 of lung tissue or the percentage area of CD42b 
positive staining in sham versus RP73 infected tissue sections. Results demonstrated a 
significant increase in the number of CD42b positive events per mm2 of lung tissue following 
infection with RP73, when compared to sham controls (RP73: 9672±1456 platelets/ mm2, 
versus sham: 3809±455.1 platelets/ mm2, p<0.01, Figure 4.2A), which represents a significant 
increase in the number of platelets/ mm2 of lung tissue following infection. Furthermore, a 
significant increase in the percentage area of CD42b positive staining was observed following 
infection with RP73, when compared to sham controls (RP73: 2.80 ± 0.65%, versus sham: 
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1.17±0.27%, p<0.05, Figure 4.2B) which represents an increase in the total number of 
platelets recruited to the lung following infection. 
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Mice were infected (o.a) with either sham or 1x106 cfu/mouse RP73 embedded agar 
beads. At 24 h.p.i, lungs were removed, fixed in 10% formaldehyde and embedded into 
paraffin wax blocks. Tissue sections were stained with an anti-CD42b antibody and a 
biotinylated anti- rabbit secondary antibody. (A) CD42b positive events per mm2 of lung 
tissue (B) Percentage area of CD42b positive staining (C) Representative images of lung 
parenchyma at x40 magnification from CD42b stained lungs from (i-ii) sham control and 
(iii-iv) 1x106 cfu/mL P.aeruginosa strain RP73 infected animals. Unpaired two-tailed t-test, 
* p<0.05, ** p<0.01 versus sham, n=6, data are presented as mean ± SEM. 
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4.3  Investigating the Effects of Infection on Platelet Activation Markers in BAL Fluid and 
Blood Plasma 
 
Clinically, it has been demonstrated that patients admitted to the hospital with infectious 
diseases have an increased expression of platelet activation markers (O’Sullivan et al., 2005), 
as measured by increased platelet-neutrophil complexes and surface expression of adhesion 
molecules, such as P-selectin (Amison et al., 2018). Furthermore, a plethora of platelet 
microbicidal proteins and kinocidins are released upon platelet activation, including PF-4 and 
RANTES (Yeaman, 2010). Therefore, we sought to investigate the effect of infection induced 
platelet activation, by quantification of the granular secretory products PF-4 and RANTES. 
 
4.3.1 Quantification of PF-4 Levels in BAL fluid Following Infection with P.aeruginosa or MRSA 
 
48 h.p.i. with P.aeruginosa or MRSA, BAL fluid was collected and the platelet granular 
secretory product, PF-4 was quantified. Infection with RP73 did not significantly augment 
levels of PF-4 in BAL fluid, however a trend suggesting elevated levels was observed, when 
compared to sham controls (RP73: 265.10 ± 106.30 pg/mL, versus sham: 94.14 ± 19.55 pg/mL, 
Figure 4.3A). Significant increases in BAL PF-4 levels were observed following infection with 
PAO1 (PAO1: 246.10±63.83 pg/mL, versus sham: 85.17±18.46 pg/mL, Figure 4.3B, p<0.05) 
and NN2 when compared to sham controls (NN2: 298.60±89.84 pg/mL, versus sham: 
20.69±5.49 pg/mL, Figure 4.3C, p<0.05). Infection with MRSA strain USA300 appeared to 
cause platelet activation, as indicated by increased concentrations of PF-4, however this 
result did not reach statistical significance (MRSA: 236.70±82.74 pg/mL, versus sham: 
90.55±19.01 pg/mL, Figure 4.3D). 

















Figure 4.3 Effects of Infection with P.aeruginosa and MRSA on PF-4 Levels in BAL Fluid 
Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain RP73, 
PAO1 or NN2 or MRSA strain USA300 embedded agar beads. At 48 h.p.i, a BAL of the lungs 
was performed. The concentration of PF4 present in BAL fluid was measured using a 
murine PF4 Duoset ELISA, DY595. (A) RP73, (B) PAO1, (C) NN2, (D) USA300, unpaired two-
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4.3.2 Quantification of RANTES Levels in BAL fluid Following Infection with P.aeruginosa or 
MRSA 
 
48 h.p.i. with P.aeruginosa or MRSA, BAL fluid was collected and the platelet granular 
secretory product, RANTES was measured. These data suggested that infection with RP73 
elevated levels of RANTES in BAL fluid when compared to sham controls, although this result 
did not reach statistical significance (RP73: 217.30±64.83 pg/mL, versus sham: 75.33±40.07 
pg/mL, Figure 4.4A). A significant increase in RANTES secretion was observed in BAL fluid 
following infection with PAO1 (PAO1: 298.90±117.60 pg/mL, versus sham: 33.46±34.66 
pg/mL, Figure 4.4B, p<0.05) and NN2 when compared to sham controls, which were below 
the limit of detection (NN2: 406.10±113.4 pg/mL, versus sham: -33.4±42.0 pg/mL, Figure 
4.4C, p<0.001). Infection with MRSA strain USA300 induced a significant increase in BAL levels 
of RANTES when compared to sham controls, which were below the limit of detection (MRSA: 
317.0±-55.30 pg/mL, sham: -65.94±16.24 pg/mL, Figure 4.4D, p<0.0001). Consistent with the 
data obtained for that of PF-4, these data suggest that platelets become activated at the site 
of infection, indicated by increased secretion of granular contents. 
 
  
















Figure 4.4 Effects of Infection with P.aeruginosa and MRSA on RANTES Levels in BAL Fluid 
 
Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain RP73, 
PAO1 or NN2 or MRSA strain USA300 embedded agar beads. At 48 h.p.i, a BAL of the lungs 
was performed. The concentration of RANTES present in BAL fluid was measured using a 
murine RANTES Duoset ELISA, DY478. (A) RP73, (B) PAO1, (C) NN2, (D) USA300, unpaired 
two-tailed t-test, *p<0.05, ***p<0.001, ****p<0.0001 versus sham, n=15-23 data are 
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48 h.p.i. with P.aeruginosa or MRSA, plasma was isolated and the concentration of PF-4 in 
samples was quantified. The results collected suggested that infection with RP73 (RP73: 
94.22±31.04 ng/mL, versus sham: 160.80±4.90 ng/mL, Figure 4.5A), PAO1 (PAO1: 
359.02±134.78 ng/mL, versus sham: 248.94±52.33 ng/mL, Figure 4.5B) and NN2 (NN2: 
461.53±112.48 ng/mL, versus sham: 399.03±56.14 ng/mL, Figure 4.5C) had no significant 
effect on the concentration of PF-4 in plasma, when compared to sham controls. 
Similarly, infection with MRSA strain USA300 did not significantly increase PF-4 levels, when 
compared to sham controls (MRSA: 472.86±86.29 ng/mL, versus sham: 430.04±4.34 pg/mL, 
Figure 4.5D). These data suggest that PF-4 may only be released at the site of infection, since 
both PF4 and RANTES were significantly elevated in BAL fluid at this same time point.  
 
  

























Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain RP73, 
PAO1 or NN2 or MRSA strain USA300 embedded agar beads. At 48 h.p.i blood was taken 
via cardiac puncture and plasma was isolated. The concentration of PF-4 present in plasma 
was measured using a murine PF-4 Duoset ELISA, DY595. (A) RP73, (B) PAO1, (C) NN2, (D) 
USA300, unpaired two-tailed t-test, p>0.05 versus sham, n=8-19, data are presented as 
mean ± SEM.  
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4.4  Investigating P.aeruginosa strain RP73 Infection Induced Platelet-Leukocyte Complex 
Formation ex vivo 
 
Whilst granule secretion has been used as a marker of platelet activation, the formation of 
platelet-leukocyte complexes has also been demonstrated as a marker of platelet activation 
(Pitchford et al., 2003). Therefore, we sought to investigate whether infection increases 
platelet activation, as measured by platelet-neutrophil complex formation in the blood, 
following infection with RP73. 
Infection with 1x106 cfu/mouse RP73 induced a ~4-fold increase in circulating platelet-
neutrophil complexes when compared to sham controls (RP73: 9.24±2.45%, versus sham: 
2.45±0.48%, Figure 4.6A, p<0.01), indicative of platelet activation in the blood of infected 
mice.  Infection had no significant effect on platelet MFI on platelet-neutrophil complexes, 
when compared to sham controls (RP73: 10.57±0.96, versus sham: 11.35±1.09, Figure 4.6B), 
indicative of no change in the number of platelets per neutrophil. 
 
  



















Figure 4.6 Effects of Infection with P.aeruginosa on Platelet-Leukocyte Complex Formation 
  
Mice were infected (o.a) with either sham or 1x106 cfu/mouse RP73 embedded agar 
beads. At 24 h.p.i blood was taken via cardiac puncture and the (A) percentage of platelet-
neutrophil complexes and the (B) MFI on platelet- neutrophil complexes was measured 
using a FITC rat anti-mouse CD41 #553848 antibody and a PE rat anti-mouse Ly6g #551461 
antibody and flow cytometry analysis, unpaired two-tailed t-test, **p<0.01 versus sham, 
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4.5  Investigating Bacteria Induced Platelet Migration 
 
Having previously demonstrated pulmonary platelet recruitment following infection in vivo, 
experiments were performed to determine whether bacteria induces platelet migration in 
vitro. Platelet migration towards SDF-1α was significantly elevated when compared to the 
RPMI negative controls (SDF-1α: 2.06±0.26, versus RPMI: 1.0±0.12, Figure 4.7, p<0.01). A 
significant increase in platelet chemotaxis towards bacteria (1x107 and 1x108 cfu/mL) was 
observed (106:  1.45±0.08, 107:  2.05±0.18 p<0.001, 108:  1.74±0.27 p<0.05, CI, Figure 4.7), 













Figure 4.7 Effects of Bacteria Induced Platelet Migration  
Platelets were isolated from human citrated blood and bacterial cultures of P.aeruginosa 
strain RP73 were prepared. Platelets were stimulated with 100nM ADP and added to the 
top well of a chemotaxis chamber. Platelet chemotaxis towards either 1μg/mL SDF-1α or 
RP73 was then quantified after a 90-minute incubation period and analysed as a 
chemotactic index. One-way ANOVA and Bonferroni’s multiple comparisons post hoc test, 
*p<0.05, **p<0.01, ***p<0.001, versus RPMI control, n=8-12, data are presented as mean 
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4.6  Establishing a Thrombocytopenic Model of Pulmonary Infection with P.aeruginosa 
strain RP73 
 
Experimentally induced thrombocytopenia has been associated with enhanced pulmonary 
bacterial load and increased systemic infection in animal models of pulmonary bacterial 
infection with S.aureus and K.pneumonia (Youssefian et al., 2002), (de Stoppelaar, 2014). This 
implicates platelets in host defence against infection in the clinic and further suggests that 
drugs that are being developed to target platelet participation in atherosclerosis, by 
interfering with normal platelet function, may be detrimental to the host’s defence system 
(Pitchford., 2007).  
The aim of this study was to investigate the effect of thrombocytopenia on bacterial induced 
leukocyte recruitment, bacterial growth and the systemic dissemination of bacteria, following 
infection with the gram-negative P.aeruginosa, strain RP73. In order to determine the most 
suitable level of infection for platelet depletion studies, mice were infected with either 1x106, 
1x105 or 1x104 cfu/mouse RP73.  
 
4.6.1 Investigating the Effect of Pulmonary Infection on Circulating Platelet Numbers 
 
Similarly to the results observed in Figure 4.1, a significant decrease in circulating platelet 
numbers was observed 24 hours following infection with P.aeruginosa strain RP73, at either 
1x104 (RP73: 5.10±0.16x108 platelets/mL, versus sham: 6.28±0.23x108 platelets/mL, Figure 
4.8A, p<0.01), 1x105 (RP73: 5.58±0.25x108 platelets/mL, versus sham: 6.65±0.43x108 
platelets/mL, Figure 4.8B, p<0.05) or 1x106  (RP73: 5.94±0.17x108 platelets/mL, versus sham: 
6.77±0.42x108 platelets/mL, Figure 4.8C, p<0.05) cfu/mouse, when compared to sham 
controls.  
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4.6.2 Investigating the Effect of Experimentally Induced Platelet Depletion on the Circulating 
Platelet Numbers 
 
In order to experimentally deplete mice of circulating platelets, mice were treated with either 
1mg/kg of an anti-GPIbα platelet depleting antibody or an IgG control antibody, 24 hours prior 
to infection with either 1x104, 1x105 or 1x106 cfu/mouse P.aeruginosa strain RP73. The anti-
GPIbα platelet depleting antibody depleted circulating platelet by approximately 80% (81.56 
± 3.01%) in all 3 studies, when compared to animals treated with the IgG control (104 log cfu 
+ anti-GPIbα: 1.16±0.05x108 platelets/mL, versus 104 log cfu + IgG control: 5.10±0.16x108 
platelets/mL, Figure 4.8A, p<0.0001), (105 log cfu + anti-GPIbα: 1.12±0.09x108 platelets/mL, 
versus 105 log cfu + IgG control: 5.58±0.25x108 platelets/mL, Figure 4.8B, p<0.001) and (106 
log cfu + anti-GPIbα: 0.75±0.09x108 platelets/mL versus 106 log cfu + IgG control: 
5.94±0.17x108 platelets/mL, Figure 4.8C, p<0.001).  
 
  




















Figure 4.8 Effects of Experimentally Induced Platelet Depletion on Circulating Platelet 
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Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or (A) 1x104, (B) 1x105 or (C) 
1x106 cfu/mouse RP73 embedded agar beads. At 24 h.p.i blood was taken via cardiac 
puncture and the circulating platelet count was quantified using an improved neubauer 
haemocytometer. One-way ANOVA and Bonferroni’s multiple comparisons post hoc test, 
*p<0.05, **p<0.01 versus sham, ### p<0.001, #### p<0.0001 versus IgG control, n=4-10, 
data are presented as mean ± SEM.  
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4.6.3 Investigating the Effect of Platelet Depletion on Pulmonary Haemorrhage 
 
In order to investigate whether administration of the platelet depleting anti-GPlbα antibody 
induced pulmonary haemorrhage, haemoglobin levels present in BAL fluid were quantified 
following administration of either the IgG control or anti-GPlbα antibodies. 
The platelet depleting anti-GPlbα antibody did not cause any significant increase in pulmonary 
haemorrhage in either the sham controls (105 log cfu + anti-GPlbα: 0.11±0.03 versus 105 log 
cfu + IgG control: 0.04±0.00, Figure 4.9) or RP73 infected animals (105 log cfu + anti-GPlbα: 
0.28±0.15 versus 105 log cfu + IgG control: 0.04±0.00, Figure 4.9), when compared to mice 
treated with the IgG control. Although these data did not reach statistical significance, a trend 
was observed suggesting the platelet depleting anti-GPlbα antibody increased the optical 
density of the BAL fluid, suggestive of minor pulmonary haemorrhage. 
  














Figure 4.9 Effect of the Platelet Depleting anti-GPlbα Antibody on Pulmonary 
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Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or 1x105 cfu/mouse 
P.aeruginosa strain RP73 embedded agar beads. At 24 h.p.i, a BAL of the lungs was 
performed and the presence of red blood cells in the lavage was quantified, using a 
Spectramax 340PC microplate reader at 410nm. n=3-4, data are presented as mean ± SEM.  
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4.6.4 Investigating the Effect of Experimentally Induced Platelet Depletion on Weight Loss  
 
Severity of infection is typically associated with increased weight loss, therefore the body 
weights of sham and infected, IgG control treated, and platelet depleted animals were 
recorded prior to and post infection. 
The results obtained demonstrated that following infection with the lowest inoculum of 1x104 
cfu/mouse RP73, there was no significant difference in weight loss between any groups 
(sham: 0.28±0.18%, 104 log cfu + IgG control: 0.41±0.19%, 104 log cfu + anti-GPIbα: 
0.23±0.09%, Figure 4.10A). Following infection with the intermediate inoculum of 1x105 
cfu/mouse, there was no significant increase in weight loss when compared to the sham 
controls (sham: 0.67±0.24%, 105 log cfu + IgG control: 2.66±1.31%, Figure 4.10B). However, 
experimentally induced platelet depletion was associated with a significant increase in weight 
loss when compared to mice with normal circulating platelet levels (105 log cfu + IgG control: 
2.66±1.31%, 105 log cfu + anti-GPIbα: 7.01±1.45%, Figure 4.10B, p<0.01). 
Following infection with the highest inoculum of 1x106 cfu/mouse RP73, there was a 
significant increase in weight loss when compared to the sham controls (sham: 4.62±0.05%, 
106 log cfu + IgG control: 11.31±1.39%, Figure 4.10C, p<0.01), due to the severity of the 
infection. As observed following infection with the 1x105 cfu/mouse inoculum, experimentally 
induced platelet depletion resulted in a significant increase in weight loss compared to mice 
with normal circulating platelet levels (106 log cfu + IgG control: 11.31±1.39%, 106 log cfu + 



























Figure 4.10 Effects of Experimentally Induced Platelet Deletion on Weight Loss in a 
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Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or (A) 1x104, (B) 1x105 or (C) 
1x106 cfu/mouse P.aeruginosa strain RP73 embedded agar beads. Body weights were 
recorded prior to and post infection and percentage weight loss calculated. One-way 
ANOVA and Bonferroni’s multiple comparisons post hoc test, ** p<0.01 versus sham, ## 
p<0.01 versus IgG control, n=3-10, data are presented as mean ± SEM. 
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4.6.5 Investigating the Effect of Experimentally Induced Platelet Depletion on Pulmonary 
Bacterial Load 
 
Initial titration studies were performed to determine the optimum inoculum to investigate 
the effect of experimentally induced platelet depletion on pulmonary bacterial load. Mice 
were exposed to 3 different concentrations (1x104, 1x105 or 1x106 cfu/mouse) of RP73 
embedded agar beads and infection and inflammatory parameters were subsequently 
analysed. 
For mice infected with the lowest inoculum of 1x104 cfu/mouse RP73, 24 h.p.i, the infection 
was cleared from the lungs, since there was no evidence of pulmonary bacterial infection in 
either the sham controls or the 1x104 cfu/mouse RP73 infected animals (sham: 0.0±0.0 log 
cfu, 104 log cfu + IgG: 0.0±0.0 log cfu, 104 log cfu + anti-GPIbα: 0.0±0.0 log cfu, Figure 4.11A). 
For the intermediate inoculum of 1x105 cfu/mouse RP73, 24 h.p.i, mice inoculated with sham 
agar beads demonstrated no evidence of pulmonary bacterial infection (0.0±0.0 log cfu, 
Figure 4.11B). Mice infected with 1x105 cfu/mouse with normal circulating platelet levels, 
demonstrated a significant increase in pulmonary bacterial load when compared to sham 
controls (105 log cfu + IgG: 4.72±0.29 log cfu versus sham: 0.0±0.0 log cfu, p<0.001, Figure 
4.11B). Furthermore, for mice infected with 1x105 cfu/mouse and treated with the platelet 
depleting anti-GPIbα antibody, there was no significant increase in pulmonary bacterial load 
when compared to mice with normal circulating platelet levels (105 log cfu + anti-GPIbα: 
5.21±0.39 log cfu versus 105 log cfu + IgG: 4.72±0.29 log cfu, Figure 4.11B). Although these 
data did not reach statistical significance, a small increase of 0.5 log cfu was observed in the 
platelet depleted anti-GPIbα treated animals compared to mice with normal circulating 
platelet levels. 
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For the highest inoculum of 1x106 cfu/mouse RP73, 24 h.p.i, mice inoculated with sham agar 
beads demonstrated no evidence of pulmonary bacterial infection (0.0±0.0 log cfu, Figure 
4.11C). In contrast, mice infected with 1x106 cfu/mouse RP73 with normal circulating platelet 
levels, demonstrated a significant increase in pulmonary bacterial load when compared to 
sham controls (106 log cfu + IgG: 5.21±0.43 log cfu versus sham: 0.0±0.0 log cfu, p<0.0001, 
Figure 4.11C). In mice infected with 1x106 cfu/mouse RP73 and treated with the platelet 
depleting anti-GPIbα antibody, pulmonary bacterial load was significantly elevated, by 
approximately 1.5 logs, when compared to mice with normal circulating platelet levels (106 
log cfu + anti-GPIbα: 6.74±0.44 log cfu versus 106 log cfu + IgG: 5.21±0.43 log cfu, p<0.05, 
Figure 4.11C), demonstrating in situ bacterial growth. 
  
























Figure 4.11 Effects of Experimentally Induced Platelet Depletion on Pulmonary Bacterial 
Load in a Thrombocytopenic Model of Pulmonary Infection with P.aeruginosa strain RP73 
  
Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or (A) 1x104, (B) 1x105 or (C) 
1x106 cfu/mouse RP73 embedded agar beads. At 24 h.p.i, lungs were aseptically removed, 
homogenised and plated for quantification of bacterial load. One-way ANOVA and 
Bonferroni’s multiple comparisons post hoc test, *** p<0.001, **** p<0.0001 versus 
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4.6.6 Investigating the Effect of Experimentally Induced Platelet Depletion on Bacterial 
Dissemination 
 
It has previously been demonstrated in gram-negative bacterial induced sepsis models that 
platelet depletion enhances bacterial dissemination (de Stoppelaar, 2014). Therefore, we 
sought to investigate whether experimentally induced platelet depletion has any effect on 
gram-negative bacterial dissemination from the lungs to other peripheral organs. 
At 24 h.p.i, no evidence of bacterial dissemination to the kidney or spleen was observed in 
either the sham control or the lowest inoculum of 1x104 cfu/mouse RP73 infected animals 
(Kidney: sham: 0.0±0.0 log cfu, 104 log cfu + IgG: 0.0±0.0 log cfu, 104 log cfu + anti-GPIbα: 
0.0±0.0 log cfu, Figure 4.12A, and Spleen: sham: 0.0±0.0 log cfu, 104 log cfu + IgG: 0.0±0.0 log 
cfu, 104 log cfu + anti-GPIbα: 0.0±0.0 log cfu, Figure 4.13A).  
Following infection with the intermediate inoculum of 1x105 cfu/mouse RP73, at 24 h.p.i there 
was no evidence of bacterial dissemination to the kidney or spleen in either the sham control 
or the 1x105 cfu/mouse RP73, IgG control treated animals (Kidney: sham: 0.0±0.0 log cfu, 105 
log cfu + IgG: 0.0±0.0 log cfu, Figure 4.12B and Spleen: sham: 0.0±0.0 log cfu, 105 log cfu + 
IgG: 0.0±0.0 log cfu, Figure 4.13B). In contrast, there was a significant increase in the bacterial 
load recovered from the kidney and spleen, following infection with 1x105 cfu/mouse RP73 in 
mice depleted of circulating platelets, when compared to mice with normal circulating 
platelet levels (Kidney: 105 log cfu + anti-GPIbα: 1.56±0.39 log cfu versus 105 log cfu + IgG: 
0.0±0.0 log cfu, p<0.001, Figure 4.12B and Spleen: 105 log cfu + anti-GPIbα: 0.74±0.36 log cfu 
versus 105 log cfu + IgG: 0.0±0.0 log cfu, p<0.05, Figure 4.13B).  
Following infection with the highest level of inoculum of 1x106 cfu/mouse RP73, at 24 h.p.i 
there was no evidence of bacterial dissemination to the kidney in the sham controls (Kidney: 
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sham: 0.0±0.0 log cfu, Figure 4.12C and Spleen: sham: 0.0±0.0 log cfu, Figure 4.13C). Infection 
with 1x106 cfu/mouse RP73 and treatment with the IgG control antibody induced minimal 
bacterial dissemination to the kidney and spleen following infection, when compared to the 
sham controls (Kidney: sham: 0.0±0.0 log cfu, 106 log cfu + IgG: 0.96±0.39 log cfu, Figure 4.12C 
and Spleen: sham: 0.0±0.0 log cfu, 106 log cfu + IgG: 0.59±0.31 log cfu, Figure 4.13C).Whilst 
the significant increase in pulmonary bacterial load observed following infection with 1x106 
cfu/mouse RP73 in mice depleted of circulating platelets (Figure 4.11C) was accompanied by 
an increase in bacterial numbers in the kidney and spleen, when compared to mice with 
normal circulating platelet levels, although this did not reach statistical significance (Kidney: 
106 log cfu + anti-GPIbα: 2.64±0.43 log cfu versus 106 log cfu + IgG: 0.96±0.39 log cfu, Figure 
4.12C and Spleen: 106  log cfu + anti-GPIbα: 2.65±0.53 log cfu versus 106  log cfu + IgG: 
0.59±0.31 log cfu, Figure 4.13C). 
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Figure 4.12 Effects of Experimentally Induced Platelet Depletion on Bacterial 
Dissemination to the Kidney in a Thrombocytopenic Model of Pulmonary Infection with 
P.aeruginosa strain RP73 
  
 Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or (A) 1 x 104, (B) 1 x 105 or 
(C) 1 x 106 cfu/mouse P.aeruginosa strain RP73 embedded agar beads. At 24 h.p.i, the 
kidney was aseptically removed, homogenised and plated for quantification of bacterial 
load. One-way ANOVA and Bonferroni’s multiple comparisons post hoc test, # p<0.05 
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Figure 4.13 Effects of Experimentally Induced Platelet Depletion on Bacterial 
Dissemination to the Spleen in a Thrombocytopenic Model of Pulmonary Infection with 
P.aeruginosa strain RP73 
  
 Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or (A) 1x104, (B) 1x105 or (C) 
1x106 cfu/mouse P.aeruginosa strain RP73 embedded agar beads. At 24 h.p.i, the spleen 
was aseptically removed, homogenised and plated for quantification of bacterial load.  
One-way ANOVA and Bonferroni’s multiple comparisons post hoc test, # p<0.05 versus 
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4.6.7 Investigating the Effect of Experimentally Induced Platelet Depletion on Pulmonary 
Leukocyte Recruitment 
 
It has been demonstrated previously that platelets are essential for pulmonary leukocyte 
recruitment in allergic inflammation (Pitchford et al., 2003), therefore we sought to 
investigate whether experimentally induced platelet depletion had any effect on pulmonary 
leukocyte recruitment following infection with P.aeruginosa strain RP73.  
Infection with the lowest inoculum of 1x104 cfu/mouse increased pulmonary total leukocyte 
and neutrophil recruitment when compared to sham controls, although this data did not 
reach statistical significance (Total leukocytes: 104 log cfu + IgG: 3.04±0.79x105 cells/mL, 
versus sham: 1.23±0.29x105 cells/mL, Figure 4.14A, and Neutrophils: 104 log cfu + IgG: 
0.20±0.08x105 cells/mL, versus sham: 0.00± 0.00x105 cells/mL, Figure 4.15A). In mice 
experimentally depleted of platelets and infected with 1x104 cfu/mouse RP73, no significant 
effect on pulmonary total leukocyte and neutrophil recruitment was observed (Total 
leukocytes: 104 log cfu + anti-GPIbα: 3.49±0.70x105 cells/mL, versus 104 log cfu + IgG: 
3.04±0.79x105 cells/mL, Figure 4.14A and Neutrophils: 104 log cfu + anti-GPIbα: 
0.34±0.09x105 cells/mL, versus 104 log cfu + IgG: 0.20±0.08x105 cells/mL, Figure 4.15A), when 
compared to mice with normal circulating platelet levels.  
24 h.p.i with 1x104 cfu/mouse RP73, no significant increase in pulmonary macrophage or 
lymphocyte recruitment was observed when compared to sham controls (Macrophages: 104 
log cfu + IgG: 2.83±0.72x105 cells/mL, versus sham: 1.22±0.28x105 cells/mL, Figure 4.16A and 
Lymphocytes: 104 log cfu + IgG: 0.0±0.0x105 cells/mL, versus sham: 0.0±0.0x105 cells/mL). 
Similarly, experimentally induced platelet depletion had no significant effect on pulmonary 
macrophage or lymphocyte recruitment at 24 h.p.i with 1x104 cfu/mouse RP73 
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(Macrophages: 104 log cfu + anti-GPIbα: 3.15±0.61x105 cells/mL, versus 104 log cfu + IgG: 
2.83±0.72x105 cells/mL, Figure 4.16A, and Lymphocytes: 104 log cfu + anti-GPIbα: 0.0±0.0x105 
cells/mL, versus 104 log cfu + IgG: 0.0±0.0x105 cells/mL), when compared to mice with normal 
circulating platelet levels. 
Infection with the intermediate inoculum of 1x105 cfu/mouse induced a significant increase 
in pulmonary total leukocyte and neutrophil recruitment (Total leukocytes: 105 log cfu + IgG: 
5.0±0.40x105 cells/mL, versus sham: 1.39±0.11x105 cells/mL, Figure 4.14B, p<0.001 and 
Neutrophils: 105 log cfu + IgG: 1.66±0.22x105 cells/mL, versus sham: 0.02± 0.01x105 cells/mL, 
Figure 4.15B, p<0.001), when compared to sham controls. In mice experimentally depleted 
of platelets and infected with 1x105 cfu/mouse RP73, a significant decrease in pulmonary total 
leukocyte and neutrophil recruitment was observed (Total leukocytes: 105 log cfu + anti-
GPIbα: 3.03±0.51x105 cells/mL, versus 105 log cfu + IgG: 5.0±0.40x105 cells/mL, Figure 4.14B, 
p<0.01, and Neutrophils: 105 log cfu + anti-GPIbα: 0.91±0.26x105 cells/mL, versus 105 log cfu 
+ IgG: 1.66±0.22x105 cells/mL, p<0.05, Figure 4.15B), when compared to mice with normal 
circulating platelet levels.  
 24 h.p.i with 1x105 cfu/mouse RP73, a significant increase in pulmonary macrophage 
recruitment was observed when compared to sham controls (Macrophages: 105 log cfu + IgG: 
3.34±0.26x105 cells/mL, versus sham: 1.37±0.11x105 cells/mL, Figure 4.16B, p<0.001). 
Experimentally induced platelet depletion significantly decreased macrophage recruitment to 
the lungs (Macrophages: 105 log cfu + anti-GPIbα: 2.11±0.33x105 cells/mL, versus 105 log cfu 
+ IgG: 3.34±0.26x105 cells/mL, Figure 4.16A, p<0.05), when compared to sham controls. 
Neither infection with 1x105 cfu/mouse RP73 or experimentally induced platelet depletion 
had any significant effect on lymphocyte recruitment to the lungs (Lymphocytes: 105 log cfu 
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+ anti-GPIbα: 0.0±0.0x105 cells/mL, 105 log cfu + IgG: 0.0±0.0x105 cells/mL and sham: 
0.0±0.0x105 cells/mL), when compared to sham controls and mice with normal circulating 
platelet levels. 
Infection with the highest inoculum of 1x106 cfu/mouse induced a significant increase in 
pulmonary total leukocyte and neutrophil recruitment (Total leukocytes: 106 + IgG: 
34.42±11.07x105 cells/mL, versus sham: 3.48±1.07x105 cells/mL, Figure 4.14C, p<0.05 and 
Neutrophils: 106 log cfu + IgG: 14.88±2.96x105 cells/mL, versus sham: 0.64± 0.32x105 cells/mL, 
Figure 4.15C, p<0.001), when compared to sham controls. In mice experimentally depleted 
of platelets and infected with 1x106 cfu/mouse RP73, a decrease in pulmonary total leukocyte 
and neutrophil recruitment was observed when compared to mice with normal circulating 
platelet levels, although this only reached statistical significance for the neutrophils (Total 
leukocytes: 106 log cfu + anti-GPIbα: 14.60±3.16x105 cells/mL, versus 106 log cfu + IgG: 
34.42±11.07x105 cells/mL, Figure 4.14C and Neutrophils: 106 log cfu + anti-GPIbα: 
5.41±1.96x105 cells/mL, versus 106 log cfu + IgG: 14.88±2.96x105 cells/mL, p<0.05, Figure 
4.15C). 
24 h.p.i with 1x106 cfu/mouse RP73, there was no significant difference in either macrophage 
or lymphocyte recruitment to the lungs when compared to sham controls (Macrophages: 106 
log cfu + IgG: 3.31±0.55x105 cells/mL, versus sham: 2.82±0.75x105 cells/mL, Figure 4.16C and 
Lymphocytes: 106 log cfu + IgG: 0.0±0.0x105 cells/mL, versus sham: 0.0±0.0x105 cells/mL). 
Similarly, in mice depleted of circulating platelets there was no significant effect in either 
macrophage or lymphocyte recruitment to the lungs (Macrophages: 106 log cfu + anti-GPIbα: 
2.83±0.60x105 cells/mL, versus 106 log cfu + IgG: 3.31±0.55x105 cells/mL, Figure 4.16C and 
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Lymphocytes: 106 log cfu + anti-GPIbα: 0.0±0.0x105 cells/mL, versus 106 log cfu + IgG: 




















Figure 4.14 Effect of Experimentally Induced Platelet Depletion on Pulmonary Total 
Leukocyte Recruitment in a Thrombocytopenic Model of Pulmonary Infection with 
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Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or (A) 1x104, (B) 1x105 or (C) 
1x106 cfu/mouse P.aeruginosa strain RP73 embedded agar beads. At 24 h.p.i, a BAL of the 
lungs was performed for inflammatory cell quantification. One-way ANOVA and 
Bonferroni’s multiple comparisons post hoc test, * p<0.05, *** p<0.001 versus sham, ## 
p<0.01 versus IgG control, n=4-8, data are presented as mean ± SEM. 























Figure 4.15 Effects of Experimentally Induced Platelet Depletion on Pulmonary Neutrophil 
Recruitment in a Thrombocytopenic Model of Pulmonary Infection with P.aeruginosa 
strain RP73 
  
Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or (A) 1x104, (B) 1x105 or (C) 
1x106 cfu/mouse P.aeruginosa strain RP73 embedded agar beads. At 24 h.p.i, a BAL of the 
lungs was performed for neutrophil quantification. One-way ANOVA and Bonferroni’s 
multiple comparisons post hoc test, *** p<0.001 versus sham, # p<0.05 versus IgG control, 
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Figure 4.16 Effects of Experimentally Induced Platelet Depletion on Pulmonary 
Macrophage Recruitment in a Thrombocytopenic Model of Pulmonary Infection with 
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Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or (A) 1x104, (B) 1x105 or (C) 
1x106 cfu/mouse P.aeruginosa strain RP73 embedded agar beads. At 24 h.p.i, a BAL of the 
lungs was performed for macrophage quantification. One-way ANOVA and Bonferroni’s 
multiple comparisons post hoc test, *** p<0.001 versus sham, # p<0.05 versus IgG control, 
n=4-8, data are presented as mean ± SEM. 
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4.6.8 Investigating the Effect of Experimentally Induced Platelet Depletion on Mortality 
 
Previous studies, using experimental models of bacterial derived sepsis, have demonstrated 
experimentally induced platelet depletion enhances mortality (de Stoppelaar, 2014). 
Therefore, we investigated the effect of experimentally induced platelet depletion on 
mortality, following infection with P.aeruginosa strain RP73. 
No significant differences in mortality were observed following infection with the lowest 
inoculum level of 1x104 cfu/mouse RP73, in groups experimentally depleted of platelets and 
in mice with normal circulating platelet levels (104 log cfu + anti-GPIbα: 0%, versus 104 log cfu 
+ IgG:  0%, Figure 4.17A). 
Following infection with the intermediate inoculum level of 1x105 cfu/mouse RP73, a 
significant increase of 20% was observed in mortality rate in mice depleted of platelets, when 
compared to mice with normal circulating platelet levels (105 log cfu + anti-GPIbα: 20%, versus 
105 log cfu + IgG:  0%, Figure 4.17B, p<0.05). 
In mice infected with the highest inoculum level of 1x106 cfu/mouse RP73 and experimentally 
depleted of platelets, a significant increase of 40% was observed in mortality rate at 24 h.p.i, 
when compared to mice with normal circulating platelet levels (106 log cfu + anti-GPIbα: 40%, 
versus 106 log cfu + IgG:  0%, Figure 4.17C, p<0.05). 
The 40% mortality rate observed following experimental depletion of platelets and infection 
with 1x106 cfu/mouse demonstrated a more severe pulmonary infection and was associated 
with a worsened phenotype. Therefore, in order to refine and reduce severity of the model, 
the optimum level of inoculum for future experimentally induced platelet depletion studies 
was determined to be 1x105 cfu/mouse. This level of inoculum was associated with a reduced 
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mortality rate when compared to that observed with the 1x106 cfu/mouse inoculum level, 
and the pulmonary infection was well established unlike that observed with the 1x104 
cfu/mouse inoculum level.  


























Figure 4.17 Effects of Experimentally Induced Platelet Depletion on Mortality in a 
Thrombocytopenic Model of Pulmonary Infection with P.aeruginosa strain RP73 
Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or (A) 1x104, (B) 1x105 or (C) 
1x106 cfu/mouse P.aeruginosa strain RP73 embedded agar beads. Survival numbers were 
collected following infection. Mantel-Cox test, * p<0.05 versus IgG control, n=4-10. 
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4.6.9 Investigating the Effect of Experimentally Induced Platelet Depletion on Cause of Death 
 
The previous findings in this study suggested that experimental induced platelet depletion 
coverts the non-lethal, localised infection to one with a more severe phenotype, displaying 
systemic infection and increased mortality. Furthermore, it has previously been 
demonstrated that normal circulating platelet numbers are requisite in protecting against 
organ damage during gram-negative sepsis (de Stoppelaar, 2014). For this reason, core body 
temperatures and biochemical markers of metabolic acidosis were monitored in sham 
controls and 1x105 cfu/mouse infected, IgG control treated and platelet depleted animals, to 
ascertain possible causes of death in these mice. 
The results obtained demonstrated that there was no significant difference in the percentage 
loss in body temperature between the sham controls (-0.82±0.71%), 1x105 cfu/mouse RP73 
infected, with normal circulating platelet levels (0.84±0.74%) and 1x105 cfu/mouse RP73 
infected and anti-GPIbα platelet depleted (-0.11 ± 0.76 %) groups (Figure 4.18).  
Subtle increases in biochemical markers of metabolic acidosis were observed following 
infection with 1x105 cfu/mouse RP73 in animals depleted of circulating platelets, when 
compared to the IgG control treated animals, as measured by slight changes in urea (105 log 
cfu + IgG control: 5.72±0.37 mmol/L, versus 105 log cfu + anti-GPIbα: 9.08±3.32 mmol/L, Figure 
4.19), pH (105 log cfu + IgG control: 7.15±0.03, versus 105 log cfu + anti-GPIbα: 7.07±0.04, 
Figure 4.19), base excess (105 log cfu + IgG control: -12.88±0.91 mmol/L, versus 105 log cfu + 
anti-GPIbα: -16.61±1.49 mmol/L, Figure 4.19), Hydrogen Carbonate (HCO3-) (105  log cfu + IgG 
control: 16.58±0.87 mmol/L, versus 105 log cfu + anti-GPIbα: 12.91±1.04 mmol/L, Figure 4.19) 
and partial pressure of carbon dioxide (PCO2) (105 log cfu + IgG control: 44.37±1.38 mmHg, 
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versus 105 log cfu + anti-GPIbα: 41.15±3.07 mmHg, Figure 4.19). These data suggest markers 
consistent with metabolic acidosis as has previously been published (Sand et al., 2015). 
These data obtained for this experiment, suggest that the platelet depleting anti-GPIbα 
antibody caused a decrease in both Haematocrit (Hct) (Hct: Sham + IgG control: 38.0±2.0% 
packed cell volume (PCV), versus sham + anti-GPIbα: 19.5±3.18 %PCV and 105 log cfu + IgG 
control: 37.67±1.20 %PCV, versus 105 log cfu + anti-GPIbα: 19.0±1.15 %PCV, Figure 4.19) and 
Haemoglobin (Hb) (Hb: Sham + IgG control: 12.93±0.68 g/dL, versus sham + anti-GPIbα: 
6.65±1.10 g/dL and 105 log cfu + IgG control: 12.80±0.41 g/dL, versus 105 log cfu + anti-GPIbα: 
6.45±0.39g/dL, Figure 4.19) when compared to IgG control treated animals. 
  














Figure 4.18 Effects of Experimentally Induced Platelet Depletion on Change in 
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Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or 1x105 cfu/mouse 
P.aeruginosa strain RP73 embedded agar beads. Core body temperatures were recorded 
prior to and post infection and the percentage loss in body temperature was calculated. 
One-way ANOVA and Bonferroni’s multiple comparisons post hoc test, p>0.05 versus 
sham, p>0.05 versus IgG control, n=4-6, data are presented as mean ± SEM. 
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Figure 4.19 Effects of Experimentally Induced Platelet Depletion on Changes in 
Biochemical Markers of Metabolic Acidosis in a Thrombocytopenic Model of Pulmonary 
Infection with P.aeruginosa strain RP73 
 
Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or 1x105 cfu/mouse 
P.aeruginosa strain RP73 embedded agar beads. Blood was taken via cardiac puncture, 
transferred to EC8+ blood analyser cartridges and processed using a handheld i-STAT 
blood analyser. HCO3- (Hydrogen Carbonate), PCO2 (partial pressure carbon dioxide), 
TCO2 (total carbon dioxide), AnGAP (Anion Gap), Hct (Haematocrit), Hb (Haemoglobin), 
PCV (packed cell volume). One-way ANOVA and Bonferroni’s multiple comparisons post 
hoc test ***p<0.001 ****p<0.0001 versus IgG control, n=4-6, data are presented as mean 
± SEM. 
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4.6.10 Investigating the Effect of Experimentally Induced Thrombocytopenia on Pulmonary 
Alveolar Integrity 
 
Experiments were performed to investigate the effect of experimentally induced 
thrombocytopenia on pulmonary alveolar integrity, following infection with P.aeruginosa 
strain RP73. Results demonstrated a significant increase in Evans Blue extravasated from lung 
tissue in RP73 infected mice depleted of circulating platelets, when compared to sham mice 
depleted of circulating platelets (sham + anti-GPIbα: 675.4±173.3 ng Evans Blue/ mg lung 
tissue, versus 105 RP73 + anti-GPIbα: 3737.0±742.3 ng Evans Blue/ mg lung tissue, p<0.001, 
Figure 4.20). Furthermore, results demonstrated a significant increase in Evans Blue 
extravasated from lung tissue in RP73 infected mice depleted of circulating platelets, when 
compared to RP73 infected mice with normal circulating platelet numbers (105 RP73 + anti-
GPIbα: 944.5±110.6 ng Evans Blue/ mg lung tissue, versus 105 RP73 + anti-GPIbα: 
3737.0±742.3 ng Evans Blue/ mg lung tissue, p<0.01, Figure 4.20). 
 
  












Figure 4.20 Effects of Experimentally Induced Thrombocytopenia on Pulmonary Alveolar 
Integrity in a Thrombocytopenic Model of Pulmonary Infection with P.aeruginosa strain 
RP73 
  
Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or 1x105 cfu/mouse 
P.aeruginosa strain RP73 embedded agar beads. At 23 h.p.i mice were administered 0.5% 
Evans Blue (i.v.). Lungs were removed, weighed and added to 500μL Formamide, which 
was subsequently incubated for 24 hours at 65oC. 24 hours post incubation absorbance 
values were measured at 620nm and a standard curve was used to calculate nanograms 
(ng) Evans Blue dye per mg lung tissue. One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, *** p<0.001 versus sham + anti-GPIbα, ## p<0.01 versus RP73 
+ IgG control, n=4 data are presented as mean ± SEM. 
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4.7  Establishing a Thrombocytopenic Model of Pulmonary Infection with MRSA strain 
USA300 
 
Having established a thrombocytopenic model of pulmonary infection with the gram-negative 
P.aeruginosa strain RP73, we aimed to establish the model with the gram-positive MRSA 
strain USA300, to determine whether my findings could be reproduced with a different 
bacterial species. The optimum level of inoculum for experimentally induced platelet 
depletion studies with P.aeruginosa strain RP73 was determined to be 1x105 cfu/mouse 
therefore this level of inoculum was used to establish a thrombocytopenic model of 
pulmonary infection with the gram-positive MRSA strain USA300. 
 
4.7.1 Investigating the Effect of Experimentally Induced Platelet Depletion on the Circulating 
Platelet Count 
 
In order to experimentally induce platelet depletion, mice were treated (i.m) with either 
1mg/kg anti-GPIbα platelet depleting antibody or IgG control antibody, 24 hours prior to 
infection with 1x105 cfu/mouse MRSA strain USA300. Infection with 1x105 cfu/mouse reduced 
circulating platelet count when compared to sham controls, although these data did not reach 
statistical significance (MRSA + IgG: 9.18±0.60x108 platelets/mL, versus sham: 10.30±1.05x108 
platelets/mL, Figure 4.21).  
The anti-GPIbα platelet depleting antibody significantly reduced circulating platelets by ~96%, 
compared to the infected IgG control treated animals (105 log cfu + anti-GPIbα: 0.37±0.03x108 
platelets/mL, versus IgG control: 9.18±0.60x108 platelets/mL, Figure 4.21, p<0.0001). 












Figure 4.21 Effects of Experimentally Induced Platelet Depletion on the Circulating Platelet 
Count in a Thrombocytopenic Model of Pulmonary Infection with MRSA strain USA300 
 
 
4.7.2 Investigating the Effect of Experimentally Induced Platelet Depletion on Weight Loss 
 
The body weights of sham and infected, IgG control treated and platelet depleted animals 
were recorded pre and post infection. 1x105 cfu/mouse USA300 infected, IgG control treated 
animals demonstrated a slight increase in weight loss when compared to the sham controls 
(sham: -0.54±0.23%, 105 log cfu + IgG control: 0.15±0.61 %, Figure 4.22), although this did not 
reach statistical significance. In addition, following infection with 1x105 cfu/mouse USA300, 
animals depleted of circulating platelets showed a further increase in weight loss compared 
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Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or 1x105 cfu/mouse MRSA 
strain USA300 embedded agar beads. At 24 h.p.i blood was taken via cardiac puncture and 
the circulating platelet count was quantified using an improved neubauer 
haemocytometer. One-way ANOVA and Bonferroni’s multiple comparisons post hoc test, 
#### p<0.0001 versus IgG control, n=4-6, data are presented as mean ± SEM.  
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Figure 4.22 Effects of Experimentally Induced Platelet Depletion on Weight Loss in a 





Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or 1x105 cfu/mouse MRSA 
strain USA300 embedded agar beads. Body weights were recorded prior to and post 
infection and percentage weight loss calculated. One-way ANOVA and Bonferroni’s 
multiple comparisons post hoc test, p>0.05 versus sham, p>0.05 versus IgG control, n=4-


















S h a m
1 x 1 0
5
 c fu /m o u s e
M R S A  U S A 3 0 0
+
Ig G
C o n t r o l
+
a n t i - G P Ib 
213 | Chapter IV: Results II 
 
4.7.3 Investigating the Effect of Platelet Depletion on Pulmonary Haemorrhage 
 
In order to investigate whether administration of the platelet depleting anti-GPlbα antibody 
has any effect on pulmonary haemorrhage following infection with MRSA, red blood cells 
present in BAL fluid were qualitatively analysed following administration of either the IgG 
control or anti-GPlbα antibodies. 
Results indicated that the platelet depleting anti-GPlbα antibody appeared to increase 
pulmonary haemorrhage, as indicated by the red colouration of BAL samples in both the sham 











Figure 4.23 Effects of the Platelet Depleting anti-GPlbα Antibody on Pulmonary 
Haemorrhage in a Thrombocytopenic Model of Pulmonary Infection with MRSA strain 
USA300 
Sham + 












 MRSA + 
IgG Control  
 
Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or 1x105 cfu/mouse MRSA 
strain USA300 embedded agar beads. At 24 h.p.i, a BAL of the lungs was performed and 
the presence of red blood cells in the lavage was qualitatively analysed. n=3-4, data are 
presented as mean ± SEM.  
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4.7.4 Investigating the Effect of Experimentally Induced Platelet Depletion on Pulmonary 
Bacterial Load 
 
Mice were treated with either IgG control antibody or the platelet depleting anti-GPIbα 
antibody and infected with 1x105 cfu/mouse USA300 to determine the effect of platelet 
depletion on pulmonary bacterial load. 24 hours following infection, mice inoculated with 
sham agar beads demonstrated no evidence of pulmonary bacterial infection (0.0±0.0 log cfu, 
Figure 4.24). In contrast, mice infected with 1x105 cfu/mouse USA300 and treated with an IgG 
control antibody, demonstrated a significant increase in pulmonary bacterial load when 
compared to sham controls (105 log cfu + IgG: 3.01±0.23 log cfu, versus sham: 0.0±0.0 log cfu, 
p<0.0001, Figure 4.24). This was further increased in mice infected with 1x105 cfu/mouse 
USA3000 depleted of circulating platelets, with a significant increase of approximately 0.9 
logs, when compared to the infected IgG controls (105 log cfu + anti-GPIbα: 3.92±0.29 log cfu, 
versus 105 log cfu + IgG: 3.01±0.23 log cfu, p<0.05, Figure 4.24). 
  















Figure 4.24 Effects of Experimentally Induced Platelet Depletion on Pulmonary Bacterial 
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Mice were treated with either 1mg/kg of an anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or 1x105 cfu/mouse MRSA 
strain USA300 embedded agar beads. At 24 h.p.i, lungs were aseptically removed, 
homogenised and plated for quantification of bacterial load. One-way ANOVA and 
Bonferroni’s multiple comparisons post hoc test, **** p<0.0001 versus sham, # p<0.05 
versus IgG control, n=4-6, data are presented as mean ± SEM. 
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4.7.5 Investigating the Effect of Experimentally Induced Platelet Depletion on Bacterial 
Dissemination to the Kidney and Spleen 
 
In order to investigate whether experimentally induced platelet depletion induced bacterial 
dissemination from the lungs to other peripheral organs, the cfu content of the kidney and 
spleen was quantified. 
At 24 h.p.i, no evidence of bacterial dissemination to the kidney was observed in sham 
controls (sham: 0.0±0.0 log cfu, Figure 4.25A). Following infection with 1x105 cfu/mouse 
USA300 and in mice depleted of circulating platelets, an incidence of bacterial dissemination 
to the kidney was observed, although these data did not reach statistical significance when 
compared to the infected IgG controls (105 log cfu + anti-GPIbα: 1.98±0.89 log cfu, versus 105 
log cfu + IgG: 0.72±0.45 log cfu, Figure 4.25A). 
No evidence of bacterial dissemination to the spleen was observed in shams (sham: 0.0±0.0 
log cfu, Figure 4.25B), although there was a significant increase in bacterial dissemination to 
the spleen in infected animals depleted of circulating platelets (105 log cfu + anti-GPIbα: 

















Figure 4.25 Effects of Experimentally Induced Platelet Depletion on Bacterial 
Dissemination to the Kidney and Spleen in a Thrombocytopenic Model of Pulmonary 




4.7.6 Investigating the Effect of Experimentally Induced Platelet Depletion on Pulmonary 
Leukocyte Recruitment 
 
As gram-negative bacteria induced leukocyte recruitment was platelet dependent, we sought 
to investigate whether experimentally induced platelet depletion had any effect on 
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Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or 1x105 cfu/mouse MRSA 
strain USA300 embedded agar beads. At 24 h.p.i, the kidney and spleen were aseptically 
removed, homogenised and plated for quantification of bacterial load. One-way ANOVA 
and Bonferroni’s multiple comparisons post hoc test, # p<0.05 versus IgG control, n=4-6, 
data are presented as mean ± SEM.  
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Infection with 1x105 cfu/mouse, increased pulmonary total cell recruitment when compared 
to sham controls, although this data did not reach statistical significance (105 log cfu + IgG: 
2.23±0.38x105 cells/mL, versus sham: 1.60±0.40x105 cells/mL, Figure 4.26A). For animals 
depleted of circulating platelets, there was no significant effect on pulmonary total cell 
recruitment when compared to mice with normal circulating platelet levels (105 log cfu + anti-
GPIbα: 2.73±0.22x105 cells/mL, versus 105 log cfu + IgG: 2.23±0.38x105 cells/mL, Figure 
4.26A). 
Infection with 1x105 cfu/mouse significantly elevated pulmonary neutrophil recruitment 
when compared to sham controls (105 log cfu + IgG: 0.42±0.04x105 cells/mL, versus sham: 
0.0±0.0x105 cells/mL, Figure 4.26B, p<0.001), which was significantly attenuated in platelet 
depleted mice (105 log cfu + anti-GPIbα: 0.29±0.03x105 cells/mL, versus 105 log cfu + IgG: 
0.42±0.04x105 cells/mL, p<0.05, Figure 4.26B), further highlighting the importance of 
platelets in pulmonary leukocyte recruitment. 
No significant effects were observed in platelet depleted mice on macrophage (105 log cfu + 
IgG: 1.84±0.42x105 cells/mL, versus 105 log cfu + anti-GPIbα: 2.43±0.19x105 cells/mL, Figure 
4.26C) and lymphocyte numbers (105 log cfu + IgG: 0.0±0.0x105 cells/mL, versus 105 log cfu + 


























Figure 4.26 Effects of Experimentally Induced Platelet Depletion on Pulmonary Leukocyte 




Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or 1x105 cfu/mouse MRSA 
strain USA300 embedded agar beads. At 24 h.p.i, a BAL of the lungs was performed for 
total and differential leukocyte quantification. (A) Total cells, (B) Neutrophils, (C) 
Macrophages. One-way ANOVA and Bonferroni’s multiple comparisons post hoc test, *** 
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4.7.7 Investigating the Effect of Experimentally Induced Platelet Depletion on Mortality 
 
Having demonstrated that depletion of circulating platelets enhances mortality following 
infection with P.aeruginosa strain RP73, we investigated whether this phenomenon was 
replicated following infection with MRSA strain USA300. 
In mice infected with 1x105 cfu/mouse USA300 and experimentally depleted of platelets, we 
observed no significant difference in mortality at 24 h.p.i (0%) when compared to the infected 
IgG controls (0%). 
 
4.7.8 Investigating the Effect of Experimentally Induced Platelet Depletion on Changes in 
Biochemical Markers of Metabolic Acidosis 
 
Results obtained in section 4.6.9 demonstrated subtle increases in biochemical markers of 
metabolic acidosis following infection with 1x105 cfu/mouse P.aeruginosa RP73 in platelet 
depleted mice. Therefore, we measured changes in biochemical markers of metabolic acidosis 
following infection with MRSA strain USA300. 
Results demonstrated subtle increases in biochemical markers of metabolic acidosis following 
infection with 1x105 cfu/mouse MRSA strain USA300 in mice depleted of platelets, when 
compared to the IgG control treated animals, as measured by slight changes in base excess 
(105  log cfu + IgG control: -13.17±0.70 mmol/L, 105 log cfu + anti-GPIbα: -15.53±0.65 mmol/L, 
Figure 4.27), HCO3- (105 log cfu + IgG control: 16.65±0.57 mmol/L, 105 log cfu + anti-GPIbα: 
13.62±0.59 mmol/L, Figure 4.27) and PCO2 (105 log cfu + IgG control: 55.25±3.99 mmHg, 105  
log cfu + anti-GPIbα: 48.48±3.11 mmHg, Figure 4.27). 
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In contrast to the data obtained in section 4.6.9, which suggested that the platelet depleting 
anti-GPIbα antibody caused a decrease in both Hct and Hb, the results from this experiment 
suggested platelet depletion had no significant decrease in Hct (Hct: Sham + IgG control: 
41.0±1.83 %PCV, versus sham + anti-GPIbα: 19.5±3.18 %PCV and 105 log cfu + IgG control: 
37.67±1.20 %PCV, versus 105 log cfu + anti-GPIbα: 38.5±1.83 %PCV, Figure 4.27) and Hb (Hb: 
Sham + IgG control: 13.95±0.61 g/dL, versus sham + anti-GPIbα: 13.08 ± 0.69 g/dL and 105 log 
cfu + IgG control: 12.70±0.66 g/dL, 105 log cfu + anti-GPIbα: 10.32±1.01 g/dL, Figure 4.27) 
when compared to the IgG controls. 
In order to investigate these results further, naïve mice were administered either IgG control 
or platelet depleting anti- GPIbα antibody and the effects of platelet depletion on Hct and Hb 
were determined at 24 hours post treatment. The results from this experiment further 
support that platelet depletion had no significant decrease in Hct (Hct: IgG control: 39.5±1.50 
%PCV, versus anti-GPIbα: 40.5±3.50 %PCV) and Hb (Hb: IgG control: 13.25±0.65 g/dL, versus 
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Figure 4.27 Effects of Experimentally Induced Platelet Depletion on Changes in 
Biochemical Markers of Metabolic Acidosis in a Thrombocytopenic Model of Pulmonary 
Infection with MRSA strain USA300 




Mice were treated with either 1mg/kg of anti-GPIbα platelet depleting antibody or IgG 
control antibody 24 hours prior to infection with either sham or 1x105 cfu/mouse MRSA 
strain USA300 embedded agar beads. Blood was taken via cardiac puncture, transferred 
to EC8+ blood analyser cartridges and processed using a handheld i-STAT blood analyser. 
HCO3- (Hydrogen Carbonate), PCO2 (partial pressure carbon dioxide), TCO2 (total carbon 
dioxide), AnGAP (Anion Gap), Hct (Haematocrit), Hb (Haemoglobin), PCV (packed cell 
volume). n=4-6, data are presented as mean ± SEM. 
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4.8  Investigating the Mechanisms of Platelet Involvement in Infection 
 
4.8.1 The Role of Platelet TLR4 in the Regulation of Pulmonary Infection 
 
Platelets express functional TLRs, which participate in platelet responsiveness to bacterial 
components such as LPS, and are known to be involved in LPS mediated inflammation 
(Hoshino et al., 1999). We investigated whether platelet TLR4 was involved in inflammatory 
leukocyte recruitment in response to pulmonary infection. Male C57/BI6J wild type and TLR4 
knockout mice were infected with 1x105 cfu/mouse with P.aeruginosa strain RP73 and the 
effects on bacteria induced leukocyte recruitment and bacterial growth were determined. 
Significant increases in pulmonary bacterial load were observed at 24 h.p.i, in both C57/BI6J 
wild type and TLR4 knockout mice, when compared with sham controls (105 log cfu + C57/BI6J 
wild type: 4.98±0.03 log cfu, 105 log cfu + TLR4 knockout: 4.74±0.25 log cfu and sham: 0.0±0.0 
log cfu, p<0.0001, Figure 4.28A). However, TLR4 knockout did not induce a significant increase 
in pulmonary bacterial load when compared to C57/BI6J wild type mice (105 log cfu + C57/BI6J 
wild type: 4.98±0.03 log cfu, 105 log cfu + TLR4 knockout: 4.74±0.25 log cfu and sham: 0.0±0.0 
log cfu, Figure 4.28A). 
Infection of both C57/BI6J wild type and TLR4 knockout mice with 1x105 cfu/mouse RP73 
induced a significant increase in pulmonary total leukocyte recruitment, when compared to 
sham controls (105 log cfu + C57/BI6J wild type: 82.0±25.42x105 cells/mL, versus sham + 
C57/BI6J wild type: 2.53±0.41x105 cells/mL, and 105 log cfu + TLR4 knockout: 69.67±15.92x105 
cells/mL, versus sham + TLR4 knockout: 3.13±0.07x105 cells/mL, Figure 4.28B). However, no 
significant difference in pulmonary total leukocyte recruitment was observed between 
infected C57/BI6J wild type and TLR4 knockout mice (105 log cfu + C57/BI6J wild type: 
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82.0±25.42x105 cells/mL, versus 105 log cfu + TLR4 knockout: 69.67±15.92x105 cells/mL, 
Figure 4.28B). 
This pattern was reflected in neutrophils, where infection of C57/BI6J wild type and TLR4 
knockout mice with 1x105 cfu/mouse RP73 increased pulmonary neutrophil recruitment 
when compared to sham controls (105 log cfu + C57/BI6J wild type: 76.70±24.94x105 cells/mL, 
versus sham + C57/BI6J wild type: 0.0±0.0x105 cells/mL, p<0.05 and 105 log cfu + TLR4 
knockout: 57.16±16.18x105 cells/mL, versus sham + TLR4 knockout: 0.0±0.0x105 cells/mL, 
Figure 4.28C). Whilst a trend suggesting a decrease in neutrophil recruitment in infected TLR4 
knockout mice was observed compared to C57/BI6J mice, this did not reach statistical 
significance (105 log cfu + C57/BI6J wild type: 76.70±24.94x105 cells/mL, versus 105 log cfu + 
TLR4 knockout: 57.16±16.18x105 cells/mL, Figure 4.28C). 
Infection of TLR4 knockout mice with 1x105 cfu/mouse RP73 induced a significant increase in 
macrophage recruitment when compared to sham TLR4 knockout controls (105 log cfu + TLR4 
knockout: 12.7±0.39x105 cells/mL, versus sham + TLR4 knockout: 2.03±0.80x105 cells/mL, 
p<0.01, Figure 4.28D). In addition, there was a significant increase in pulmonary macrophage 
recruitment in 1x105 cfu/mouse infected TLR4 knockout compared to C57/BI6J wild type mice 
(Macrophages: 105 log cfu + C57/BI6J wild type: 5.35±2.54x105 cells/mL, versus 105 log cfu + 
TLR4 knockout: 12.75±0.39x105 cells/mL, p<0.05, Figure 4.28D). No significant increase in 
pulmonary lymphocyte recruitment was observed in either wild type or TLR4 knockout mice, 
when compared to sham controls (Lymphocytes: 105 log cfu + C57/BI6J wild type: 0.0±0.0x105 
cells/mL, versus sham + C57/BI6J wild type: 0.0±0.0x105 cells/mL and 105 log cfu + TLR4 
knockout: 0.0±0.0x105 cells/mL, versus sham + TLR4 knockout: 0.0±0.0x105 cells/mL). 
 

















Figure 4.28 The Role of Platelet TLR4 in the Regulation of Pulmonary Infection with 





C57/BI6J wild type and TLR4 knockout mice were infected (o.a) with either sham or 1x105 
cfu/mouse P.aeruginosa strain RP73 embedded agar beads. A BAL of the lungs was 
performed for inflammatory cell quantification and lungs were aseptically removed, 
homogenised and plated for quantification of bacterial load at 24 h.p.i. Pulmonary 
Bacterial Load (A), Total Cells (B), Neutrophils (C) and Macrophages (D). One-way ANOVA 
and Bonferroni’s multiple comparisons post hoc test, *p<0.05, ** p<0.01, **** p<0.0001 
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4.8.1.1 PCR Analysis of Murine TLR4 cDNA 
 
In order to confirm that the TLR4 knockout mice used in section 4.8.1 were indeed knockout 
mice, DNA was extracted from murine tails and PCR analysis was performed. The results 
obtained demonstrated that the DNA extracted from TLR4 knockout mice showed a band at 
>1000Kb (Figure 4.29), indicating that the gene knockout is present in these mice, whilst no 
band was present in the DNA extracted from C57/BI6J wild type mice, suggesting that these 



















DNA was extracted from tail clips of TLR4 knockout and C57/BI6J wild type mice. PCR was 
performed on the samples using a PCR Reaction Kit (Sigma Aldrich R2648 20RXN) 
according to manufacturer’s instructions. (A) Agarose gel for TLR4 knockout primers (B) 
Agarose gel for TLR4 knockout and C57/BI6J wild type mice. 
 
227 | Chapter IV: Results II 
 
4.8.2 The Role of Platelet Purinergic Receptors in the Regulation of Pulmonary Infection 
 
As the worsened phenotype observed in platelet depleted mice was not reproduced in the 
TLR4 knockout mice, other potential platelet receptors involved in the regulation of 
pulmonary infection were investigated.  
Previous work has demonstrated that allergen induced pulmonary leukocyte recruitment is 
dependent upon the purinergic receptor P2Y1 (Amison et al., 2017). Furthermore, a protective 
role for the P2Y1 receptor has been suggested following infection with P.aeruginosa (Geary et 
al., 2005). Therefore, the role of purines and purinergic receptors in the regulation of 
pulmonary infection was investigated. 
 
4.8.2.1 Investigating the Effect of Apyrase Treatment on Circulating Platelet Count 
 
Apyrase is a purine hydrolysing enzyme, which converts ATP and ADP into inactive AMP, thus 
preventing activation of the platelet purinergic receptors.  
100 units/mL Apyrase was administered to mice 30 minutes prior to infection with 1x105 
cfu/mouse RP73 and the effect on the circulating platelet count was determined. Infection 
with 1x105 cfu/mouse reduced circulating platelet count when compared to sham controls, 
although these data did not reach statistical significance (105 log cfu + vehicle: 6.19±0.28x108 
platelets/mL, versus sham: 7.00±0.28x108 platelets/mL, Figure 4.30). Animals Infected and 
treated with Apyrase showed slightly increased circulating platelet counts when compared to 
vehicle controls, although these data also did not reach statistical significance (105 log cfu + 
vehicle: 6.19±0.28x108 platelets/mL, versus 105 log cfu + Apyrase: 6.77±0.28x108 
platelets/mL, Figure 4.30). 














Figure 4.30 Effects of Apyrase on Circulating Platelet Count in a Murine Model of 




4.8.2.2 Investigating the Effect of Apyrase Treatment on Weight Loss 
 
1x105 cfu/mouse RP73 infected, vehicle control treated animals showed a slight increase in 
weight loss when compared to sham controls (sham: 0.89±0.37%, 105 log cfu + vehicle control: 
3.13±0.61%, Figure 4.31). In addition, following infection with 1x105 cfu/mouse RP73, 
Apyrase treatment was associated with a further increase in weight loss when compared to 
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Mice were infected (o.a) with either sham or 1x105 cfu/mouse P.aeruginosa strain RP73 
embedded agar beads. 30 minutes prior to infection, mice were treated with either 100 
units/mL Apyrase or vehicle control. At 24 h.p.i blood was taken via cardiac puncture and 
the circulating platelet count was quantified using an improved neubauer 
haemocytometer. One-way ANOVA and Bonferroni’s multiple comparisons post hoc test, 
p>0.05 versus vehicle, n=9-10, data are presented as mean ± SEM.  















Figure 4.31 Effects of Apyrase on Weight Loss in a Murine Model of Pulmonary Infection 
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Mice were infected (o.a) with either sham or 1x105 cfu/mouse P.aeruginosa strain RP73 
embedded agar beads. 30 minutes prior to infection, mice were treated with either 100 
units/mL Apyrase or vehicle control. Body weights were recorded prior to and 24 h.p.i and 
percentage weight loss calculated. One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, ***p<0.001 versus sham, n=10, data are presented as mean ± 
SEM. 
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4.8.2.3 Investigating the Effect of Apyrase Treatment on Pulmonary Bacterial Load and 
Leukocyte Recruitment 
 
A significant increase in pulmonary bacterial load was observed at 24 h.p.i when compared to 
sham controls (105 log cfu + vehicle control: 4.83±0.10 log cfu, versus sham: 0.0 ± 0.0 log cfu, 
p<0.0001, Figure 4.32A). 100 units/mL Apyrase significantly increased pulmonary bacterial 
load when compared to vehicle control treated animals (105 log cfu + vehicle control: 
4.83±0.10 log cfu, versus 105 log cfu + Apyrase: 5.28±0.12 log cfu, p<0.01, Figure 4.32A), 
indicating in situ bacterial growth, similar to that observed in animals depleted of circulating 
platelets. 
Infection with RP73 induced a significant increase in pulmonary total leukocyte recruitment, 
when compared to sham controls (105 log cfu + vehicle control: 10.55±1.49x105 cells/mL, 
versus sham: 1.43±0.11x105 cells/mL, p<0.001, Figure 4.32B). 100 units/mL Apyrase 
significantly reduced infection induced pulmonary total leukocyte recruitment compared to 
vehicle control treated animals (105 log cfu + vehicle control: 10.55±1.49x105 cells/mL, versus 
105 log cfu + Apyrase: 5.39±0.57x105 cells/mL, p<0.001, Figure 4.32B). 
This was reflected in neutrophil numbers, where a significant increase in pulmonary 
neutrophil recruitment was observed following infection with 1x105 cfu/mouse compared to 
sham controls (105 log cfu + vehicle control: 9.14±1.47x105 cells/mL, versus sham: 
0.01±0.01x105 cells/mL, p<0.0001, Figure 4.32C). This was significantly reduced in animals 
pre-treated with 100 units/mL Apyrase (105 log cfu + vehicle control: 9.14±1.47x105 cells/mL 
versus 105 log cfu + Apyrase: 3.94±0.64x105 cells/mL, p<0.001, Figure 4.32C). No significant 
changes in macrophages (Macrophages: 105 log cfu + vehicle control: 0.95±0.35x105 cells/mL, 
105 log cfu + Apyrase: 0.65±0.26x105cells/mL, versus sham: 0.98±0.27x105 cells/mL, Figure 
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4.32D) or lymphocytes (Lymphocytes: 105 log cfu + vehicle control: 0.0±0.0x105 cells/mL, 105 
log cfu + Apyrase: 0.0±0.0x105cells/mL, versus sham: 0.0±0.0x105 cells/mL, Figure 4.32D) 
were observed in any groups. 
These data suggest a potential role of platelet purinergic receptors in the regulation of the 
host response to infection in the mouse.  
  



















Figure 4.32 Effects of Apyrase on Pulmonary Bacterial Load and Leukocyte Recruitment in 
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Mice were infected (o.a) with either sham or 1x105 cfu/mouse P.aeruginosa strain RP73 
embedded agar beads. 30 minutes prior to infection, mice were treated with either 100 
units/mL Apyrase or vehicle control. A BAL of the lungs was performed for inflammatory 
cell quantification and lungs were aseptically removed, homogenised and plated for 
quantification of bacterial load at 24 h.p.i. Pulmonary Bacterial Load (A), Total Cells (B), 
Neutrophils (C) and Macrophages (D). One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, *** p<0.001, **** p<0.0001 versus sham, ## p<0.01 versus 
vehicle control, n=8-10, data are presented as mean ± SEM. 
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4.8.2.4 Investigating the Effect of Apyrase Treatment on Bacterial Dissemination to the Kidney 
and Spleen 
  
As Apyrase treatment reflected the phenomena of platelet depletion observed on bacterial 
load and inflammatory leukocyte recruitment, we assessed whether this was also reflected 
on the systemic dissemination of bacteria. 
At 24 h.p.i, no evidence of bacterial dissemination to the kidney or spleen was observed in 
sham or vehicle control animals (sham: 0.0±0.0 log cfu, and 105 log cfu + vehicle: 0.0±0.0 log 
cfu, Figure 4.33A and Figure 4.33B). However, treatment with Apyrase induced a significant 
increase in bacterial dissemination to both the kidney and spleen, when compared to vehicle 
control treated animals (Kidney: 105 + Apyrase: 1.07 ± 0.45 log cfu, versus 105 + vehicle: 0.0 ± 
0.0 log cfu, p<0.01, Figure 4.33A and Spleen: 105 log cfu + Apyrase: 0.52±0.26 log cfu, versus 
105 log cfu + vehicle: 0.0±0.0 log cfu, p<0.05, Figure 4.33B).  












Figure 4.33 Effects of Apyrase on Bacterial Dissemination to the Kidney and Spleen in a 
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Mice were infected (o.a) with either sham or 1x105 cfu/mouse P.aeruginosa strain RP73 
embedded agar beads. 30 minutes prior to infection, mice were treated with either 100 
units/mL Apyrase or vehicle control. At 24 h.p.i, the kidney and spleen were aseptically 
removed, homogenised and plated for quantification of bacterial load. One-way ANOVA 
and Bonferroni’s multiple comparisons post hoc test, * p<0.05, ** p<0.01 versus vehicle 
control, n=9-10, data are presented as mean ± SEM.  
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4.8.2.5  Investigating the Effect of Purinergic Receptor Antagonists on Pulmonary Bacterial Load 
and Leukocyte Recruitment 
 
To further investigate the role of specific platelet purinergic receptors, mice were treated 
with either a P2Y1 antagonist, MRS2500, a P2Y12 antagonist, AR-C66096, a P2X1 antagonist, 
NF-279 or a P2Y14 antagonist, PPTN, and the effects on pulmonary bacterial load and 
leukocyte recruitment were observed. 
A significant increase in pulmonary bacterial load was observed at 24 h.p.i when compared to 
sham controls (105 log cfu + vehicle control: 4.69±0.11 log cfu, versus sham: 0.0 ± 0.0 log cfu, 
p<0.0001, Figure 4.34A). Treatment with the P2Y14 receptor antagonist, PPTN, significantly 
increased pulmonary bacterial load when compared to the vehicle controls (105 log cfu + 
PPTN: 5.30±0.15 log cfu, p<0.05, 105 log cfu + MRS2500: 4.57±0.18 log cfu, 105 log cfu + AR-
C66096: 4.79±0.16 log cfu, 105 log cfu + NF-279: 4.99±0.25 log cfu, versus vehicle: 4.69±0.11 
log cfu, Figure 4.34A). 
Infection with 1x105 cfu/mouse RP73 significantly increased total leukocyte recruitment to 
the lungs compared to sham controls (105 log cfu + vehicle control: 12.04±1.33x105 cells/mL, 
versus sham: 1.75±0.36x105 cells/mL, p<0.05, Figure 4.34B). This was significantly reduced 
following treatment with MRS2500, AR-C66096 and PPTN (105 log cfu + MRS2500: 
3.74±1.36x105 cells/mL, p<0.01, 105 log cfu + AR-C66096: 7.13±1.41x105 cells/mL, p<0.05, 105 
log cfu + NF-279: 7.44±1.82x105 cells/mL, 105 log cfu + PPTN: 6.39±0.52x105 cells/mL, p<0.05, 
versus 105 log cfu + vehicle: 12.04±1.33x105 cells/mL, Figure 4.34B) when compared to vehicle 
controls. This pattern was reflected in neutrophils, where treatment with MRS2500 and PPTN 
significantly reduced neutrophil recruitment to the lungs, when compared to vehicle controls 
(105 log cfu + MRS2500: 3.59±1.12x105 cells/mL, p<0.001, 105 log cfu + AR-C66096: 
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6.25±1.26x105 cells/mL, 105 log cfu + NF-279: 6.31±1.57x105 cells/mL, 105 log cfu + PPTN: 
4.96±0.37x105 cells/mL, p<0.05, versus 105 log cfu + vehicle: 10.28±1.20x105 cells/mL, Figure 
4.34C). No significant difference in pulmonary macrophage (105 log cfu + MRS2500: 
2.13±0.59x105 cells/mL, 105 log cfu + AR-C66096: 0.88±0.16x105 cells/mL, 105 log cfu + NF-
279: 1.12±0.31x105 cells/mL, 105 log cfu + PPTN: 1.44±0.22x105 cells/mL, versus 105 log cfu + 
vehicle: 1.76±0.24x105 cells/mL, Figure 4.34D) or lymphocyte (105 log cfu + MRS2500: 
0.0±0.0x105 cells/mL, 105 log cfu + AR-C66096: 0.0±0.0x105 cells/mL, 105 log cfu + NF-279: 
0.0±0.0x105 cells/mL, 105 log cfu + PPTN: 0.0±0.0x105 cells/mL, versus 105 log cfu + vehicle: 
0.0±0.0x105 cells/mL) recruitment was observed between any groups.  
  



















Figure 4.34 Effects of Purinergic Receptor Antagonists on Pulmonary Bacterial Load and 
Leukocyte Recruitment in a Murine Model of Pulmonary Infection with P.aeruginosa 
strain RP73 
 
Mice were infected (o.a) with either sham or 1x105 cfu/mouse P.aeruginosa strain RP73 
embedded agar beads. 30 minutes prior to infection, mice were administered a single 
dose of either vehicle, a P2Y1 antagonist, MRS2500 (3mg/kg), a P2Y12 antagonist, AR-
C66096 (3mg/kg), a P2X1 antagonist, NF-279 (3mg/kg) or a P2Y14 antagonist, PPTN 
Mesylate (10mg/kg) (i.v). A second dose of PPTN was administered at 6 h.p.i. A BAL of the 
lungs was performed for inflammatory cell quantification and lungs were aseptically 
removed, homogenised and plated for quantification of bacterial load at 24 h.p.i. 
Pulmonary Bacterial Load (A), Total Cells (B), Neutrophils (C) and Macrophages (D). One-
way ANOVA and Bonferroni’s multiple comparisons post hoc test, * p<0.05, **** 
p<0.0001 versus sham, #p<0.05, ## p<0.01, ### p<0.001 versus vehicle control, n=6-8, 
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4.8.2.6 Investigating the Effect of Purinergic Receptor Antagonists on Bacterial Dissemination to 
the Kidney and Spleen 
  
As inhibition of the platelet purinergic P2Y14 receptor reflected the phenomena of platelet 
depletion observed on bacterial load and inflammatory leukocyte recruitment, we assessed 
whether this was also reflected on the systemic dissemination of bacteria. 
At 24 h.p.i, no evidence of bacterial dissemination to the kidney or spleen was observed in 
sham animals, or in mice treated with vehicle control or MRS2500 (sham: 0.0±0.0 log cfu, 105 
log cfu + vehicle: 0.0±0.0 log cfu, 105 log cfu + MRS2500: 0.0±0.0 log cfu, Figure 4.35A and 
Figure 4.35B). However, treatment with PPTN induced an increase in bacterial dissemination 
to the kidney and spleen, although these data reached statistical significance only for the 
kidney (Kidney: 105 log cfu + AR-C66096: 0.16±0.16 log cfu, 105 log cfu + NF-279: 0.36±0.24 
log cfu, 105 log cfu + PPTN: 1.00±0.40 log cfu, p<0.01 and Spleen: 105 log cfu + AR-C66096: 
0.32±0.21 log cfu, 105 log cfu + NF-279: 0.25±0.25 log cfu, 105 log cfu + PPTN: 0.55±0.37 log 
cfu, Figure 4.35A and Figure 4.35B) when compared to vehicle controls. 
  












Figure 4.35 Effects of Purinergic Receptor Antagonists on Bacterial Dissemination to the 
Kidney and Spleen in a Murine Model of Pulmonary Infection with P.aeruginosa strain 
RP73 
  
Mice were infected (o.a) with either sham or 1x105 cfu/mouse P.aeruginosa strain RP73 
embedded agar beads. 30 minutes prior to infection, mice were administered a single 
dose of either vehicle, a P2Y1 antagonist, MRS2500 (3mg/kg), a P2Y12 antagonist, AR-
C66096 (3mg/kg), a P2X1 antagonist, NF-279 (3mg/kg) or a P2Y14 antagonist, PPTN 
Mesylate (10mg/kg) (i.v). A second dose of PPTN was administered at 6 h.p.i. At 24 h.p.i, 
the kidney and spleen were aseptically removed, homogenised and plated for 
quantification of bacterial load. One-way ANOVA and Bonferroni’s multiple comparisons 
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4.8.3 Investigating the Effect of Platelets on Growth of P.aeruginosa strain RP73 in vitro 
 
From the in vivo experiments performed, experimentally induced platelet depletion was 
associated with an increase in pulmonary bacterial load. Animals infected with the higher 
inoculum of 1x106 cfu/mL RP73 demonstrated a significant 1.5 log increase when compared 
to the IgG control treated animals. (Figure 4.11C). Interestingly, this particular strain of 
P.aeruginosa has previously demonstrated a similar log cfu increase over the same time 
period in in vitro cultures (Bragonzi et al., 2012). 
For this reason, platelet-bacteria co-culture experiments were performed to determine 
whether platelets modulate bacterial growth kinetics in vitro. 1x106 cfu/mL RP73 was 
incubated both in the presence and absence of 1x106 platelets/mL and aliquots of the co-
culture were taken periodically over an 8-hour time period. 
My results demonstrated that bacteria cultured in the presence of 1x106/mL platelets 
demonstrated a significant decrease in bacterial growth at both 6 (Bacteria alone: log 
8.49±0.22 cfu/mL, versus bacteria + platelets: log 7.74±0.42 cfu/mL, p<0.05, Figure 4.36) and 
8 hours (Bacteria alone: log 8.91±0.19 cfu/mL, versus bacteria + platelets: log 7.80±0.28 
cfu/mL, p<0.001, Figure 4.36), when compared to bacterial cultures in the absence of 
platelets. 
  












Figure 4.36 Effect of Platelets on Growth of P.aeruginosa strain RP73 in vitro 
 
 
4.8.4 Investigating the Effect of Platelets on Death of P.aeruginosa strain RP73 in vitro 
 
As my previous experiments highlighted the ability of platelets to modulate bacterial growth 
kinetics in vitro, we performed additional experiments to determine whether this was via 
increased bacterial death in vitro. A LIVE/DEAD BacLight bacterial viability kit was therefore 
used to monitor the viability of bacteria as a function of membrane integrity of the cell. For 
these experiments, 1x106 cfu/mL RP73 was incubated with and without platelets at either 
1x106, 1x107 or 1x108 platelets/mL. Aliquots were taken periodically over an 8-hour time 
period and bacteria with a compromised cell membrane were considered dead and stained 
red with the DNA stain PI. 
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In vitro cultures of 1x106 cfu/mL P.aeruginosa strain RP73 were prepared alone or in the 
presence of 1x106 platelets/mL at a 1:1 ratio. Aliquots were taken at 0, 2, 4, 6 and 8 hours 
and viable colony forming units were quantified on TSA plates. Unpaired two-tailed t-test, 
* p<0.05, *** p<0.001 versus bacterial control cultures, n=6, data are presented as mean 
± SEM.  
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My findings suggested that incubation of 1x107 platelets/mL significantly enhanced bacterial 
death of P.aeruginosa strain RP73 at 6 hours when compared to bacterial cultures in the 
absence of platelets (Bacteria alone: 724.1±35.5 RFU PI, versus bacteria + 107 platelets: 
880.30±24.17 RFU PI, p<0.05, Figure 4.37A). Similarly, incubation of 1x107 platelets/mL 
enhanced bacterial death of P.aeruginosa strain RP73 at 8 hours compared to bacterial 
cultures in the absence of platelets, although these data did not reach statistical significance. 
(Bacteria alone: 639.0±54.37 RFU PI, versus bacteria + 107 platelets: 827.50±24.54 RFU PI, 
Figure 4.37A). 
The RFU of PI decreased between 6 and 8 hours. Therefore, to assess whether the platelets 
remained viable after prolonged culture with bacteria, aliquots of the 107 co-culture were 
taken periodically between 0 and 8 hours and stimulated with either vehicle, 100µM ADP or 
10µM TRAP and the percentage of CD62P positive events was quantified, as a functional 
marker of platelet viability. Platelets remained viable at 8 hours, since the percentage of 
CD62P positive events continued to increase. Furthermore, there appeared to be no 
difference between vehicle control, ADP and TRAP stimulated platelets, perhaps suggesting 
that the platelets have already reached their maximum activated state in the presence of 
bacteria (vehicle: 52.79%, ADP: 51.88% and TRAP 54.75%, Figure 4.37B). 
  



















Figure 4.37 Effect of Platelets on Death of P.aeruginosa strain RP73 in vitro
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Cultures of 1x106 cfu/mL P.aeruginosa strain RP73 were prepared alone or in the presence 
of either 1x106,107 or 108 platelets/mL. Aliquots were taken at 0, 2, 4, 6 and 8 hours and 
stained with 2.5uM SYTO9 and 15uM Propidium Iodide. Samples were read on a 
fluorescent plate reader at 488/20nm excitation and either 528/20nm or 645/20nm 
emission. (A) Relative fluorescent units of PI. Platelets were stimulated with either 100µM 
ADP, 10µM TRAP or vehicle to determine the percentage CD62P positive events (B), using 
a Beckman Coulter Cytomics FC 500 flow cytometer. One-way ANOVA and Bonferroni’s 
multiple comparisons post hoc test, *p<0.05, 107 platelets versus bacterial control cultures 
at 6 hours, n=6, data are presented as mean ± SEM. 
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Pulmonary Infection for Therapeutic 
Analysis 
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5.1 Investigating the Effect of HT61 in Model of Pulmonary Infection with the Gram-
Negative P.aeruginosa 
 
One approach to provide improved treatments for infectious diseases is the use of enhancer 
compounds, which act by restoring sensitivity of resistant bacteria to currently available 
antibiotics. Hu and colleagues (Hu et al., 2010) have developed such a drug, the antibiotic 
enhancer, HT61, a small quinolone derived compound as an exemplar of this novel approach. 
HT61 has previously been reported to show efficacy against gram-positive bacteria, 
particularly MRSA and MSSA, in vitro (Hu et al., 2010). Therefore, the aim of this work was to 
determine the effect of HT61, as a singular treatment, in vivo, using a murine model of 
pulmonary infection with the gram-negative bacterial species, P.aeruginosa 
 
5.1.1 Investigating the Effect of HT61 in a Model of Pulmonary Infection with P.aeruginosa 
strain RP73 
 
Mice were inoculated with either sham or 1x106 cfu/mouse RP73 embedded agar beads and 
treated with a singular dose of HT61 at either 0.1, 1 or 5 mg/kg HT61 to determine the efficacy 
of HT61 as a singular treatment. The effect on pulmonary leukocyte recruitment and 
pulmonary bacterial load was determined. 
Data from these experiments indicated that infection with 1x106 cfu/mouse P.aeruginosa 
strain RP73 induced a significant increase in pulmonary bacterial load when compared to 
sham controls (6.16±0.22 log cfu, versus sham: 0.0±0.0 log cfu, p<0.0001, Figure 5.1A). 
Furthermore, HT61 treatment demonstrated no significant attenuation of bacterial load at 
any tested dose when compared to vehicle controls (0.1 mg/kg: 5.91±0.12 log cfu, 1 mg/kg: 
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6.45±0.12 log cfu and 5 mg/kg: 6.64±0.41 log cfu, versus vehicle: 6.16 ± 0.22 log cfu, Figure 
5.1A). 
Infection with 1x106 cfu/mouse RP73 induced a significant increase in total leukocyte 
(28.7±2.63x105 cells/mL, versus sham: 1.98±0.01x105 cells/mL, p<0.01, Figure 5.1B). and 
neutrophil (26.96±3.11x105 cells/mL, versus sham: 0.06±0.01x105 cells/mL, p<0.01, Figure 
5.1C) recruitment to the lungs when compared to sham controls. HT61 treatment at any 
tested dose had no significant reduction in total leukocyte recruitment (0.1 mg/kg: 
25.33±2.14x105  cells/mL, 1 mg/kg: 33.0±1.0x105  cells/mL, 5 mg/kg: 25.97±2.84 x105 
cells/mL, versus vehicle: 28.7±2.63x105  cells/mL, Figure 5.1B) or neutrophil recruitment to 
the lungs  (0.1 mg/kg: 23.79±2.13x105  cells/mL, 1 mg/kg: 31.61±1.21x105  cells/mL, 5 mg/kg: 
24.13±2.88x105  cells/mL, versus vehicle: 26.96±3.11x105  cells/mL, Figure 5.1C) compared to 
vehicle controls. Data from this study indicated that infection with RP73 had no significant 
effect on macrophage (vehicle: 1.74±0.48x105 cells/mL, versus sham: 1.40±0.26x105 cells/mL, 
Figure 5.1D) or lymphocyte (vehicle: 0.0±0.0x105 cells/mL, versus sham: 0.0±0.0x105 cells/mL) 
recruitment to the lungs compared to sham controls. This was consistent with macrophage 
recruitment following HT61 treatment, whereby HT61 treatment had no significant effect on 
macrophages at any dose tested (0.1 mg/kg: 1.54±0.12x105 cells/mL, 1 mg/kg: 1.40±0.21x105 
cells/mL, 5 mg/kg: 1.84±0.16x105 cells/mL, versus vehicle: 1.74±0.48x105 cells/mL, Figure 
5.1D) or lymphocyte (0.1 mg/kg: 0.0±0.0x105 cells/mL, 1 mg/kg: 0.0±0.0x105 cells/mL, 5 
mg/kg: 0.0±0.0x105 cells/mL, versus vehicle: 0.0±0.0x105 cells/mL) recruitment to the lungs 
when compared to vehicle controls. 
  
  





















Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain RP73 
embedded agar beads. 24 hours post infection, mice were administered with either 0.1, 1 
or 5 mg/kg HT61 or vehicle, via i.p injection. A BAL of the lungs was performed for 
inflammatory cell quantification and lungs were aseptically removed, homogenised and 
plated for quantification of bacterial load at 48 h.p.i. Pulmonary Bacterial Load (A), Total 
Cells (B), Neutrophils (C) and Macrophages (D). One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, ** p<0.01, **** p<0.0001 versus sham, n=2-4, data are 
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5.1.2 Investigating the Effect of HT61 in a Model of Pulmonary Infection with P.aeruginosa 
strain PAO1 
 
Having determined the effect of HT61, as a singular treatment, against infection with a 
multidrug resistant P.aeruginosa strain, RP73, HT61 was tested against a Tobramycin 
susceptible strain, P.aeruginosa, strain PAO1. The effect of HT61 on pulmonary leukocyte 
recruitment and pulmonary bacterial load was determined. 
Infection with 1x106 cfu/mouse PAO1 induced a significant increase in pulmonary bacterial 
load when compared to sham controls (5.56±0.31 log cfu, versus sham: 0.0±0.0 log cfu, 
p<0.0001, Figure 5.2A). HT61 treatment demonstrated no significant attenuation of bacterial 
load at any tested dose when compared to vehicle controls (0.1 mg/kg: 6.98±0.17 log cfu, 1 
mg/kg: 5.74±0.14 log cfu and 5 mg/kg: 5.74±0.33 log cfu, versus vehicle: 5.56±0.31 log cfu, 
Figure 5.2A). 
Infection with 1x106 cfu/mouse PAO1 induced a significant increase in total leukocyte 
(26.93±0.52x105 cells/mL, versus sham: 1.98±0.01x105 cells/mL, p<0.001, Figure 5.2B) and 
neutrophil (23.60±1.11x105 cells/mL, versus sham: 0.01±0.01x105 cells/mL, p<0.001, Figure 
5.2C) recruitment to the lungs when compared to sham controls.  HT61 treatment had no 
significant effect on total leukocyte number at any dose tested (0.1 mg/kg: 31.15±3.63x105 
cells/mL, 1 mg/kg: 23.5±1.78x105 cells/mL, 5 mg/kg: 22.80±6.03x105 cells/mL, versus vehicle: 
26.9±0.52x105 cells/mL, Figure 5.2B) or neutrophil recruitment to the lungs (0.1 mg/kg: 
27.72±2.85x105 cells/mL, 1 mg/kg: 20.57±1.89x105 cells/mL, 5 mg/kg: 19.44±5.14x105 
cells/mL, versus vehicle: 23.60±1.11x105 cells/mL, Figure 5.2C) when compared to vehicle 
controls. Additionally, infection with PAO1 had no significant effect on macrophage (vehicle: 
3.43±1.29x105 cells/mL, versus sham: 1.70±0.20x105 cells/mL, Figure 5.2D) or lymphocyte 
249 | Chapter V: Results III 
 
(vehicle: 0.0±0.0x105 cells/mL, versus sham: 0.0±0.0x105 cells/mL) recruitment to the lungs 
when compared to sham controls. This was consistent with HT61 treatment, whereby no 
tested doses of HT61 had a significant effect on macrophage (0.1 mg/kg: 3.43±0.80x105 
cells/mL, 1 mg/kg: 3.58±0.26x105 cells/mL, 5 mg/kg: 3.40±0.88x105 cells/mL, versus vehicle: 
3.43±1.29x105 cells/mL, Figure 5.2D) or lymphocyte (0.1 mg/kg: 0.0±0.0x105 cells/mL, 1 
mg/kg: 0.0±0.0x105 cells/mL, 5 mg/kg: 0.0±0.0x105 cells/mL, versus vehicle: 0.0±0.0x105 
cells/mL) recruitment to the lungs when compared to vehicle controls.  
















Figure 5.2 Effects of HT61 as a Singular Treatment on Infection with P.aeruginosa strain 
PAO1 
  
Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain PAO1 
embedded agar beads. 24 hours post infection, mice were administered with either 0.1, 1 
or 5 mg/kg HT61 or vehicle, via i.p injection. A BAL of the lungs was performed for 
inflammatory cell quantification and lungs were aseptically removed, homogenised and 
plated for quantification of bacterial load at 48 h.p.i. Pulmonary Bacterial Load (A), Total 
Cells (B), Neutrophils (C) and Macrophages (D). One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, *** p<0.001, **** p<0.0001 versus sham, n=3-4, data are 
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5.1.3 Investigating the Effect of HT61 in a Model of Pulmonary Infection with P.aeruginosa 
strain NN2 
 
Having determined the efficacy of HT61 against infection with a multidrug resistant 
P.aeruginosa strain, RP73 and a Tobramycin susceptible strain of P.aeruginosa, PAO1, HT61 
was tested against a Tobramycin resistant strain of P.aeruginosa, NN2. The effect of HT61 on 
pulmonary leukocyte recruitment and pulmonary bacterial load was determined. 
Infection with 1x106 cfu/mouse NN2 induced a significant increase in pulmonary bacterial 
load when compared to sham controls (4.85±0.18 log cfu, versus sham: 0.0±0.0 log cfu, 
p<0.0001, Figure 5.3A). HT61 treatment demonstrated no significant attenuation of bacterial 
load at any tested dose when compared to vehicle controls (0.1 mg/kg: 5.34±0.32 log cfu, 1 
mg/kg: 5.12±0.43 log cfu and 5 mg/kg: 5.8±0.69 log cfu, versus vehicle: 4.85±0.18 log cfu, 
Figure 5.3A). 
Infection with 1x106 cfu/mouse NN2 induced a significant increase in total leukocyte 
(13.13±1.86x105 cells/mL, versus sham: 1.93±0.18x105 cells/mL, p<0.01, Figure 5.3B) and 
neutrophil (10.45±1.53x105 cells/mL, versus sham: 0.0±0.0x105 cells/mL, p<0.01, Figure 5.3C) 
recruitment to the lungs when compared to sham controls.  HT61 treatment at any tested 
dose had no significant reduction in either total leukocyte (0.1 mg/kg: 12.30±2.60x105 
cells/mL, 1 mg/kg: 11.58±1.51x105 cells/mL, 5 mg/kg: 11.73±2.89x105 cells/mL, versus 
vehicle: 13.13±1.86x105 cells/mL, Figure 5.3B) or neutrophil recruitment to the lungs (0.1 
mg/kg: 10.63±2.49x105 cells/mL, 1 mg/kg: 9.70±1.19x105 cells/mL, 5 mg/kg: 9.70±2.91x105 
cells/mL, versus vehicle: 10.45±1.53x105 cells/mL, Figure 5.3C) when compared to vehicle 
controls. Additionally, infection with NN2 had no significant effect on macrophage or (vehicle: 
2.40±0.24x105 cells/mL, versus sham: 1.93±0.18x105 cells/mL, Figure 5.3D) lymphocyte 
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(vehicle: 0.0±0.0x105 cells/mL, versus sham: 0.0±0.0x105 cells/mL) recruitment to the lungs 
when compared to sham controls. The data obtained suggested HT61 treatment at any tested 
dose had no significant effect on macrophage (0.1 mg/kg: 1.71±0.50x105 cells/mL, 1 mg/kg: 
1.88±0.43x105 cells/mL, 5 mg/kg: 2.02±0.42x105 cells/mL, versus vehicle: 2.40±0.24x105 
cells/mL, Figure 5.3D) or lymphocyte (0.1 mg/kg: 0.0±0.0x105 cells/mL, 1 mg/kg: 0.0±0.0x105 
cells/mL, 5 mg/kg: 0.0±0.0x105 cells/mL, versus vehicle: 0.0±0.0x105 cells/mL) recruitment to 
the lungs when compared to vehicle controls.  






















Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain NN2 
embedded agar beads. 24 hours post infection, mice were administered with either 0.1, 1 
or 5 mg/kg HT61 or vehicle, via i.p injection. A BAL of the lungs was performed for 
inflammatory cell quantification and lungs were aseptically removed, homogenised and 
plated for quantification of bacterial load at 48 h.p.i. Pulmonary Bacterial Load (A), Total 
Cells (B), Neutrophils (C) and Macrophages (D). One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, ** p<0.01, **** p<0.0001 versus sham, n=3-4, data are 
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5.2 Investigating the Effect of HT61 in a Model of Pulmonary Infection with the 
Gram-Positive MRSA 
 
5.2.1 Investigating the Effect of HT61 in a Model of Pulmonary Infection with MRSA strain 
USA300 
 
The data suggested HT61, as a singular treatment, had no significant effect on infection with 
gram-negative P.aeruginosa, although HT61 has previously been reported to show efficacy 
against gram-positive bacteria, particularly MRSA and MSSA, in vitro (Hu et al., 2010). 
Therefore, we sought to investigate the effect of this compound on the gram-positive 
bacterial species, MRSA, strain USA300, in vivo. 
Infection with 1x106 cfu/mouse USA300, induced a significant increase in pulmonary bacterial 
load when compared to sham controls (4.62±0.31 log cfu, versus sham: 0.0±0.0 log cfu, 
p<0.0001, Figure 5.4A). HT61 treatment demonstrated no significant attenuation of bacterial 
load at any tested dose when compared to vehicle controls (0.1 mg/kg: 4.36±0.19 log cfu, 1 
mg/kg: 4.27±0.19 log cfu and 10 mg/kg: 3.92±0.22 log cfu, versus vehicle: 4.62±0.31 log cfu, 
Figure 5.4A). Although no significant effect was observed, these data indicated a trend 
towards a dose dependent reduction in pulmonary bacterial load with increasing doses of 
HT61. 
Furthermore, infection with 1x106 cfu/mouse USA300 induced a significant increase in total 
leukocyte (4.99±0.73x105 cells/mL, versus sham: 2.01±0.32x105 cells/mL, p<0.001, Figure 
5.4B) and neutrophil recruitment to the lungs (2.78±0.61x105 cells/mL, versus sham: 
0.0±0.0x105 cells/mL, p<0.0001, Figure 5.4C) when compared to sham controls.  HT61 
treatment at any tested dose had no significant reduction in total leukocyte recruitment (0.1 
mg/kg: 4.04±0.28x105 cells/mL, 1 mg/kg: 5.29±0.39x105 cells/mL, 10 mg/kg: 4.17±0.48x105 
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cells/mL, versus vehicle: 4.99±0.73x105 cells/mL, Figure 5.4B) to the lungs when compared to 
vehicle controls. At the highest tested dose of 10mg/kg, HT61 significantly reduced neutrophil 
recruitment to the lungs when compared to vehicle controls (0.1 mg/kg: 1.84±0.26x105 
cells/mL, 1 mg/kg: 1.79±0.37x105 cells/mL and 10 mg/kg: 0.69±0.12x105 cells/mL p<0.001, 
versus vehicle: 2.78±0.61x105 cells/mL, Figure 5.4C). 
Infection with MRSA strain USA300 had no significant effect on either macrophage (vehicle: 
2.33±0.39x105 cells/mL, versus sham: 2.01±0.32x105) or lymphocyte (vehicle: 0.0±0.0x105 
cells/mL, versus sham: 0.0±0.0x105) recruitment to the lungs when compared to vehicle 
controls. This was consistent with HT61 treatment, whereby no tested dose had a significant 
effect on either macrophage (0.1 mg/kg: 2.20±0.30x105 cells/mL, 1 mg/kg: 3.34±0.18x105 
cells/mL, 10 mg/kg: 3.47±0.41x105 cells/mL, versus vehicle: 2.33±0.39x105 cells/mL, Figure 
5.4D) or lymphocyte (0.1 mg/kg: 0.0±0.0x105 cells/mL, 1 mg/kg: 0.0±0.0x105 cells/mL, 10 
mg/kg: 0.0±0.0x105 cells/mL, versus vehicle: 0.0±0.0x105 cells/mL) recruitment to the lungs 
when compared to vehicle controls. 
  

















Figure 5.4 Effects of HT61 as a Singular Treatment on Infection with MRSA strain USA300 
 
 
Mice were infected (o.a) with either sham or 1x106 cfu/mouse MRSA strain USA300 
embedded agar beads. 24 hours post infection, mice were administered with either 0.1, 1 
or 10 mg/kg HT61 or vehicle, via i.p injection. A BAL of the lungs was performed for 
inflammatory cell quantification and lungs were aseptically removed, homogenised and 
plated for quantification of bacterial load at 48 h.p.i. Pulmonary Bacterial Load (A), Total 
Cells (B), Neutrophils (C) and Macrophages (D). One-way ANOVA and Bonferroni’s multiple 
comparisons post hoc test, *** p<0.001, **** p<0.0001 versus sham, ### p<0.001 versus 
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5.3 Investigating the Effect of HT61 and Tobramycin Combination Therapy in a 
Model of Pulmonary Infection with Gram- Negative P.aeruginosa 
 
The data in this chapter suggests that HT61 has no significant anti-microbial effect, when 
administered as a singular treatment. In vitro studies however have demonstrated an 
enhancement of the activity of older generation antibiotics (gentamicin, neomycin and 
chlorhexidine) when used in combination with HT61 (Hu, 2013) (Hu, 2010) against MRSA. The 
aim of this work was to determine whether the novel enhancer compound HT61 is able to 
potentiate the effect of low doses of Tobramycin or Vancomycin on attenuating the 
pulmonary bacterial load induced by the gram-negative P.aeruginosa and the gram-positive 
MRSA. 
 
5.3.1 Investigating the Effect of HT61 and Tobramycin in a Model of Pulmonary Infection with 
P.aeruginosa RP73 
 
Initial experiments were performed to determine whether combination treatment with HT61 
and Tobramycin significantly attenuates pulmonary bacterial infection with a multidrug 
resistant strain of P.aeruginosa, RP73, compared to singular treatment alone. 
Infection with 1x106 cfu/mouse RP73 induced a significant increase in pulmonary bacterial 
load when compared to sham control animals (5.54±0.01 log cfu, versus sham: 0.0±0.0 log 
cfu, p<0.0001, Figure 5.5A). Singular treatments of 100 mg/kg Tobramycin (5.56±0.01 log cfu) 
or 1 mg/kg HT61 (5.65±0.02 log cfu) had no significant reduction in bacterial load when 
compared to vehicle controls (5.54±0.01 log cfu, Figure 5.5A). However, following 
combination treatment with 100 mg/kg Tobramycin and 1 mg/kg HT61, bacterial load was 
significantly reduced (4.51±0.12 log cfu, p<0.0001, Figure 5.5A) when compared to vehicle 
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controls (5.54±0.01 log cfu). A similar significant reduction in bacterial load was observed 
following treatment with 300 mg/kg Tobramycin (4.36±0.07 log cfu, p<0.0001, Figure 5.5A). 
Infection with 1x106 cfu/mouse RP73 induced a significant increase in total leukocyte 
(6.35±0.72x105 cells/mL, versus sham: 3.40±0.06x105 cells/mL, p<0.05, Figure 5.5B) and 
neutrophil recruitment to the lungs (5.34±0.40x105 cells/mL, versus sham: 0.10±0.02x105 
cells/mL, p<0.0001, Figure 5.5C) when compared to sham controls.   
These data demonstrated that singular treatments of 100 or 300 mg/kg Tobramycin or 1 
mg/kg HT61 had no significant reduction in total leukocyte recruitment to the lungs when 
compared to vehicle controls (100 mg/kg Tobramycin: 4.23±1.05x105 cells/mL, 300 mg/kg 
Tobramycin: 6.45±0.46x105 cells/mL, 1 mg/kg HT61: 7.37±0.58x105 cells/mL versus vehicle: 
6.35±0.72x105 cells/mL, Figure 5.5B). Similarly, combination therapy of Tobramycin and HT61 
caused no significant reduction in total leukocyte recruitment to the lungs (5.88 x 105 ± 0.26 
cells/mL, versus vehicle: 6.35 x 105 ± 0.72 cells/mL, Figure 5.5B) when compared to vehicle 
controls. 
Furthermore, both singular and combination therapies had no significant reduction in 
neutrophil recruitment to the lungs compared to vehicle controls (100 mg/kg Tobramycin: 
3.16±1.03x105 cells/mL, 300 mg/kg Tobramycin: 4.76±0.29x105 cells/mL, 1 mg/kg HT61: 
6.62±0.51x105 cells/mL, combination therapy: 4.38±0.20x105 cells/mL, versus vehicle: 
5.34±0.40x105 cells/mL, Figure 5.5C). 
Infection with 1x106 cfu/mouse RP73 induced a significant decrease in macrophage 
recruitment (1.01±0.32x105 cells/mL, versus sham: 3.30±0.08x105 cells/mL, p<0.0001, Figure 
5.5D) to the lungs, when compared to sham controls. Both singular and combination 
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therapies had no significant reduction in macrophage (100 mg/kg Tobramycin: 1.10±0.05x105 
cells/mL, 300 mg/kg Tobramycin: 1.69±0.18x105 cells/mL, 1 mg/kg HT61: 0.76±0.08x105 
cells/mL, combination therapy: 1.68±0.10x105 cells/mL, versus vehicle: 1.01±0.32x105 
cells/mL, Figure 5.5D) or lymphocyte (100 mg/kg Tobramycin: 0.0±0.0x105 cells/mL, 300 
mg/kg Tobramycin: 0.0±0.0x105 cells/mL, 1 mg/kg HT61: 0.0±0.0x105 cells/mL, combination 
therapy: 0.0±0.0x105  cells/mL, versus vehicle: 0.0±0.0x105 cells/mL)  recruitment to the lungs 
when compared to vehicle controls.  




















Figure 5.5 Effects of Combination Therapy of HT61 and Tobramycin on Infection with 
P.aeruginosa strain RP73 
  
Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain RP73 
embedded agar beads. 24 hours post infection, mice were administered with singular 
treatments of either 100 or 300 mg/kg Tobramycin or 1 mg/kg HT61, combination therapy 
of 1 mg/kg HT61 and 100 mg/kg Tobramycin or vehicle, via i.p injection. A BAL of the lungs 
was performed for inflammatory cell quantification and lungs were aseptically removed, 
homogenised and plated for quantification of bacterial load at 48 h.p.i. Pulmonary 
Bacterial Load (A), Total Cells (B), Neutrophils (C) and Macrophages (D). One-way ANOVA 
and Bonferroni’s multiple comparisons post hoc test, * p<0.05, **** p<0.0001 versus 
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5.3.2 Investigating the Effect of HT61 and Tobramycin in a Model of Pulmonary Infection with 
P.aeruginosa PAO1 
 
Combination therapy with HT61 and Tobramycin significantly attenuated infection with RP73. 
We therefore performed additional experiments to determine whether combination therapy 
with HT61 and Tobramycin also significantly attenuates pulmonary bacterial infection with 
P.aeruginosa strain PAO1, a Tobramycin susceptible strain. 
Infection with 1x106 cfu/mouse PAO1 induced a significant increase in pulmonary bacterial 
load when compared to sham controls (4.70±0.13 log cfu, versus sham: 0.0±0.0 log cfu, 
p<0.0001, Figure 5.6A). Singular treatments of 50 mg/kg Tobramycin (5.06±0.11 log cfu) or 1 
mg/kg HT61 (4.97±0.06 log cfu) had no significant reduction in bacterial load compared to 
vehicle controls (4.70±0.13 log cfu, Figure 5.6A). Similarly, combination therapy with 50 
mg/kg Tobramycin and 1 mg/kg HT61, had no significant reduction in pulmonary bacterial 
load (5.0±0.06 log cfu, Figure 5.6A) when compared to vehicle controls (4.70±0.13 log cfu). 
These data suggested that infection with 1x106 cfu/mouse PAO1 induced a significant 
increase in total leukocyte (9.70±1.06x105 cells/mL, versus sham: 1.40±0.22x105 cells/mL, 
p<0.0001, Figure 5.6B) and neutrophil recruitment to the lungs (6.65±0.94x105 cells/mL, 
versus sham: 0.0±0.00x105 cells/mL, p<0.0001, Figure 5.6C) when compared to sham 
controls. 
Singular treatments with 50 mg/kg Tobramycin or 1 mg/kg HT61 and combination  therapy 
had no significant reduction in total leukocyte (50 mg/kg Tobramycin: 8.96±0.37x105  
cells/mL, 1 mg/kg HT61: 8.10±0.39x105 cells/mL, combination therapy: 7.19±0.49x105  
cells/mL, versus vehicle: 9.70±1.06x105 cells/mL, Figure 5.6B) or neutrophil recruitment to 
the lungs when compared to vehicle controls (50 mg/kg Tobramycin: 6.16±0.65x105  cells/mL, 
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1 mg/kg HT61: 4.77±0.74x105  cells/mL, combination therapy: 4.06±0.67x105  cells/mL, versus 
vehicle: 6.65±0.94x105 cells/mL, Figure 5.6C). 
Infection with 1x106 cfu/mouse PAO1 had no significant effect on macrophage (3.07±0.44x105 
cells/mL, versus sham: 1.39±0.22x105 cells/mL, Figure 5.6D) or lymphocyte (0.0±0.0x105 
cells/mL, versus sham: 0.0±0.0x105 cells/mL) recruitment to the lungs, when compared to 
sham controls. Furthermore, both singular and combination therapies had no significant 
effect on macrophage (50 mg/kg Tobramycin: 2.69±0.33x105 cells/mL, 1 mg/kg HT61: 
3.55±0.33x105 cells/mL, combination therapy: 3.62±0.52x105 cells/mL, versus vehicle: 
3.07±0.44x105 cells/mL, Figure 5.6D) or lymphocyte (50 mg/kg Tobramycin: 0.0±0.0x105 
cells/mL, 1 mg/kg HT61: 0.0±0.0x105 cells/mL, combination therapy: 0.0±0.0x105 cells/mL, 

























Figure 5.6 Effects of Combination Therapy of HT61 and Tobramycin on Infection with 
P.aeruginosa strain PAO1 
 
  
Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain PAO1 
embedded agar beads. 24 hours post infection, mice were administered with singular 
treatments of either 50 mg/kg Tobramycin or 1 mg/kg HT61, combination therapy of 1 
mg/kg HT61 and 50 mg/kg Tobramycin or vehicle, via i.p injection. A BAL of the lungs was 
performed for inflammatory cell quantification and lungs were aseptically removed, 
homogenised and plated for quantification of bacterial load at 48 h.p.i. Pulmonary 
Bacterial Load (A), Total Cells (B), Neutrophils (C) and Macrophages (D). One-way ANOVA 
and Bonferroni’s multiple comparisons post hoc test, **** p<0.0001 versus sham, n=3-4, 
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5.3.3 Investigating the Effect of HT61 and Tobramycin in a Model of Pulmonary Infection 
with P.aeruginosa NN2 
 
Experiments were performed to determine whether combination therapy with HT61 and 
Tobramycin significantly attenuates pulmonary bacterial infection with a Tobramycin 
resistant strain of P.aeruginosa, compared to singular treatment alone. 
Infection with 1x106 cfu/mouse NN2 induced a significant increase in pulmonary bacterial 
load when compared to sham controls (6.64±0.28 log cfu, versus sham: 0.0±0.0 log cfu, 
p<0.0001, Figure 5.7A). Singular treatments of 100 mg/kg Tobramycin (6.02±0.13 log cfu), 
200 mg/kg Tobramycin (6.63±0.32 log cfu), or 1 mg/kg HT61 (6.61±0.26 log cfu) had no 
significant reduction in bacterial load when compared to vehicle controls (6.64±0.28 log cfu, 
Figure 5.7A). However, following combination therapy of 100 mg/kg Tobramycin and 1 mg/kg 
HT61, a significant synergistic reduction in bacterial load was observed (5.49±0.33 log cfu, 
p<0.05, Figure 5.7A) when compared to vehicle controls (6.64±0.28 log cfu). 
Infection with 1x106 cfu/mouse NN2 induced a significant increase in total leukocyte 
(4.53±0.21x105 cells/mL, versus sham: 0.17±0.0x105 cells/mL, p<0.01, Figure 5.7B) and 
neutrophil recruitment to the lungs (4.46±0.19x105 cells/mL, versus sham: 0.0±0.0x105 
cells/mL, p<0.01, Figure 5.7C) when compared to sham controls. 
Singular treatments of 100 and 200 mg/kg Tobramycin and 1 mg/kg HT61 and combination 
therapy of 100 mg Tobramycin and 1 mg/kg HT61 had no significant reduction in total 
leukocyte (100 mg/kg Tobramycin: 2.37±0.31x105 cells/mL, 200 mg/kg Tobramycin: 
3.76±0.46x105 cells/mL, 1 mg/kg HT61: 4.07±0.99x105 cells/mL, combination therapy: 
2.84±1.24x105 cells/mL, versus vehicle: 4.53±0.21x105 cells/mL, Figure 5.7B) and neutrophil 
recruitment (100 mg/kg Tobramycin: 2.07±0.29x105 cells/mL, 200 mg/kg Tobramycin: 
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3.73±0.43x105 cells/mL, 1 mg/kg HT61: 3.69±0.91x105 cells/mL, combination therapy: 
2.25±1.13x105  cells/mL, versus vehicle: 4.46±0.19x105 cells/mL, Figure 5.7C) to the lungs 
when compared with vehicle controls. 
Infection with 1x106 cfu/mouse NN2 had no significant effect on macrophage (0.07±0.02x105 
cells/mL, versus sham: 0.17±0.00x105 cells/mL, Figure 5.7D) or lymphocyte (0.0±0.0x105 
cells/mL, versus sham: 0.0±0.00x105 cells/mL) recruitment to the lungs, when compared to 
sham controls. Singular treatment of 100 mg/kg Tobramycin had no significant effect on 
macrophage recruitment to the lungs when compared to vehicle controls (100 mg/kg 
Tobramycin: 0.30±0.03x105 cells/mL, Figure 5.7D). However, singular treatments of 200 
mg/kg Tobramycin or 1 mg/kg HT61 and combination therapy of 100 mg/kg Tobramycin and 
1 mg/kg HT61 had a significant increase in macrophage recruitment to the lungs when 
compared to vehicle controls (200 mg/kg Tobramycin: 0.39±0.02x105 cells/mL, 1 mg/kg HT61: 
0.38±0.08x105 cells/mL, combination therapy: 0.60±0.12x105 cells/mL, versus vehicle: 
0.07±0.02x105 cells/mL, Figure 5.7D). Both singular and combination therapies had no 
significant effect on lymphocyte recruitment to the lungs when compared to vehicle controls 
(100 mg/kg Tobramycin: 0.0±0.0x105 cells/mL, 200 mg/kg Tobramycin: 0.0±0.0x105 cells/mL, 
1 mg/kg HT61: 0.0±0.0x105 cells/mL, combination therapy: 0.0±0.0x105 cells/mL, versus 
vehicle: 0.0±0.0x105 cells/mL). 
 
  





















Figure 5.7 Effects of Combination Therapy of HT61 and Tobramycin on Infection with 
P.aeruginosa strain NN2 
  
Mice were infected (o.a) with either sham or 1x106 cfu/mouse P.aeruginosa strain NN2 
embedded agar beads. 24 hours post infection, mice were administered with singular 
treatments of either 100 or 200 mg/kg Tobramycin or 1 mg/kg HT61, combination 
therapies of 1 mg/kg HT61 and 100 mg/kg Tobramycin or vehicle, via i.p injection. A BAL 
of the lungs was performed for inflammatory cell quantification and lungs were aseptically 
removed, homogenised and plated for quantification of bacterial load at 48 h.p.i. 
Pulmonary Bacterial Load (A), Total Cells (B), Neutrophils (C) and Macrophages (D). One-
way ANOVA and Bonferroni’s multiple comparisons post hoc test, ** p<0.01, **** 
p<0.0001 versus sham, # p<0.05, ## p<0.01 versus vehicle, n=3-4, data are presented as 
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5.4 Investigating the Effect of HT61 and Vancomycin Combination Therapy in a Model 
of Pulmonary Infection with Gram- Positive MRSA 
 
5.4.1 Investigating the Effect of HT61 and Vancomycin in a Model of Pulmonary Infection with 
MRSA strain USA300 
 
A synergistic effect and a significant attenuation of pulmonary bacterial load was observed 
following combination therapy of HT61 and Tobramycin against two out of the three tested 
P.aeruginosa strains. Therefore, additional experiments were performed to determine 
whether this effect could be replicated against a gram-positive species of bacteria, MRSA, 
strain USA300. 
Infection with 1x106 cfu/mouse USA300 induced a significant increase in pulmonary bacterial 
load when compared to sham controls (5.57±0.11 log cfu, versus sham: 0.0±0.0 log cfu, 
p<0.0001, Figure 5.8A). Single treatments of 100 mg/kg Vancomycin (5.81±0.30 log cfu) or 1 
mg/kg HT61 (6.03±0.36 log cfu) had no significant reduction in bacterial load when compared 
to vehicle controls (5.57±0.11 log cfu, Figure 5.8A). Furthermore, combination therapy of 100 
mg/kg Vancomycin and 1 mg/kg HT61, had no significant reduction in pulmonary bacterial 
load (5.92±0.13 log cfu, Figure 5.8A) when compared to vehicle controls (5.57±0.11 log cfu). 
Infection with 1x106 cfu/mouse USA300 induced a significant increase in total leukocyte 
(27.90±7.92x105 cells/mL, versus sham: 2.01±0.30x105 cells/mL, p<0.01, Figure 5.7B) and 
neutrophil recruitment to the lungs (24.31±6.73x105 cells/mL, versus sham: 0.04±0.03x105 
cells/mL, p<0.01, Figure 5.8C) when compared to sham controls. 
Both singular treatments of 100 mg/kg Vancomycin and 1 mg/kg HT61 and combination 
therapy produced no significant reduction in total leukocyte recruitment to the lungs, when 
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compared to vehicle controls (100 mg/kg Vancomycin: 19.93±5.84x105 cells/mL, 1 mg/kg 
HT61: 20.18±1.98x105 cells/mL, combination therapy: 17.30±4.14x105 cells/mL, versus 
vehicle: 27.90±7.92x105 cells/mL, Figure 5.8B). 
This was also reflected by the neutrophil quantification, whereby both singular treatments 
and combination therapy had no significant reduction on neutrophil recruitment to the lungs 
when compared to vehicle controls (100 mg/kg Vancomycin: 16.82±6.12x105 cells/mL, 1 
mg/kg HT61: 17.82±1.61x105 cells/mL, combination therapy: 15.0±3.74x105 cells/mL, versus 
vehicle: 24.31±6.73x105 cells/mL, Figure 5.8C). 
Infection with 1x106 cfu/mouse USA300 had no significant effect on macrophage 
(3.59±1.21x105 cells/mL, versus sham: 1.98±0.32x105cells/mL, Figure 5.8D) or lymphocyte 
(0.0±0.0x105 cells/mL, versus sham: 0.0±0.0x105cells/mL) recruitment to the lungs when 
compared to sham controls. Furthermore, both singular and combination therapy had no 
significant effect on macrophage (100 mg/kg Vancomycin: 3.11±0.41x105 cells/mL, 1 mg/kg 
HT61: 2.46±0.56x105 cells/mL, combination therapy: 2.31±0.42x105 cells/mL, versus vehicle: 
3.59±1.21x105 cells/mL, Figure 5.8D) or lymphocyte recruitment (100 mg/kg Vancomycin: 
0.0±0.0x105 cells/mL, 1 mg/kg HT61: 0.0±0.0x105 cells/mL, combination therapy: 0.0±0.0x105 
cells/mL, versus vehicle: 0.0±0.0x105 cells/mL) to the lungs, when compared to vehicle 
controls.  
  






















Figure 5.8 Effects of Combination Therapy of HT61 and Vancomycin on Infection with 
MRSA strain USA300 
  
Mice were infected (o.a) with either sham or 1x106 cfu/mouse MRSA strain USA300 
embedded agar beads. 24 hours post infection, mice were administered with singular 
treatments of either 100 mg/kg Vancomycin or 1 mg/kg HT61, combination therapy of 1 
mg/kg HT61 and 100 mg/kg Vancomycin or vehicle, via i.p injection. A BAL of the lungs was 
performed for inflammatory cell quantification and lungs were aseptically removed, 
homogenised and plated for quantification of bacterial load at 48 h.p.i. Pulmonary 
Bacterial Load (A), Total Cells (B), Neutrophils (C) and Macrophages (D). One-way ANOVA 
and Bonferroni’s multiple comparisons post hoc test, ** p<0.01, **** p<0.0001 versus 
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6.1  Establishment and Validation of a Murine Model of Pulmonary Infection 
 
Initial experiments were required to establish a murine model of pulmonary infection using 
three strains of P.aeruginosa and one strain of MRSA, to produce an infection and 
inflammatory profile representative of a chronic pulmonary infection observed in the clinic.   
Experimental models may be established in order to investigate infection and inflammatory 
parameters, and the underlying signalling pathways associated with chronic pulmonary 
infections. P.aeruginosa is an opportunistic pathogen that exploits immunocompromised 
hosts. P.aeruginosa is frequently associated with the CF lung and the establishment of chronic 
infection, and is also a common cause of acute lower-respiratory tract infections in critically 
ill patients. Intrapulmonary infection with P.aeruginosa was initially profiled in vivo as it is 
plays a critical role in the development and progression of multiple pulmonary diseases (Van 
Heeckeren et al., 1997) (Growcott et al., 2011) (Bragonzi et al., 2012). My findings 
demonstrated that pulmonary instillation of 1x106 cfu/mouse P.aeruginosa embedded into 
agar beads resulted in the establishment of a non-lethal localised infection. The establishment 
of infection is one of the major challenges in experimental models of pulmonary infection, 
with previous studies demonstrating that both aerosol and direct tracheal instillation have 
resulted in the establishment of a transient pulmonary infection (Cash et al., 1979). Literature 
has suggested that the establishment of a chronic pulmonary infection can be achieved only 
if mice are inoculated with bacteria embedded in an immobilising agent such as agar, agarose, 
or seaweed alginate (Facchini et al., 2014) (Bragonzi, 2010). Therefore, bacteria were 
embedded into agar beads for the induction of an infection in my studies.  1x106 cfu/mouse 
was chosen as the optimum inoculum for pulmonary infection studies with P.aeruginosa 
strains RP73, PAO1 and NN2 producing the desired infection profile. Similar studies 
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performed by (Facchini et al., 2014), demonstrated that infection with 1x106 cfu/mouse 
P.aeruginosa RP73 resulted in a bacterial burden of 1.3x106 cfu/lung recovered from the 
lungs, however this data represented the sum of the bacterial burden present in both BAL 
fluid and the lungs and was determined at 3 d.p.i. Other dose-dependent infection studies 
using PAO1 embedded into agar beads have indicated that a dose in the range of 106-107 
cfu/mouse established an infection associated with low mortality, thus showing consistency 
with my findings (Bragonzi, 2010). 
The emergence of community acquired MRSA, as distinct from hospital strains, has been 
reported in Australasia, Europe, and North America (Durrington and Summers, 2008). MRSA 
strain USA300 is a major source of community acquired infections and has been implicated in 
epidemiologically outbreaks of skin and soft tissue infections in healthy individuals (Diep et 
al., 2006) (Klevens et al., 2007). I therefore investigated the infection and inflammatory 
parameters associated with intrapulmonary infection with MRSA strain USA300. Similar to 
the results obtained for P.aeruginosa, intrapulmonary infection with MRSA induced a non-
lethal, localised infection, associated with a neutrophilic infiltrate. Studies performed by 
others  (Cigana et al., 2018) have demonstrated that infection with 1x106 cfu/mouse USA300 
produced a similar inflammatory profile, although infection in this model was associated with 
a high mortality occurring within 4 days. Mortality was not directly quantified in my model 
however, at 48 h.p.i no mortality was observed.  
Pulmonary bacterial infections are typically characterised by an inflammatory response 
dominated by a neutrophilic infiltrate in the airways (Courtney et al., 2004) (Houston et al., 
2013). Consistent with clinical observations, the findings shown in this study highlighted a 
clear pro-inflammatory effect of both P.aeruginosa and MRSA infection as measured by a 
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significant increase in both neutrophils and cytokines in the BAL fluid and lung tissue of 
infected mice when compared to sham controls. An inflammatory infiltrate primarily 
neutrophilic in nature in response to infection is consistent with published literature in a rat 
model of chronic respiratory infection with P.aeruginosa (Cash et al., 1979) and in murine 
models of pulmonary infection with P.aeruginosa (Bayes et al., 2016) (Tam et al., 1999) (Van 
Heeckeren et al., 2002) (Van Heeckeren et al., 2006) (Bragonzi, 2010), compared to the 
presence of alveolar macrophages in sham controls. These findings are further supported 
following infection with RP73, whereby the inflammatory infiltrate in the airway lumen and 
alveolar spaces is predominantly composed of neutrophils (80%), (Facchini et al., 2014), 
although the inflammatory profile in this case was characterised at 7 days post infection. 
Moreover, the histological features and the increase in neutrophils observed in BAL fluid are 
consistent with data published by others (Boyer et al., 2005) (Growcott et al., 2011) (Liu et al., 
2013) (Gregory et al., 2007) at the same time point following infection with PAO1 in mice and 
rats. 
Inflammatory markers, including IL-6 and IL-8, are significantly elevated in chronic 
neutrophilic inflammation (Carpagnano et al., 2003) and infection (Takahashi et al., 2016). IL-
6 contributes to host defence through stimulation of the acute phase response and 
haematopoiesis (Tanaka et al., 2014) and IL-8 is involved in neutrophil activation and 
recruitment (Sawant et al., 2016). The findings shown in this study suggested that pulmonary 
infection with P.aeruginosa and MRSA is associated with significant increases in the pro-
inflammatory cytokines IL-6 and KC (the murine analogue of human IL-8). These data are 
consistent with studies performed by others (Van Heeckeren et al., 2000), whereby 
P.aeruginosa infected mice had a rapid, transient rise in IL-6, KC and absolute neutrophil 
counts in BAL fluid. Similarly, others (Cigana et al., 2018) have demonstrated a significant 
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increases in BAL levels of IL-6 following infection with clinical isolates of S.aureus. 
Interestingly, the significant rise in the neutrophil chemoattractant KC correlated with the rise 
in neutrophils observed in this model, perhaps suggesting a mechanism underlying neutrophil 
recruitment, although this requires further investigation.  
The standard of care therapy for patients with pulmonary infections with P.aeruginosa, such 
as CF, involves the use of aminoglycoside and β-lactam antibiotics (Marier et al., 2003).  
Aggressive treatment regimens using aerosolised Tobramycin have been shown to improve 
the quality of life of patients, reducing symptoms of acute pulmonary exacerbations (Marier 
et al., 2003) (Scheinberg and Shore, 2005). Following establishment of the murine model of 
pulmonary infection, I aimed to validate the model using drugs used clinically to treat 
pulmonary infections with P.aeruginosa and MRSA.  
For mice infected with the multidrug resistant strain of P.aeruginosa, RP73, high doses of 
Tobramycin (~300 mg/kg) were required to significantly attenuate pulmonary bacterial load 
at 48 h.p.i. Additionally, for the remaining strains of P.aeruginosa complete eradication of 
P.aeruginosa was not achieved, although, this may be due to the dosing regimen used in my 
studies as only a single treatment was administered. In comparison, single intratracheal 
treatments with conventional formulations of Tobramycin had no significant effect against 
P.aeruginosa infection in rats, although multiple doses of Tobramycin have previously shown 
efficacy (Marier et al., 2003). Similarly, previous studies using a murine model of P.aeruginosa 
PAO1 pneumonia have indicated a 4 log reduction in pulmonary bacterial load following i.p 
treatment of 150 mg/kg/day of Tobramycin (Louie et al., 2013). Although in this instance, 
Tobramycin was administered on a humanised dosing scheme administered every 4 hours 
over a 24-hour time period. This suggests that altering the dosing regimen in my model may 
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improve the efficacy of Tobramycin in this model, whereby multiple doses may increase 
penetration of the antibiotic, improve pulmonary function and eradicate the colonisation of 
P.aeruginosa. Other research suggests that the combination of Tobramycin with additional 
antibiotics, such as Meropenem may also enhance the reduction in bacterial burden (Louie et 
al., 2013). 
Tobramycin treatment appeared to reduce the inflammatory infiltrate in response to 
infection with PAO1, although these data did not reach statistical significance. This result may 
be an indirect effect on inflammation as a result of Tobramycin reducing the pulmonary 
bacterial burden. These findings are supported by a clinical study, which demonstrated that 
inhaled Tobramycin therapy eradicated P.aeruginosa infection from the lower airways in 74% 
of patients and significantly reduced airway neutrophilic inflammation (Chuchalin et al., 
2009). 
Moreover, other literature has suggested through both clinical studies and experimental 
models that Tobramycin treatment failed to reduce bacterial numbers yet significantly 
reduced P.aeruginosa exoenzyme activity (Grimwood et al., 1993), which contributes to lung 
injury frequently observed during pulmonary infection. These results suggest that Tobramycin 
may improve pulmonary function by decreasing P.aeruginosa exoenzyme expression, 
regardless of any other antimicrobial effect. Whilst research has demonstrated that 
Tobramycin reduces pro-inflammatory cytokines, including IL-8, IL-6 and TNF-α, in 
P.aeruginosa infected CF patients (Husson et al., 2005), this was not quantified in my model.  
Vancomycin has been considered to be the reference standard of therapy for the treatment 
of infections with MRSA (Tang et al., 2015), hence I validated the murine model of pulmonary 
infection with MRSA using this antibiotic. My results demonstrated that Vancomycin 
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treatment at 200 mg/kg significantly attenuated pulmonary infection with MRSA at 48 h.p.i, 
in agreement with results obtained in the literature using a murine model of pulmonary 
infection with MRSA embedded into agar beads (Harada et al., 2013). In these experiments a 
2.5 log reduction in pulmonary bacterial load was obtained at 3 days post infection, although 
Vancomycin treatment was administered at 50 mg/kg i.p. every 12 hours (Harada et al., 2013), 
perhaps explaining the more dramatic decrease in pulmonary bacterial burden when 
compared to those observed in these studies. This study further highlights that the optimum 
dosing regimen and formulation of antibiotic are essential in order to achieve the greatest 
possible reduction in bacterial load. 
After validation of these models, subsequent research was performed to investigate the role 
of platelets in the regulation of pulmonary infection and host defence, as described in the 
next section.  
 




The role of platelets in haemostatic and thrombotic processes has been extensively 
documented in response to vascular injury (Brass, 2010) (Kuijpers et al., 2004) (Li et al., 2010) 
(Rivera et al., 2009) (Andrews and Berndt, 2004). More recently however, platelets have 
received increasing attention for their role in the pathophysiology of inflammation, infection 
and immunity (Pitchford et al., 2003) (Bunescu et al, 2004) (Gresele et al., 1993) (Ortiz-Muñoz 
et al., 2014) (Van den Boogaard et al., 2015) (de Stoppelaar, 2014) (Wuescher et al., 2015) 
(Amison et al., 2015) (Amison et al., 2018). 
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Thrombocytopenia is a common finding in patients with sepsis (de Stoppelaar, 2014) (Hurley 
et al,. 2016), and is a well-known biomarker for disease severity (Gafter-Gvili et al., 2011) 
(Claushuis et al., 2016) (Goto et al., 2018). A low platelet count is associated with an adverse 
outcome and strongly impaired host defence system, significantly enhancing morality in 
critically ill patients (Xiang et al., 2013) (Claushuis et al., 2016) (Goto et al., 2018). Initial 
experiments were therefore performed to determine whether systemic thrombocytopenia 
occurs during pulmonary infection with P.aeruginosa or MRSA. Here, I demonstrated that 
intrapulmonary infection with both P.aeruginosa and MRSA induced a mild peripheral 
thrombocytopenia, demonstrated by a significant decrease in circulating platelet numbers. In 
comparison, other experimental models have verified platelet consumption in a mouse model 
of invasive S.pyogenes infection. At 12 and 18 h.p.i, mice exhibited significantly decreased 
circulating platelet numbers (Hurley et al., 2016) when compared to the initial time of 
infection. Collectively, these data provide evidence that platelets rapidly respond to infection 
and support the clinical observation that patients with sepsis display thrombocytopenia. 
There are several proposed mechanisms to explain the occurrence of infection induced 
thrombocytopenia, including platelet sequestration (Aster, 1966) and direct platelet 
activation during acute inflammation, resulting in a shortened platelet lifespan (Taytard et al., 
1986). Previous research has stated that platelets are recruited to sites of inflammation 
(Pitchford et al., 2003)(Lax et al., 2017) (Boilard et al., 2010), and there is now compelling 
evidence to suggest that individual platelets can migrate towards bacterial products (Ortiz-
Muñoz et al., 2014) (Czapiga et al., 2005) and act as cellular scavengers, migrating towards 
and collecting deposited bacteria (Gaertner et al., 2017). 
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It was therefore hypothesized that the occurrence of peripheral thrombocytopenia in 
response to infection may occur as a consequence of platelet activation and accumulation of 
activated platelets in lung tissue. It has been demonstrated that platelets are the first and 
most abundant inflammatory cell type recruited in response to infection  (Kerrigan, 2015). 
Therefore, experiments were performed to investigate whether platelet activation and 
accumulation occurred in lung tissue at 24 h.p.i. A significant increase in extravascular 
pulmonary platelet accumulation was observed following infection with 1x106 cfu/mouse 
P.aeruginosa, providing a plausible mechanism to explain the observed systemic 
thrombocytopenia. This is in agreement with published literature demonstrating pulmonary 
platelet accumulation following exposure to E.coli endotoxin (Itoha et al., 1996) and platelet 
accumulation in the liver sinusoids and hepatic circulation in response to infection with 
S.pyogenes (Hurley et al., 2016) and E.coli (Gaertner et al., 2017). Moreover, an in vitro 
chemotaxis model was developed to determine whether platelets are able to directly migrate 
towards bacterial stimuli. Further supporting my in vivo findings, the chemotaxis assay 
validated platelet migration across a membrane towards bacteria, further describing the 
potential for platelet accumulation at sites of infection. 
Numerous reports have indicated that platelets possess direct antimicrobial functions, acting 
as a source of an array of antimicrobial peptides (Yang et al., 2015) (Yeaman, 2010) (Krijgsveld 
et al., 2000) (Tang et al., 2002) (Kraemer et al., 2011) (Dewitte et al., 2017) (Ali et al., 2017), 
which are released from internal granules upon platelet activation. Furthermore, 
experimental models of pulmonary infection have demonstrated platelet activation in 
response to bacterial infection, with an array of bacterial species including S.aureus, 
S.pyogenes and K.pneumoniae (Youssefian et al., 2002) (Hurley et al., 2016) (Shannon, 2015) 
(de Stoppelaar, 2014) (de Stoppelaar et al., 2015). Platelet activation induced by bacteria has 
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resulted in marked increases in P-selectin surface expression (Youssefian et al., 2002), 
platelet-neutrophil complexes (Hurley et al., 2016) and PF-4 secretion from platelet granules 
(de Stoppelaar, 2014). Consistent with bacterial induced platelet activation observed in the 
literature (Youssefian et al., 2002) (Hurley et al., 2016) (Shannon, 2015) (de Stoppelaar, 2014) 
(de Stoppelaar et al., 2015) (Kahn et al., 2013), my results demonstrated enhanced platelet 
activation in response to infection with 1x106 cfu/mouse P.aeruginosa, as measured by 
significant increases in platelet-neutrophil complexes and BAL levels of RANTES and PF-4 
released in infected mice. Intriguingly, plasma levels of PF-4 were not significantly elevated, 
perhaps indicating PF-4 is only released at the site of the infection. This is consistent with 
other findings (Amison et al., 2018), whereby it was demonstrated that PF-4 is only 
significantly elevated at the site of infection. It is worth noting that platelet-neutrophil 
complexes have been reported to increase during early sepsis but decreased significantly 
during late sepsis (Hurley et al., 2016). This perhaps suggests that platelets have reached their 
maximum activation state and become exhausted in response to infection, although this 
requires further investigation. As platelet-neutrophil complexes were only quantified at 24 
h.p.i in my model, it would therefore be interesting to monitor this at a later time point. 
Platelets express an array of cell surface receptors allowing both direct and indirect 
interactions with bacteria (Dewitte et al., 2017) (Deppermann and Kubes, 2016). Platelets 
express functional Toll-like receptors (TLR2, TLR4), which recognise bacterial peptidoglycans 
and LPS in gram-positive and gram-negative pathogens respectively (Andonegui et al., 2005) 
(Aslam et al., 2016). In addition, platelets variably express GPIbα, FcγRIIa, αIIbβ3 receptors 
(Bennett, 2005) (Karas et al., 1982) (Lopez, 1994), which facilitate direct and indirect 
interactions with bacteria. This provides a plausible mechanism that may contribute to 
bacterial induced platelet activation in numerous infectious diseases, including sepsis, CF and 
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multiple organ dysfunction syndrome (MODS) (Russwurm et al., 2002) (Ogura et al., 2001) 
(O’Sullivan et al., 2005) (Gawaz et al., 1997), which has been suggested to precede platelet 
recruitment (Hurley et al., 2016). 
To further investigate the role of platelets in infection and host defence, I established an 
experimentally induced platelet depletion model with pulmonary infection using 
P.aeruginosa and MRSA, adapted from a well-documented model originally described by 
(Cash et al., 1979), and used regularly to date (Facchini et al., 2014) (Bayes et al., 2016) (Van 
Heeckeren et al., 2000). In order to produce profound platelet depletion, an anti-GPIbα 
platelet depleting antibody was utilised to deplete mice of circulating platelets. This method 
of platelet depletion significantly reduced circulating platelet numbers and has been used 
previously in the literature in both models of infection (de Stoppelaar, 2014) (Asaduzzaman 
et al., 2009) and inflammation (Amison et al., 2018). In addition, peripheral blood leukocyte 
populations remained unaltered by this method of platelet depletion, although these data 
were not shown. Alternative methods of platelet depletion have also been utilised in order to 
render animals thrombocytopenic in the literature, including an anti-mouse CD42b antibody 
(Kahn et al., 2013), anti-platelet anti-serum and bulsulfan (Pitchford et al., 2003)(Amison et 
al., 2015). Other methods of platelet depletion have been associated with inherent problems 
regarding long-term infection and chronic disease, including aIIbβ3 inducing anaphylactic shock 
in mice (Wuescher et al., 2015). My rationale for choosing the anti- GPIbα platelet depleting 
antibody was due to reports in the literature that mice receiving this antibody do not display 
pulmonary oedema, haemorrhage or weight loss beyond 10% (Amison et al., 2018) (Xiang et 
al., 2013). However, the results were suggestive of minor pulmonary haemorrhage in 
response to administration of the anti-GPIbα platelet depleting antibody in both sham and 
infected groups. Indeed, other groups have reported that thrombocytopenia results in lung 
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haemorrhage following exposure to both inflammatory (Goerge et al., 2008) and infectious 
stimuli (de Stoppelaar, 2014), consistent with my findings. In these studies, very low platelet 
count mice demonstrated severe haemorrhaging in the lungs following infection with 
K.pneumonaie, whereas infected low platelet count mice revealed sites of haemorrhage 
albeit to a much lesser extent than in very low platelet count mice (de Stoppelaar, 2014). 
Similarly, other published research has reported that i.v administration of the anti-GPIbα 
platelet depleting antibody, which lowered platelet count to less than 2.5%, induced severe 
lung haemorrhage, however 10-15% of normal platelet counts was sufficient to prevent 
inflammatory bleeding (Goerge et al., 2008). This suggests that the level of platelet depletion 
in my studies may account for the observed haemorrhaging in the lungs in platelet depleted 
groups. 
Consistent with my preliminary pulmonary infection studies (discussed in section 6.1), mice 
experimentally depleted of circulating platelets were initially infected with 1x106 cfu/mouse 
P.aeruginosa. Here I provided compelling evidence to suggest that platelet depletion in mice 
enhances the pathogenicity of pulmonary infection with P.aeruginosa, with an increased 
weight loss, increased mortality and higher pulmonary bacterial burden observed. Compared 
to non-thrombocytopenic mice, pulmonary bacterial load significantly increased by 1.5 logs 
over the course of 24 hours, whilst the mortality rate observed in these mice was greatly 
elevated (40%). In order to refine and reduce severity of the model, thrombocytopenic mice 
were infected with the lower inocula of 1x104 and 1x105 cfu/mouse P.aeruginosa. Intriguingly, 
the 1x104 cfu/mouse level of inoculum was completely cleared by 24 hours, whilst 1x105 
cfu/mouse was associated with an increased pulmonary bacterial load (0.5 logs) and mortality 
rate (20%) when compared to non-thrombocytopenic mice, albeit to a lesser extent than that 
of the 1x106 cfu/mouse inoculum. Having established a thrombocytopenic infection model 
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with P.aeruginosa, thrombocytopenic mice were infected with 1x105 cfu/mouse MRSA. 
Similarly, platelet depletion in this model resulted in a higher bacterial burden and increased 
weight loss, suggesting that platelets protect against both gram-negative and gram-positive 
bacterial species. 
Similar studies using experimentally induced thrombocytopenic infection models have 
demonstrated an enhanced total bacterial burden per mouse following infection with 
S.aureus, strain USA300 (Wuescher et al., 2015). However, a novel experimental model of 
conditional platelet depletion based on the Cre-recombinase cell ablation system was used 
to obtain these data (Wuescher et al., 2015), therefore a direct comparison with my data 
which used a different method of platelet depletion cannot be performed. Consistent with 
my findings, experimentally induced thrombocytopenia has been shown to dramatically 
impair host defence during infection, increasing mortality and enhancing bacterial growth 
during both Klebsiella and Streptococcus-induced pneumonia (de Stoppelaar, 2014) (van den 
Boogaard et al., 2015) and also in LPS-induced endotoxemia (Xiang et al., 2013). In contrast, 
it has been reported that weight loss in response to infection with S.pyogenes is less 
aggressive and less bacteria were recovered from the lungs of platelet depleted animals (Kahn 
et al., 2013). In these studies, an anti-CD42b antibody (i.p) was used to render mice 
thrombocytopenic to 15% of their normal circulating platelet levels and infection was induced 
using a bacterial culture of 1.5-3x107 cfu S.pyogenes (i.p) (Kahn et al., 2013), perhaps 
suggesting  that different bacterial provocations and different methods of platelet depletion 
may elicit a different response. Moreover, I demonstrated that the removal of circulating 
platelets from the 1x105 and 1x106 infection models converts the infection from non-lethal 
and non-systemic, to one displaying the presence of systemic infection in both the kidneys 
and spleen. Similarly in the literature, mice experimentally depleted of circulating platelets 
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are associated with higher systemic bacterial loads in the blood and distal organs in 
pneumococcal pneumonia (van den Boogaard et al., 2015), Klebsiella-derived pneumonia (de 
Stoppelaar, 2014) and S.aureus bacteraemia (Wuescher et al., 2015). In addition, research has 
stated that bacterial sepsis and organ failure is exacerbated in mice experimentally depleted 
of circulating platelets. Significant increases in the inflammatory cytokines IL-10, IL-6, IFN-γ 
and TNF-α were observed in mice experimentally depleted of circulating platelets, cytokines 
which are frequently associated with sepsis lethality and play important roles in the 
development of ARDS (Wuescher et al., 2015) (de Stoppelaar, 2014) (Xiang et al., 2013). These 
studies provide compelling evidence to suggest that thrombocytopenic mice succumbed to 
infection much more rapidly than non-thrombocytopenic mice.    
Metabolic acidosis is a common finding in patients with sepsis and is indicative of MODS 
(Kellum, 2004). Having observed an increase in mortality in platelet depleted animals, I 
investigated the potential cause of death in these animals by assessing biochemical markers 
of metabolic acidosis present in the blood following infection with P.aeruginosa 1x105 
cfu/mouse. Consistent with my previous findings, the data suggested the conversion of a 
phenotype associated with localised infection to one displaying systemic infection, as 
demonstrated by subtle increases in key biochemical markers of metabolic acidosis, including 
pCO2, base excess and HCO3-. Whilst these data did not show any significant differences, the 
absolute values observed were comparable with previously published murine models of 
septic infection (Sand et al., 2015), which have been known to correlate with MODS (Kellum, 
2004), providing a potential cause of mortality in these mice. The degree of change observed 
in biochemical markers of metabolic acidosis may have been more pronounced in mice that 
failed to reach the 24-hour end point, although further work is required to determine whether 
this is the primary cause of death.  
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Previous studies have suggested that thrombocytopenia leads to increased permeability of 
pulmonary vessels in several models, and platelets are important regulators of pulmonary 
endothelial barrier function and integrity (Middleton et al., 2016) (Ho-Tin-Noé et al., 2011) 
(Weyrich and Zimmerman, 2013). My observations suggested that pulmonary vascular 
permeability was enhanced in infected mice depleted of circulating platelets. However, 
pulmonary oedema was not a consequence of the anti-GPIbα antibody, consistent with 
findings published by (Amison et al., 2018). Indeed, this has been demonstrated in other 
experimental models; in mice with LPS-induced ALI, severe thrombocytopenia was associated 
with alveolar haemorrhage whereas animals with the same degree of thrombocytopenia 
without LPS-induced lung inflammation did not spontaneously bleed into the lungs (Goerge 
et al., 2008). This is consistent with my findings whereby haemorrhaging was observed in 
infected mice depleted of circulating platelets. This suggests that platelets are required for 
maintenance of the endothelial barrier and this may be mediated by platelet and endothelial 
selectins, since studies have demonstrated P-selectin deficient mice displayed enhanced 
bacterial outgrowth in their lungs and distant organs (de Stoppelaar, 2014). That said, the 
intrapulmonary administration of Evan’s Blue dye could have been used as a more 
representative measure of pulmonary alveolar integrity, since bacteria are disseminating 
from the lungs to the distal organs in my model. These data suggest that platelets may play a 
requisite role in maintaining the integrity of the pulmonary vasculature under basal 
conditions, preventing bacterial dissemination from the lung to the distal organs. 
Platelets have previously been reported to contribute towards pulmonary neutrophil 
recruitment in response to infection in animal models of sepsis (Asaduzzaman et al., 2009), in 
addition to leukocyte recruitment induced by allergic and non-allergic insults (Pitchford et al., 
2003) (Kornerup et al., 2010) (Amison et al., 2015) (Amison et al., 2017). This was consistent 
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with my findings, whereby I observed a significant decrease in pulmonary neutrophil 
recruitment in platelet depleted mice. Although, other studies have reported that 
thrombocytopenia did not influence lung inflammation or neutrophil recruitment in response 
to infection (Kahn et al., 2013) (de Stoppelaar, 2014), whereby there was no significant 
difference in pulmonary neutrophil accumulation between thrombocytopenic and non-
thrombocytopenic mice. This suggests a platelet-independent recruitment of neutrophils to 
the lung and perhaps explains why I observed partial neutrophil recruitment in response to 
infection in my studies. However, another explanation could also be through the increased 
haemorrhaging of the lungs observed in infected mice depleted of circulating platelets, 
resulting in vascular leakage into the lung tissue distorting the cellular infiltrate response to 
infection. 
Neutrophils are the first line of innate defence against infection, directly engulfing and killing 
bacteria in blood and tissues during infection (Clark et al., 2007), whilst they can also release 
dense web-like structures of DNA, called NETs, which possess proteolytic activity (Yost et al., 
2015) (Clark et al., 2007).  These NETs have been shown to exhibit antimicrobial activity by 
trapping and killing bacteria during infection (McDonald et al., 2012) (Clark et al., 2007) 
(Caudrillier et al., 2012). This observed reduction in pulmonary neutrophil recruitment may 
therefore account for the worsened phenotype observed in platelet depleted mice, through 
decreased NETosis. However, the role of platelets in inducing NET formation from neutrophils 
was not assessed in this model and requires further evaluation. 
Numerous studies have stated that platelets and platelet signalling factors, including PAF, can 
induce NET formation (Kraemer et al., 2011) (Yost et al., 2015) (McDonald et al., 2012) 
following platelet activation via platelet TLR4 in response to a bacterial trigger, such as LPS 
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(Clark et al., 2007). For example, in sepsis, activation of platelet TLR4 is a potent stimulus for 
neutrophil activation and NETosis (Caudrillier et al., 2012). Intriguingly (Clark et al., 2007) have 
demonstrated that platelets are requisite for LPS-induced neutrophil NET formation, since 
high concentrations of LPS were unable to induce NET formation from neutrophils directly. In 
comparison, depletion of circulating platelets was shown to prevent the release of NETs and 
enhance bacterial dissemination in an E.coli infection model (McDonald et al., 2012), 
highlighting that the release of intravascular NETs is dependent on contact dependent 
platelet-neutrophil interactions . Similarly, studies (Kraemer et al., 2011) have shown that 
human platelets express and release type 1 beta-defensins in response to infection, which are 
responsible for NET formation (Kraemer et al., 2011). These data may provide a possible 
additional mechanism by which platelets may be involved in indirect killing of bacteria. 
Interestingly, the in situ bacterial growth rate observed in the P.aeruginosa RP73 model (1.5 
logs per 24 hours) is comparable to that reported for the same strain in in vitro cultures over 
the same time period (Bragonzi et al., 2012). This led to the hypothesis that platelets may act 
independent of neutrophils to limit bacterial growth and serve an additional function of direct 
host defence against infection, given that platelets have previously been shown to interact 
directly with bacteria independent of neutrophils (Kraemer et al., 2011) (Ali et al., 2017). To 
this end, bacterial growth curves were performed both in the presence and absence of 
platelets in vitro. Here a significant reduction in pulmonary bacteria load was observed at 
both 6 and 8 hours in the presence of platelets when compared to bacteria alone, suggestive 
of a direct mechanism by which platelets can limit bacterial growth in vitro. Indeed, other 
published literature has suggested a direct mechanism of platelet modulation on bacterial 
growth. (Ali et al., 2017) indicated that platelets kill S.aureus directly in an activation-
dependent manner, whilst (Kraemer et al., 2011) have demonstrated that platelets can limit 
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the growth rate of S.aureus in vitro. These findings supported by the fact that the platelet is 
the first and most abundant cell type present, indicate the possibility that platelets serve as 
an early and independent function of direct host defence against bacterial pathogens. 
Furthermore, previous published work has suggested that platelets possess the capacity to 
directly internalise and phagocytose pathogens (Youssefian et al., 2002); and indeed, platelets 
contain many mediators with antimicrobial activity that are secreted from their granules upon 
platelet activation (Yeaman, 2014). However, the relative contribution of platelet microbicidal 
activity to host defence against infection remains unclear and further work is required to fully 
determine the mechanisms by which platelets independently modulate bacterial growth/ 
survival.  
In order to elucidate the mechanism by which platelets defend against infection and to 
determine whether there were specific components of platelets that mediate protection 
against infection, additional studies were performed to investigate potential mechanisms. 
Literature published by (Clark et al., 2007) and (Caudrillier et al., 2012) indicated that platelet 
TLR4 induces NET formation from activated neutrophils, therefore I speculated that a 
worsened phenotype would be observed using TLR4 knockout mice. As expected pulmonary 
neutrophil recruitment was reduced, however the severity of infection was not enhanced in 
TLR4 knockout mice when compared to wild type mice, suggesting a more direct mechanism 
for platelets. In contrast, studies performed by (Oliveira et al., 2010) demonstrated a higher 
mortality in TLR4 deficient mice following parasitic infection with Trypanosoma cruzi. 
However, these studies highlighted that older (>7 weeks) TLR4 deficient mice did not elicit 
enhanced susceptibility to infection, which perhaps helps to explain the data observed in the 
current study. 
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Recent studies have also postulated that the purinergic receptors exert a protective role 
against infection, whereby it was reported that P2Y1 and P2Y2 single and double knockout 
mice displayed increased susceptibility and increased morality to pulmonary infection with 
P.aeruginosa (Geary et al., 2005). Therefore, the purine (ATP/ ADP) hydrolysing enzyme, 
Apyrase, was used to investigate the role of ATP/ADP and purinergic receptors in the 
regulation of pulmonary infection. My results provided compelling evidence to suggest that 
activation of the purinergic receptors exerts a protective effect against infection, since the 
inhibition of these receptors enhanced the pathogenicity of P.aeruginosa infection, with 
enhanced pulmonary bacterial load, bacterial dissemination and increased weight loss. 
Administration of Apyrase also induced a significant reduction in both pulmonary total cell 
and neutrophil recruitment induced by P.aeruginosa infection. This is consistent with findings 
published by (Kukulski et al., 2010), whereby Apyrase was seen to abrogate LPS-induced 
neutrophil migration. 
 The contribution of the purinergic receptors to host defence remains unclear, however (Trier 
et al., 2008) suggests an association between purinergic receptor inhibition (P2X1/ P2Y12) and 
decreased production of PMPs and kinocidins from platelets. To this end, I sought to identify 
specific purinergic receptors implicated in host defence through the use of purinergic 
receptor antagonists. Consistent with previous findings (Amison et al., 2017), results 
demonstrated that inhibition of the P2Y1 and P2Y14 receptors significantly attenuated 
infection induced pulmonary neutrophil recruitment by 2-3 fold. It is therefore plausible to 
suggest that these receptors are involved in pulmonary neutrophil recruitment in this model, 
comparable to that observed in the literature (Amison et al., 2017) (Amison et al., 2015). 
Intriguingly, inhibition of the P2Y14 receptor with PPTN demonstrated evidence of enhanced 
pulmonary bacterial load and bacterial dissemination to the kidney. The increase in 
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pulmonary bacterial load observed following P2Y14 receptor inhibition was equivalent to the 
increase observed following depletion of circulating platelets in mice. This is perhaps 
suggestive of an involvement of the purinergic receptors in host defence against infection 
with P.aeruginosa, although further work is required to investigate this further. It is also 
possible to postulate that the worsened phenotype may be as a result of a diminished 
neutrophil population at the site of infection and reduced NETosis, in addition to a direct 
function of platelets.  
(Trier et al., 2008) have reported the platelet anti-staphylococcal responses occur through the 
P2X1 and P2Y12 purinergic receptors, since Apyrase, Suramin (a general P2 receptor 
antagonist), Pyridoxal (a P2X1 receptor antagonist) and Cangrelor (a P2Y12 receptor 
antagonist) reduced levels of PMP present in reaction supernatant. These studies suggest that 
bacteria induced platelet activation results in the release of ATP and ADP (Figure 6.1), which 
subsequently activates resting platelets within close proximity to augment platelet activation. 
This response is inhibited using the ATP/ADP hydrolysing agent, Apyrase (Figure 6.1). In 
addition, (Trier et al., 2008) highlight that activated platelets release PMPs to target bacteria 
and this response can be inhibited using both P2X1 and P2Y12 purinergic receptors (Figure 6.1).  
It is thought that P2Y14 is coupled to the same G-protein as P2Y12 (Gi) (Dovlatova et al., 2008), 
however the exact signalling mechanism associated with P2Y14 remains controversial. In the 
current study no effects were observed following administration of P2X1 and P2Y12 receptor 
antagonists, demonstrating conflicting results and highlighting the requirement for further 
research to deduce the signalling pathways associated with P2Y14. To this end, I propose that 
inhibition of the P2Y14 receptor using PPTN was associated with a worsened phenotype due 
to the inhibition of the release of PMPs from platelets, thereby reducing the direct killing 
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effect of platelets (Figure 6.1), although this requires further investigation. It is worthy to note 
that (Trier et al., 2008) did not investigate the effect of P2Y14 receptor antagonism on the 
platelet anti-staphylococcal response and indeed, different platelet signalling pathways and 













Figure 6. 1 A Proposed Mechanism of Action of the Platelet Antimicrobial Response 
Adapted from (Trier et al., 2008) 
 














P2Y14 Antagonist- PPTN? 
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What’s more, these receptor antagonists do not specifically target platelet purinergic 
receptors and indeed the use of P2 receptor knockout mice may be a useful tool for 
investigating purinergic receptor function in host defence against infection, although this was 
beyond the scope of the project.   
 A role for purinergic receptors in response to infection has been detailed elsewhere in the 
literature (Coutinho-Silva and Ojcius, 2012) (Miller et al., 2011), whereby a loss of function in 
the human P2X7 receptor led to increased susceptibility to infection, bolstering claims of 
purinergic involvement in infection, however this receptor subtype is not expressed by 
platelets suggesting that its effects are attributed to different cell types. It is reported that 
different pathogens use different strategies to manipulate purinergic signalling, therefore 
further identification of these may clarify platelet involvement in infection and host defence 
in my model. 
 
6.3 The Use of a Murine Model of Pulmonary Infection for Therapeutic 
Analysis 
 
Having established and validated a murine model of pulmonary infection with P.aeruginosa 
and MRSA, another part of this project was aimed at demonstrating the use of the model for 
therapeutic analysis with novel compounds. 
The rapid era of antibiotic discovery led to overconfidence that infectious diseases could be 
eradicated (Coates et al., 2002). However, the overuse and misuse of antibiotics has led to a 
crisis where many antibiotics are no longer effective against even the simplest infections 
(Laxminarayan, 2014). The emergence of antibiotic resistance has led to an urgent need for 
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novel approaches for treating infectious diseases. One such approach is the development of 
enhancer compounds, which act by restoring sensitivity of resistant bacteria to currently 
available antibiotics. (Hu, 2013) and colleagues have developed such a drug, the antibiotic 
enhancer, HT61, a small quinolone derived compound as an exemplar of this novel approach.  
Prior to testing this novel enhancer compound in vivo, in vitro studies were performed by 
collaborators to compare HT61 to commercially available antibiotics, including Amoxicillin 
and Levofloxacin, and to test its activity against different strains of bacteria (Hu et al., 2010).  
This research demonstrated that HT61 as a singular treatment produced a 7 log CFU/ml 
reduction against MSSA, although no activity was observed against gram-negative bacteria, 
including P.aeruginosa (Hu et al., 2010). Subsequent in vitro experiments were performed 
using HT61 in combination with commercially available antibiotics, with the aim of restoring 
sensitivity to drug resistant bacteria (Hu, 2013). These studies reported an enhancement of 
the activity of older generation antibiotics (gentamicin, neomycin and chlorhexidine) when 
used in combination with HT61 (Hu, 2013) in vitro against MRSA and MSSA, eradicating the 
total bacterial population by 2-8 hours.  
To this end, we sought to investigate whether the effects of HT61 observed in vitro could be 
reproduced in this in vivo model of pulmonary infection. Here I demonstrated for the first 
time that the novel enhancer compound HT61 is able to potentiate the effect of low doses of 
Tobramycin on attenuating the pulmonary bacterial load induced by two drug resistant 
clinical isolate strains of the gram-negative P.aeruginosa, RP73 and NN2, whilst having no 
direct anti-microbial effect itself. Furthermore, this combination approach may lead to the 
use of lower doses of antibiotics, particularly aminoglycosides, which have significant toxic 
side-effects. 
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It has previously been reported that combination treatments using different antibiotic classes 
induced synergistic antimicrobial effects against Tobramycin resistant strains of P.aeruginosa 
(Chan and Zabransky, 1987). In comparison to my work, this research detailed the synergistic 
effect following co-treatment of Tobramycin and Ceftazidime in vitro using the checkerboard 
technique. In addition, the combination treatment of Colistin and Ceftazidime had an additive 
effect against Tobramycin resistant P.aeruginosa, demonstrated using the time kill curve 
technique (Chan and Zabransky, 1987). Such observations highlight the potential beneficial 
effects of utilising combination treatments and enhancer compounds to optimally kill 
bacteria. These observations have been supported by other studies (Pieri et al., 2014), which 
have demonstrated an enhancement of the activity of Doxycycline with ianthelliformisamine 
derivatives against resistant Gram-negative bacteria. These studies, consistent with my work, 
highlight the importance of combining treatments in order to slow the emergence of 
resistance and reduce the concentrations of single treatment antibiotics. However, these 
previous studies have been largely in vitro and I have now demonstrated that it is possible to 
enhance the effect of Tobramycin in vivo against lung infections with P.aeruginosa, by 
restoring the sensitivity of resistant strains to this antibiotic. 
However, despite the enhancing effect of HT61 I observed against the two Tobramycin 
resistant strains of P.aeruginosa, I saw no significant reduction in pulmonary bacterial load 
following co-treatment of Tobramycin and HT61 against the Tobramycin susceptible strain of 
P.aeruginosa PAO1. This observation contrasts with other findings (Chan and Zabransky, 
1987), that have demonstrated a synergistic effect of Tobramycin in combination with 
azlocillin, piperacillin, ceftazidime and imipenem against the Tobramycin susceptible strain of 
P.aeruginosa PAO1. Other investigators (Pieri et al., 2014) have demonstrated that 
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ianthelliformisamine derivatives, as enhancer compounds, restore the activity of Doxycycline 
against P.aeruginosa PAO1 in vitro. Comparable results were observed in work carried out by 
(Borselli et al., 2017), whereby polyamine derivatives were used as antibiotic enhancers to 
restore sensitivity to Doxycycline against P.aeruginosa strain PAO1. My results suggest that 
HT61 may be best utilised in combination with Tobramycin against resistant organisms, rather 
than with Tobramycin in the treatment of sensitive strains.  
HT61 was initially developed as a topical agent for the decolonisation of nasal S.aureus and 
mini pig skin was used to test HT61 for potential dermal toxicity, which demonstrated 14 days 
of administration to 10% of the body surface had no related adverse effects (irritation, 
inflammation, itching) (Hu et al., 2010) (Hu, 2013). Consequently prior to initiating in vivo 
studies, little information was known regarding the pharmacokinetics/ pharmacodynamics 
and the bioavailability of HT61. Similarly, no prior experiments were performed to deduce the 
safety profile of HT61, therefore the optimum concentrations, dosing regimens and route of 
administration of HT61 may not have been adequately identified for these experiments. The 
synergistic effect observed against RP73 and NN2 may in fact be augmented if additional 
experiments were performed to deduce further information about HT61, including drug 
toxicology and bioavailability, and similarly, an effect may be observed against PAO1 and 
MRSA following administration of HT61 at an optimum concentration, dosing regimens and 
route. 
No significant reduction in pulmonary bacterial load was observed with HT61 and Vancomycin 
against the MRSA strain USA300 in vivo, which was surprising as other work has demonstrated 
a significant augmentation of the bactericidal efficacy of older generation antibiotics in vitro 
(Gentamycin, Neomycin, Chlorhexidine) in the presence of HT61 by (Hu, 2013) (Hu et al., 
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2010). However, as this is the first study to investigate HT61 in the lung in vivo, it is plausible 
that the optimal dosing regimen has not yet been identified and as discussed previously, 
further work is required to optimise the in vivo therapeutic regimen of HT61 to enhance the 
reduction in pulmonary bacterial load when administered with different antibiotics. 
Using membrane potential and ATP release assays, it has been reported that HT61 acts on the 
bacterial cell membrane, causing cell depolarisation and the release of the intracellular 
contents of the cell (Hubbard et al., 2017), leading to bacterial destruction. Furthermore, 
HT61 at high concentrations (40 µg/mL) has been shown to nick the bacterial cell wall 
structure following 10 minutes of treatment (Hu et al., 2010). This has been suggested as a 
possible mechanism of action of HT61 as this would increase the permeability of the bacterial 
membrane allowing greater cellular access to the antibiotic (Hu et al., 2010). It is also thought 
that when HT61 exerts its action on the bacterial cell membrane, the membrane-embedded 
enzymes that are involved in anaerobic metabolism and disrupted (Hu, 2013). As a result, 
non-multiplying bacteria are required to activate their anaerobic metabolic pathways when 
they are oxygen deprived and consequently become susceptible to killing by compounds that 
poison the respiratory chain (Hu, 2013). This provides a plausible explanation for my in vivo 
findings, although the mechanisms of action of this compound requires further research and 




In chapter IV it was demonstrated that the depletion of circulating platelets results in 
enhanced pathogenicity of infection with P.aeruginosa and MRSA, as measured by enhanced 
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weight loss, a higher bacterial burden and evidence of systemic infection. Platelets were also 
seen to decrease pulmonary neutrophil recruitment in response to infection. This research 
has raised several key questions, including what is the nature of the interaction between 
platelets and P.aeruginosa and MRSA and can activated platelets directly engulf bacteria in 
this model? This would provide a plausible mechanism for the worsened phenotype observed 
following experimentally induced platelet depletion. What's more, this work has highlighted 
the points of whether bacteria can trigger the destruction of host tissue in a manner that 
necessitates the protective effect of platelets and whether platelet derived PMPs and 
kinocidins can potentially exert a direct bacterial killing effect both in vitro and in vivo. 
Whilst modulation of the purinergic pathways appeared to be associated with a worsened 
phenotype comparable to that observed following depletion of circulating platelets, it 
remains unclear as to why activation of P2Y14 exerts a protective effect against infection. 
Future work is therefore required to investigate in more detail how purinergic signalling is 
affected during infection, and whether this effect is replicated in experimental models of both 
gram-negative and gram-positive infection. 
I have demonstrated that platelets can directly modulate bacterial growth kinetics, however 
future work is required to elucidate the relative contribution of platelet microbicidal activity 
to host defence against infection. It has previously been demonstrated that platelet reinfusion 
reduces mortality in LPS- induced endotoxemia and a bacterial infusion sepsis model (Xiang 
et al., 2013) and the protective role of platelets in this context has highlighted the potential 
beneficial effect of platelet transfusions in infection and sepsis (Yeaman, 2010). Future 
experiments could therefore be performed to determine whether the protective role of 
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platelets could be reinstated in conditions such as sepsis and CF, where platelets dysfunction 
or thrombocytopenia is observed.  
The murine model of pulmonary infection that was established during the course of this 
project could be extended to 14-28 days post infection to be more representative of the 
processes occurring in chronic diseases, including CF and COPD. Heparan Sulfate competitors 
have been shown to attenuate P.aeruginosa lung infection and decrease P.aeruginosa biofilm 
formation upon treatment (Lorè et al., 2018), however most studies that investigate the effect 
of certain compounds on biofilm formation are performed in vitro. In the future, this model 
could be adapted and used to investigate the effect of certain antimicrobials on biofilm 
formation in vivo, or even to examine platelet involvement in biofilm formation and tissue 
remodelling in the context of infection. 
Concerning the use of the model for therapeutic analysis, further experiments could be 
performed to determine the mechanism of action of HT61, in addition to toxicity, 
bioavailability and pharmacokinetics studies. These results may highlight the most effective 
dose regime, route of administration and concentration of HT61 to ensure total bacterial 
eradication. Several chronic respiratory diseases are characterized by incessant cycles of 
chronic airway inflammation, tissue remodelling and persistent infections (Lorè et al., 2018). 
Aggressive treatment regimens, using high, sometimes toxic doses of antibiotics are used and 
therefore a better understanding of the pathophysiological mechanisms underlying infection 
may improve future treatments. Different isolates of P.aeruginosa display considerable 
variation in both their phenotypic and genotypic characteristics, including swimming and 
twitching motility, expression of virulence factors and protease secretion (Cigana et al., 2018) 
and this consequently affects their susceptibility to antimicrobials.  




Here I provide compelling evidence to suggest that platelets are implicated in infection and 
host defence. I have demonstrated that intrapulmonary administration of bacteria induces 
platelet activation, as measured by the production of PF-4, RANTES and platelet-neutrophil 
complexes. Furthermore, I have revealed that infection induces peripheral thrombocytopenia 
with accumulation of activated platelets in lung tissue. The experimental depletion of 
circulating platelets in a murine model of pulmonary infection was associated with a 
worsened phenotype in both gram-negative and gram-positive infection, enhancing 
mortality, increasing pulmonary bacterial load and bacterial dissemination to the distal 
organs. This clearly highlights a critical role for platelets in host defence. I have suggested that 
signalling at the platelet purinergic receptors is implicated in infection, however further work 
is required to elucidate the mechanism by which platelets defence against infection
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